fulvestrant has been researched along with tamoxifen in 585 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 122 (20.85) | 18.2507 |
| 2000's | 247 (42.22) | 29.6817 |
| 2010's | 180 (30.77) | 24.3611 |
| 2020's | 36 (6.15) | 2.80 |
| Authors | Studies |
|---|---|
| Bryant, HU; Cullinan, GJ; Glasebrook, AL; Hauser, KL; Muehl, BS; Palkowitz, AD; Pell, TR; Phillips, DL; Sato, M; Shetler, PK; Short, LL; Thrasher, KJ | 1 |
| Bélanger, A; Caron, B; Cloutier, J; Dory, YL; Favre, A; Gauthier, S; Labrie, C; Labrie, F; Larouche, D; Leblanc, G; Mailhot, J; Martel, C; Mérand, Y; Ouellet, C; Schwerdtfeger, A; Simard, J | 1 |
| Dong, J; Filardo, EJ; Pang, Y; Thomas, P | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Abraham, DJ; Lin, HR; Safo, MK | 1 |
| Bellavance, E; Luu-The, V; Poirier, D | 1 |
| Bravo-Gómez, ME; Camacho, J; Cooney, AJ; García-Becerra, R; Hernández-Gallegos, E; Larrea, F; Morales-Ríos, MS; Ordaz-Rosado, D; Pérez-Alvarez, V; Rivera-Guevara, C | 1 |
| Bhatnagar, D; Boue, SM; Burow, ME; Collins-Burow, BM; Driver, J; Elliott, S; Jiang, Q; McLachlan, JA; Payton-Stewart, F; Rhodes, LV; Sridhar, J; Stevens, C; Wang, G; Wiese, TE; Zhang, Q; Zheng, S | 1 |
| Bearss, NR; Bhatnagar, D; Boue, SM; Burow, ME; Cleveland, TE; Erhardt, PW; Khupse, RS; Reese, MD; Sarver, JG; Trendel, JA; Wiese, TE | 1 |
| Jiang, XR; Smith, CL; Wang, P; Zhu, BT | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Grillot, K; Hager, JH; Heyman, R; Joseph, JD; Julien, J; Kahraman, M; Kaufman, J; Lai, A; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND | 1 |
| Andrews, DM; Ballard, P; Bradbury, RH; Buttar, D; Callis, RJ; Currie, GS; Curwen, JO; Davies, CD; de Almeida, C; De Savi, C; Donald, CS; Feron, LJ; Gingell, H; Glossop, SC; Hayter, BR; Hussain, S; Karoutchi, G; Lamont, SG; MacFaul, P; Moss, TA; Norman, RA; Pearson, SE; Rabow, AA; Tonge, M; Walker, GE; Weir, HM; Wilson, Z | 1 |
| Balogh, I; Kim, HY; Koczok, K; Korade, Z; Liu, W; Mirnics, K; Porter, NA; Tallman, KA; Xu, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gutgesell, LM; Karumudi, B; Lee, S; Lu, Y; Thatcher, GR; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J | 1 |
| Abrams, T; Baird, J; Burks, HE; Fekete, A; Hamann, LG; Kim, S; Kirby, CA; Lombardo, F; Loo, A; Lubicka, D; Macchi, K; McDonnell, DP; Mishina, Y; Norris, JD; Nunez, J; Peukert, S; Saran, C; Sun, Y; Thomsen, NM; Wang, C; Wang, J | 1 |
| Barrett, I; Carr, M; Fayne, D; Greene, LM; Keely, NO; Knox, AJS; Meegan, MJ; O'Boyle, NM; Twamley, B; Zisterer, DM | 1 |
| Abrams, T; Baird, J; Burks, HE; Firestone, B; Gaither, LA; Hamann, LG; He, G; Kim, S; Kirby, CA; Lombardo, F; Macchi, KJ; McDonnell, DP; Mishina, Y; Norris, JD; Nunez, J; Peukert, S; Springer, C; Sun, Y; Thomsen, NM; Tiong-Yip, CL; Tria, GS; Wang, C; Wang, J; Yu, B | 1 |
| Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Hager, JH; Heyman, R; Joseph, JD; Kahraman, M; Kaufman, J; Lai, A; Lee, K; Lu, N; Maheu, K; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND | 1 |
| Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, SP; Hager, JH; Heyman, R; Joseph, JD; Kahraman, M; Kaufman, J; Lai, A; Lee, K; Liu, N; Nagasawa, JY; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND | 1 |
| Ahmed, L; Ahmed, MS; Ali, AA; Attia, YM; Elmazar, MM; Hendy, MS; Hossam, R; Mostafa, A; Naguib, BH | 1 |
| Chen, H; Dubrovyskyii, O; Dye, K; Gordon-Blake, J; Gutgesell, LM; He, D; Hollas, M; Huang, F; Lasek, AW; Lee, S; Li, Y; Lu, Y; Rosales, CI; Shen, Z; Thatcher, GRJ; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J | 1 |
| Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Bai, C; Luo, G; Ren, S; Wu, S; Xiang, H; Zhu, M | 1 |
| Bowler, J; Wakeling, AE | 1 |
| Bowler, J; Dukes, M; Wakeling, AE | 1 |
| Catherino, WH; Jordan, VC; Wolf, DM | 1 |
| Hayashi, T; Hidaka, H; Iguchi, A; Ishikawa, T; Kuzuya, M; Naito, M; Yamada, K | 1 |
| Potter, BV; Purohit, A; Reed, MJ; Roberts, CJ; Williams, GJ | 1 |
| Ip, W; Khan, SA; Peters, GA; Tang, M; Wang, H; Zeng, X | 1 |
| Coronado-Heinsohn, EB; Hilsenbeck, SG; Manning, DL; McClelland, RA; McCue, BL; Nicholson, RI; Osborne, CK; Wakeling, AE | 1 |
| Esaki, T; Hayashi, T; Hidaka, H; Iguchi, A; Ishikawa, T; Kuzuya, M; Satake, S; Yamada, K | 1 |
| Blin, C; Colnot, S; L'Horset, F; Lambert, M; Leclerc, T; Perret, C; Thomasset, M | 1 |
| Gee, JM; Katzenellenbogen, BS; Manning, DL; Montano, MM; Nicholson, RI; Wakeling, AE | 1 |
| DeLuise, M; Hu, XF; Parisot, JP; Sutherland, RL; Wakeling, A; Zalcberg, JR | 1 |
| Collins, DC; Gagliardi, A | 1 |
| Pollak, MN; Pratt, SE | 1 |
| Briand, P; Larsen, SS; Lykkesfeldt, AE | 1 |
| Howell, A; Robertson, J | 1 |
| Blamey, R; DeFriend, D; Howell, A; Robertson, J; Walton, P | 1 |
| Thomas, ML; Xu, X | 1 |
| Dowsett, M; Iveson, TJ; Johnston, SR; Smith, IE | 1 |
| Ching, M; de Luise, M; Hu, XF; Marschner, IC; Wakeling, A; Wall, DM; Zalcberg, JR | 1 |
| Cavaillès, V; Danielian, PS; Dauvois, S; Parker, MG | 1 |
| Anderson, E; Bell, J; DeFriend, DJ; Howell, A; Mansel, RE; West, CM; Wilks, DP | 1 |
| Crew, AJ; Langdon, SP; Miller, WR; Muir, M; Ritchie, AA; Smyth, JF; Wakeling, A | 1 |
| Dauvois, S; Parker, MG; White, R | 1 |
| Briand, P; Lykkesfeldt, AE; Madsen, MW | 1 |
| Bouchoux, F; Brémaud, J; Hameau, MC; Lucas, D; Moratille, C; Nique, F; Philibert, D; Teutsch, G; Van de Velde, P; Viet, S | 1 |
| Huynh, HT; Pollak, M | 1 |
| De Luise, M; Hu, XF; Sutherland, R; Veroni, M; Wakeling, A; Watts, CK; Zalcberg, JR | 1 |
| Blaustein, JD; Gray, JM; Meredith, JM; Wade, GN | 1 |
| Choudhary, Q; Croxtall, JD; Emmas, C; Flower, RJ; White, JO | 1 |
| Brünner, N; Clarke, R; Coopman, P; Derocq, D; Garcia, M; Rochefort, H | 1 |
| Bei, M; Brünner, N; Clarke, R; Frandsen, TL; Holst-Hansen, C; Lippman, ME; Thompson, EW; Wakeling, AE | 1 |
| Poyser, NL | 1 |
| Manning, DL; Nicholson, RI | 1 |
| Hardy, SP; Higgins, CF; Jacob, TJ; Valverde, MA; Zhang, JJ | 1 |
| Clerico, L; de Cupis, A; Favoni, RE; Ferrera, A; Noonan, D; Pirani, P | 1 |
| Addeo, R; Altucci, L; Battista, T; Bonapace, IM; Bresciani, F; Cancemi, M; Cicatiello, L; Germano, D; Pacilio, C; Salzano, S; Weisz, A | 1 |
| Blair, HC; Jordan, SE; McDonald, JM; McKenna, MA; Williams, JP | 1 |
| Benedetti Panici, P; Bonanno, G; de Vincenzo, R; Ercoli, A; Fattorossi, A; Isola, G; Mancuso, S; Pernisco, S; Scambia, G | 1 |
| Caramona, MM; Lopes, MC; Mendes, AF | 1 |
| Biberger, C; von Angerer, E | 1 |
| Branham, WS; De George, JJ; Fishman, R; Medlock, KL; Sheehan, DM; Streck, RD | 1 |
| Baumann, RJ; Bitonti, AJ; Cashman, EA; Cross-Doersen, DE; Dumont, JA; Wallace, CD | 1 |
| Bliss, RD; Browell, DA; Kirby, JA; Lennard, TW | 1 |
| Benedetti Panici, P; Bonanno, G; De Vincenzo, R; Fattorossi, A; Ferlini, C; Isola, G; Mancuso, S; Pernisco, S; Scambia, G | 1 |
| Bardin, CW; Dao, B; Koide, SS; Marshall, A; Vanage, G | 1 |
| Anderson, E; Blamey, RW; Clarke, R; Dowsett, M; Gee, JM; Howell, A; Manning, DL; McClelland, RA; Nicholson, RI; Robertson, JF; Wakeling, AE | 1 |
| Berelowitz, M; Bruno, JF; Song, J; Xu, Y | 1 |
| Fuchs-Young, R; Hale, L; Howe, S; Miles, R; Walker, C | 1 |
| Brémaud, J; Hameau, MC; Magnien, V; Nique, F; Philibert, D; Planchon, P; Prévost, G; Teutsch, G; Van de Velde, P | 1 |
| Briand, P; Larsen, SS; Lykkesfeldt, AE; Madsen, MW; Reiter, BE | 1 |
| Gradishar, WJ; Jordan, VC | 1 |
| Dewhurst, LO; Gee, JW; MacNeil, S; Rennie, IG | 1 |
| Carver, JM; Lundeen, SG; McKean, ML; Winneker, RC | 1 |
| Arnold, SF; Collins, BM; McLachlan, JA | 1 |
| Dipippo, VA; Powers, CA | 1 |
| Cheskis, BJ; Karathanasis, S; Lyttle, CR | 1 |
| Katzenellenbogen, BS; Montano, MM | 1 |
| Logie, C; Nichols, M; Rientjes, JM; Stewart, AF | 1 |
| Chiappetta, C; Hyder, SM; Murthy, L; Stancel, GM | 1 |
| Koide, SS; Li, XJ; Yu, H | 1 |
| Couissi, D; Dubois, V; Remacle, C; Schonne, E; Trouet, A | 1 |
| Abbas Abidi, SM; Dmytryk, JJ; Hurt, GM; Mathew, AC; Pento, JT; Rajah, TT | 1 |
| Abbas Abidi, SM; Dmytryk, JJ; Howard, EW; Pento, JT | 1 |
| Chen, Z; German, Z; Lantin-Hermoso, RL; Rosenfeld, CR; Shaul, PW; Yuhanna, IS | 1 |
| A'Hern, R; Anderson, E; Clarke, R; Detre, S; Dowsett, M; Ellis, PA; Howell, A; Johnston, SR; Nicholson, R; Robertson, J; Saccani-Jotti, G; Salter, J; Smith, IE | 1 |
| Boysen, B; Brünner, N; Clarke, R; Frandsen, T; Fuqua, SA; Holst-Hansen, C; Jirus, S; Lippman, J; Skaar, TC; Spang-Thomsen, M | 1 |
| Belanger, A; Gauthier, S; Labrie, C; Labrie, F; Merand, Y; Poirier, D; Sanchez, R; Simard, J; Singh, SM | 1 |
| Brown, M; DiRenzo, J; Dowdy, SF; Ewen, ME; Hinds, PW; Ladha, MH; Lin, N; Miller, SJ; Neuman, E; Pestell, RG; Upton, TM | 1 |
| Bradford, PG; Dragon, MB; Homick, K; Kirkwood, KL | 1 |
| Chambon, P; Feil, R; Metzger, D; Wagner, J | 1 |
| Ali, S; Coombes, RC; Pace, P; Suntharalingam, S; Taylor, J | 1 |
| Lane, MV; Merchenthaler, I; Shughrue, PJ | 1 |
| Bonde, SK; Gori, F; Hofbauer, LC; Rickard, DJ; Riggs, BL; Spelsberg, TC | 1 |
| Jensen, EV; Knabbe, C; Müller, V | 1 |
| Chaudhuri, G; Esaki, T; Hayashi, T; Iguchi, A; Muto, E; Yamada, K | 1 |
| Dickson, RB; El-Ashry, D; Hannum, RS; Kern, FG; Kharbanda, S; Lopez, CA; Lorant, LA; McLeskey, SW; Tobias, CA; Trock, BJ; Zhang, L | 1 |
| Battaglia, A; Benedetti Panici, P; Cicchillitti, L; Ercoli, A; Fattorossi, A; Malorni, W; Mancuso, S; Rainaldi, G; Raspaglio, G; Scambia, G | 1 |
| Assikis, VJ; Bilimoria, MM; Chen, Z; England, GM; Jordan, VC; Muenzner, HD | 1 |
| Abidi, SM; Dmytryk, JJ; Howard, EW; Pento, JT | 1 |
| Garr, E; Godsland, IF; Stevenson, JC; Wingrove, CS | 1 |
| Castro-Rivera, E; Safe, S | 1 |
| Jordan, VC; Levenson, AS; Tonetti, DA | 1 |
| Averboukh, L; Biswas, DK; Ewaniuk, DS; Jawde, TF; Martin, K; Pardee, AB; Sheng, S; Wang, F | 1 |
| Anderson, KC; Chauhan, D; Ogata, A; Teoh, G; Treon, SP; Urashima, M; Webb, IJ | 1 |
| Funder, JW; Logie, C; Myles, K; Nichols, M; Stewart, AF | 1 |
| Damien, E; Lanyon, LE; Price, JS | 2 |
| Gorodeski, GI | 1 |
| Bellone, CJ; Bi, Y; D'Alonzo, R; Ruh, MF | 1 |
| Donath, J; Nishino, Y | 1 |
| Assikis, VJ; Bilimoria, MM; Chatterton, R; Cisneros, A; Dragan, YP; England, GM; Jordan, VC; MacGregor, JI; Muenzner, HD; O'Regan, RM; Piette, M; Pitot, HC | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, J; Yue, W | 1 |
| Huynh, H; Pollak, M | 1 |
| Musgrove, EA; Prall, OW; Sutherland, RL; Wilcken, NR | 1 |
| Akinaga, S; Kurebayashi, J; Kurosumi, M; Nakata, T; Otsuki, T; Sonoo, H; Yamamoto, S | 1 |
| Aldaghlas, TA; Holleran, AL; Kelleher, JK; Lindenthal, B | 1 |
| Khan, SA; Peters, GA | 1 |
| Resnick, EM; Schreihofer, DA; Shupnik, MA; Soh, AY | 1 |
| DeGregorio, MW | 1 |
| DeGeorge, GL; Gadd, SL; Harnagea-Theophilus, E; Knight-Trent, AH; Miller, MR | 1 |
| Williams, GM | 1 |
| Bolego, C; Maggi, A; Puglisi, L; Santagati, S; Vegeto, E; Zancan, V | 1 |
| Andersen, HR; Andersson, AM; Arnold, SF; Autrup, H; Barfoed, M; Beresford, NA; Bjerregaard, P; Christiansen, LB; Gissel, B; Hummel, R; Jørgensen, EB; Korsgaard, B; Le Guevel, R; Leffers, H; McLachlan, J; Møller, A; Nielsen, JB; Olea, N; Oles-Karasko, A; Pakdel, F; Pedersen, KL; Perez, P; Skakkeboek, NE; Sonnenschein, C; Soto, AM | 1 |
| Ellmén, J; Kaukonen, M; Mäenpää, J; Pasanen, T | 1 |
| Ehlers, EM; Schubert, C | 1 |
| Kuiper, GG; Pols, HA; Van Den Bemd, GJ; Van Leeuwen, JP | 1 |
| Leung, SW; Man, RY; Teoh, H | 1 |
| Clarke, R; Lavigne, MC; Ramwell, PW | 1 |
| Bae, SW; Jeong, JK; Jo, I; Kim, HP; Lee, HK; Lee, JY | 1 |
| Bach, LA; DeLuise, M; Hu, XF; Leeding, KS; Parisot, JP; Zalcberg, JR | 1 |
| Evans, A; Healy, D; Vollenhoven, B | 1 |
| Arriero, MD; Casado, S; de Frutos, T; Díaz-Recasens, J; Farré, J; García, R; García-Durán, M; García-Gálvez, G; González-Fernández, F; Jiménez, A; López-Farré, A; Montón, M; Rico, L; Sánchez de Miguel, L | 1 |
| Christensen, DJ; Fowlkes, DM; McDonnell, DP; Nagel, SC; Norris, JD; Paige, LA; Wijayaratne, AL | 1 |
| Brodie, A; Gimbel, M; Grigoryev, D; Liu, Y; Long, BJ; Lu, Q | 1 |
| Egeblad, M; Jäättelä, M; Larsen, SS; Lykkesfeldt, AE | 1 |
| Jordan, VC | 1 |
| Diel, P; Michna, H; Smolnikar, K | 1 |
| Enmark, E; Gustafsson, JA; Kuiper, G; Nguyen, T; Safe, S; Saville, B; Wang, F; Wormke, M | 1 |
| Birchmeier, W; Lichtner, RB; Parczyk, K; Schneider, MR | 1 |
| Dudley, MW; Khan, S; Sheeler, CQ; Wang, H | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q | 1 |
| Archer, C; Assersohn, L; Boeddinghaus, I; Chang, J; Dowsett, M; Ellis, PA; Gregory, RK; Johnston, SR; Mainwaring, P; Powles, TJ; Salter, J; Smith, IE | 1 |
| Leung, SW; Man, RY; Quan, A; Teoh, H | 1 |
| Graham, JD; Hodges, YK; Horwitz, KB; Horwitz, LD; Tung, L; Yan, XD | 1 |
| Allegretto, EA; Mancini, MA; Mancini, MG; Patel, K; Smith, CL; Stenoien, DL | 1 |
| Burakov, D; Cheskis, BJ; Freedman, LP; Rachez, C; Wong, CW | 1 |
| Ho, SM; LaSpina, M; Lau, KM; Long, J | 1 |
| Baker, VL; Jaffe, RB; Leitman, D | 1 |
| Fukushima, K; Kanda, Y; Kuroki, Y; Mizuno, K; Watanabe, Y | 1 |
| Pento, JT; Rajah, TT | 1 |
| Bentrem, DJ; Jordan, VC; Liu, H; MacGregor Schafer, J; Zapf, JW | 1 |
| Nomura, Y | 1 |
| Fisher, PW; Gowen, M; Nadeau, DP; Nuttall, ME; Stroup, GB; Suva, LJ | 1 |
| Conrad, SE; Varma, H | 1 |
| Collins, P; Figtree, GA; Webb, CM | 1 |
| Dorsa, DM; Shapiro, RA; Xu, C | 1 |
| Brockdorff, BL; Lykkesfeldt, AE; Reiter, BE; Skouv, J | 1 |
| Terakawa, N | 1 |
| Diel, P; Löffek, S; Michna, H; Schulz, T; Smolnikar, K | 1 |
| Alpini, G; Alvaro, D; Baiocchi, L; Folli, F; Franchitto, A; Gaudio, E; Glaser, SS; Le Sage, G; Onori, P; Perego, L; Svegliata Baroni, G | 1 |
| Baxter, JD; Chang, CY; Day, RN; Liu, W; McDonnell, DP; Nordeen, SK; Schaufele, F; Wan, Y | 1 |
| Dutertre, M; Mancini, MA; Mancini, MG; O'Malley, BW; Patel, K; Smith, CL; Stenoien, DL | 1 |
| De Los Reyes, A; England, G; Jordan, VC; Lee, ES; O'Regan, RM; Schafer, JM; Yao, K | 1 |
| Kim, J; Nardulli, AM; Petz, LN; Potthoff, SJ; Wood, JR; Ziegler, YS | 1 |
| Klinga, K; Mayer, D; Morfin, R; Schmitt, M; Schnarr, B | 1 |
| Mokbel, K | 1 |
| Gornbein, J; Koeffler, HP; Miller, CW; Nakachi, K; O'Kelly, J; Said, JW; Sakashita, A; Xie, D | 1 |
| Bernardini, R; Bianchi, A; Cantarella, G; Chiarenza, A; Lazarovici, P; Lempereur, L | 1 |
| Dorsa, DM; Robinson, S; Shapiro, RA; Wade, CB | 1 |
| Chan, TW; Huynh, H; Lim, KB; Ng, CY; Ong, CK; Ong, CS; Tran, E; Tuyen Nguyen, TT | 1 |
| Honjo, H; Hosoda, T; Nakajima, H | 1 |
| De Arment, R; Demers, L; Fischer, S; Franks, M; Griffith, J; Leiby, B; Manni, A; Mauger, D; Verderame, M; Washington, S | 1 |
| Tominaga, T | 1 |
| Kiss, AL; Müllner, N; Turi, A | 1 |
| Chan, TW; Huynh, H; Pollak, M | 1 |
| Gaido, K; Pallaroni, L; Safe, S; Stoner, M; Yoon, K | 1 |
| Anderson, E; Bundred, NJ; Dixon, M; Dowsett, M; Fox, JN; Gee, JM; Morris, C; Nicholson, RI; Rayter, Z; Robertson, JF; Wakeling, AE; Webster, A | 1 |
| Annable, T; Collins, KI; Frost, P; Greenberger, LM; Komm, BS; Lyttle, CR; Miller, CP; Satyaswaroop, PG; Zhang, Y | 1 |
| Parker, MG; Soulez, M | 1 |
| Bland, KI; Filardo, EJ; Frackelton, AR; Quinn, JA | 1 |
| Cheung, KL; Robertson, JF | 1 |
| Bogart, DF; Li, P; Lupu, R; Mehmi, I; Tsai, MS | 1 |
| Jeng, MH; Masamura, S; McPherson, R; Santen, R; Santner, S; Shim, WS; Song, R; Wang, JP; Yue, W | 1 |
| Robertson, JF | 1 |
| Aguilar, E; Barreiro, ML; Gonzalez, LC; Pinilla, L; Tena-Sempere, M | 1 |
| Baxter, JD; Carroll, DC; Chang, CY; Clegg, NJ; Day, RN; McDonnell, DP; Scanlan, TS; Schaufele, F; Weatherman, RV | 1 |
| Baum, M | 1 |
| O'Shaughnessy, J; Parker, LM; Torosian, M; Vogel, C | 1 |
| Gee, JM; Nicholson, RI; Wakeling, AE | 1 |
| Badia, E; Duchesne, MJ; Freiss, G; Pons, M; Rabenoelina, F; Semlali, A | 1 |
| Baylink, DJ; Cheng, MZ; Lanyon, LE; Mohan, S; Pitsillides, AA; Rawlinson, SC; Zaman, G | 1 |
| Bennetau-Pelissero, C; Kaushik, SJ; Latonnelle, K; Le Menn, F | 1 |
| Boyan, BD; Dean, DD; Guinee, T; Schwartz, Z; Sylvia, VL | 1 |
| Duckles, SP; Krause, DN; McNeill, AM; Stanczyk, FZ; Zhang, C | 1 |
| Arita, J; Kawashima, K; Yin, P | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jones, HE; Knowlden, JM; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| Brodie, AM; Jelovac, D; Long, BJ; Thiantanawat, A | 1 |
| Ali, S; Bates, GJ; Chen, D; Coombes, RC; Egly, JM; Epstein, RJ; Fuller-Pace, FV; Pace, PE; Sarwar, N; Taylor, J; Thirunuvakkarasu, V; Washbrook, E | 1 |
| Afzal, I; Cunningham, P; Naftalin, RJ | 1 |
| Chan, S | 1 |
| Alpini, G; Alvaro, D; Attili, AF; Folli, F; Franchitto, A; Gaudio, E; Mancino, MG; Metalli, VD; Onori, P; Svegliati-Baroni, G | 1 |
| Dick, GM | 1 |
| Huang, HJ; McDonnell, DP; Norris, JD | 1 |
| Jordan, VC; Lee, ES; Takei, H | 1 |
| Obrero, M; Shapiro, DJ; Yu, DV | 1 |
| Ali, S; Chan, CM; Dowsett, M; Johnston, SR; Martin, LA | 1 |
| Bergman, A; Brouwer, A; Giesy, JP; Lemmen, JG; Letcher, RJ; van den Berg, M; van der Burg, B | 1 |
| Calligé, M; Chailleux, C; Giamarchi, C; Richard-Foy, H; Rochaix, P; Trouche, D | 1 |
| Howell, A | 1 |
| Gyun Jung, C; Hayashi, Y; Hida, H; Kodama, Y; Kohri, K; Mogami, M; Nishino, H | 1 |
| Frye, CA; Rhodes, ME | 1 |
| Kushner, PJ; Nguyen, P; Webb, P | 1 |
| Jordan, VC; Liu, H; Pearce, ST | 1 |
| Kim, K; Safe, S; Saville, B; Thu, N | 1 |
| Bianco, NR; Montano, MM; Perry, G; Smith, MA; Templeton, DJ | 1 |
| Chaban, VV; Ennes, HS; Mayer, EA; Micevych, PE | 1 |
| Briand, P; Jensen, J; Kitlen, JW; Labrie, F; Lykkesfeldt, AE | 1 |
| Abrams, J; Deighton-Collins, S; Koide, A; Koide, S; Martinez, A; Schwartz, JA; Skafar, DF; Zhao, C | 1 |
| Chaouat, M; Forgez, P; Gompel, A; Jacob, D; Perrot, JY; Rostène, W; Somaï, S | 1 |
| Cui, X; Honda, H; Inoue, H; Inoue, S; Ito, S; Itonaga, M; Lu, G; Muramatsu, M; Okamura, Y; Shimizu, I; Shono, M | 1 |
| Becker, JB; Jackson, LR; Xiao, L | 1 |
| Eriksson, B; Eriksson, H; Muravitskaya, N; Sahlin, L; Stygar, D | 1 |
| Kelley, KM; Ratnam, M; Rowan, BG | 1 |
| Parker, LM; Piccart, M; Pritchard, KI | 1 |
| Gougelet, A; Maillard, S; Marsaud, V; Renoir, JM | 1 |
| Harrison, MP; Holcombe, C; Kohlhardt, SR; Odling-Smee, W; Robertson, JF | 1 |
| Carroll, JS; Daly, RJ; Lynch, DK; Musgrove, EA; Renoir, JM; Sarcevic, B; Sutherland, RL; Swarbrick, A | 1 |
| Endemann, G; Faridi, J; Roth, RA; Wang, L | 1 |
| Klinge, CM; Risinger, KE; Thomas, PB | 1 |
| Hultcrantz, M; Sahlin, L; Simonoska, R; Stenberg, AE; Stygar, D | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jordan, N; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| Chang, CC; Huang, BY; Lee, CL; Tsai, ML | 1 |
| Hortobagyi, GN | 1 |
| Calderone, A; Mader, S; Mercier, I | 1 |
| Amant, F; Joubert, A; Lindeque, BG; Lottering, ML; Thaver, V; Vergote, I | 1 |
| Chen, B; Gajdos, C; Jordan, VC; Liu, H; Osipo, C | 1 |
| Edwards, EA; Fulthorpe, R; Liss, SN; Wang, DY | 1 |
| Cho, S; Kim, B; Kim, J; Kwon, S; Lee, S; Park, S; Won, KJ | 1 |
| Brockdorff, BL; Heiberg, I; Lykkesfeldt, AE | 1 |
| Chiesara, E; Ferraris, M; Frigerio, S; Fumagalli, R; Marabini, L; Radice, S | 1 |
| Curran, MP; McKeage, K; Plosker, GL | 1 |
| Horwitz, KB; Hyder, SM; Richer, J; Wu, J | 1 |
| Colomer, R; Lupu, R; Menendez, JA | 1 |
| Christensen, GL; Christensen, IJ; Fog, CK; Jepsen, JS; Lykkesfeldt, AE | 1 |
| Aihara, H; Hong, T; Ikehara, T; Ito, T; Kim, MY; Kraus, WL; Muramatsu, M; Nakagawa, T; Pan, W; Takebe, M; Yasui, K | 1 |
| Buck, MB; Knabbe, C; Pfizenmaier, K | 1 |
| Barrón-González, A; Castro Romero, I | 1 |
| Koeberle, D; Perey, L; Thuerlimann, B | 1 |
| Birnbaum, D; Cohen, PA; Danis, E; Duchesne, MJ; Magnino, F; Nguyen, C; Pinloche, S; Pons, M; Theillet, C; Vendrell, JA | 1 |
| Balaguer, P; Bonnet, S; Cavaillès, V; Duong, V; Escande, A; Margueron, R; Vignon, F | 1 |
| Abram, P; Bajetta, E; Dimery, I; Elledge, R; Howell, A; Lichinitser, MR; Morris, C; Osborne, CK; Robertson, JF; Watanabe, T; Webster, A | 1 |
| Chang, T; Hayes, EC; Mitra, SW; Peekhaus, NT; Rohrer, SP; Schaeffer, JM; Wilkinson, HA | 1 |
| Balkenende, A; Floore, A; Griekspoor, A; Jalink, K; Janssen, L; Michalides, R; Neefjes, J; van't Veer, L; Velds, A; Verwoerd, D | 1 |
| Christensen, GL; Freddie, CT; Lykkesfeldt, AE | 1 |
| Ehrlich, ME; Guinea, B; Olm, V; Sheffield, R; Sommer, J; Stroppolo, A; Tian, C | 1 |
| Baker, AE; Brautigam, VM; Watters, JJ | 1 |
| Gradishar, WJ | 1 |
| Barrett, JT; Delk, JN; Gaddy, VT; Kallab, AM; Porter, AG; Schoenlein, PV | 1 |
| Tobias, JS | 1 |
| Cheng, JS; Ezaki, K; Kawashima, H; Kurisu, T; Nakatani, T; Sugita, S; Tanaka, T | 1 |
| Angle, M; Florian, M; Lu, Y; Magder, S | 1 |
| Hardin, C; Jackson, T; Lefleur, B; Pommier, R; Toth-Fejel, S | 1 |
| Body, JJ; Chaboteaux, C; Dumon, JC; Journe, F; Laurent, G; Leclercq, G | 1 |
| Cunningham, KA; Koldzic-Zivanovic, N; Seitz, PK; Thomas, ML; Watson, CS | 1 |
| Adams, M; Chen, J; Chensue, SW; Huo, J; Mo, R; Murphy, BA; Murphy, HS; Richardson, BC; Sun, Q; Yung, R | 1 |
| Häyry, P; Kangas, L; Luoto, NM; Savolainen-Peltonen, H | 1 |
| Allan, G; D'Andrea, MR; Guo, JZ; Haynes-Johnson, D; Lawrence, D; Lundeen, S; Pacia, E; Tynan, S | 1 |
| Lynn, J | 1 |
| McDonald, D; Morrissey, C; O'Sullivan, J; Schneider, MR; Tenniswood, MP; Vollmer, G; Wünsche, W; Zierau, O | 1 |
| Bhatnagar, S; Blankenship, KA; Brey, DM; Keynton, RS; Klinge, CM; Noisin, EL; Risinger, KE; Sumanasekera, WK; Zhao, L | 1 |
| Harwood, KV | 1 |
| Cherr, GN; Roepke, TA; Snyder, MJ | 1 |
| Aoyagi, Y; Asao, T; Buzdar, AU; Hashimoto, A; Sato, K; Shibata, J; Terada, T; Wierzba, K; Yamamoto, Y; Yano, S; Yonekura, K | 1 |
| Hung, H | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Deroo, BJ; Hewitt, SC; Korach, KS | 1 |
| Arreguin-Arevalo, JA; Nett, TM | 1 |
| Jakesz, R | 1 |
| Funata, N; Hayashi, S; Hirose, M; Horiguchi, S; Itoh, A; Kawakami, M; Saji, S; Schreiber, SL; Toi, M; Yoshida, M; Yoshida, N | 1 |
| Fukuyama, T; Hashiramoto, A; Kitagawa, A; Kurosaka, M; Mitani, M; Miura, Y; Saura, R; Shiozawa, S; Yoshiya, S | 1 |
| Berndtson, AK; Nephew, KP; Reed, CA | 1 |
| Jones, SE; Pippen, J | 1 |
| Bagetta, G; Corasaniti, MT; Maiuolo, J; Navarra, M; Rotiroti, D; Russo, R | 1 |
| Dodwell, D; Vergote, I | 1 |
| Bonz, AW; Ertl, G; Fritzemeier, KH; Hegele-Hartung, C; Hu, K; Jazbutyte, V; Muck, J; Nahrendorf, M; Neyses, L; Nordbeck, P; Pelzer, T; Segerer, S | 1 |
| Huuskonen, J; Nuutinen, T; Ojala, J; Salminen, A; Suuronen, T; Thornell, A | 1 |
| Ponzone, R; Sismondi, P | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Macedo, L | 1 |
| Brodie, A; Goloubeva, O; Jelovac, D; Long, B; Macedo, L; Sabnis, G | 1 |
| Gorbunova, VA; Howell, A; Lichinitser, MR; Pienkowski, T; Robertson, JF; Watanabe, T | 1 |
| Aguilar, R; Bellido, C; Garrido-Gracia, JC; Sánchez-Criado, JE | 1 |
| Navarrete, E; Perusquía, M | 1 |
| Nishio, I; Tsuda, K | 1 |
| Izewska, P; Jankevics, H; Leufgen, K; Pick, H; Prummer, M; Vogel, H | 1 |
| Fischer, PA; Peekhaus, NT; Schneeweis, JE; Shi, X; Strulovici, B; Zheng, W | 1 |
| Castiglione-Gertsch, M; Dellapasqua, S | 1 |
| Blok, LJ; Burger, CW; Gielen, SC; Hanifi-Moghaddam, P; Kühne, LC | 1 |
| Dahllund, J; Härkönen, P; Heiskanen, KM; Kallio, A; Zheng, A | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Abram, P; Vergote, I | 1 |
| Raina, V | 1 |
| Diel, P; Hertrampf, T; Laudenbach-Leschowsky, U; Schmidt, S; Seibel, J | 1 |
| Ariazi, EA; Glidewell-Kenney, C; Ishikawa, T; Jameson, JL; Lee, EJ; Pillai, S; Weiss, J | 1 |
| Jazieh, AR; Nahleh, ZA | 1 |
| Chan, CM; Dowsett, M; Farmer, I; Johnston, SR; Kimberley, C; Martin, LA; Pancholi, S | 1 |
| Haldar, C; Ortmann, O; Treeck, O | 1 |
| Custódio, J; Moreira, PI; Moreno, A; Oliveira, CR; Santos, MS | 1 |
| Body, JJ; Chaboteaux, C; Duvillier, H; Journe, F; Laurent, G; Magne, N | 1 |
| Kilker, RL; Planas-Silva, MD; Waltz, PK | 1 |
| Dodwell, D; Johnston, S; Wardley, A | 1 |
| Darbre, PD; Pugazhendhi, D; Sadler, AJ; Shaw, LE | 1 |
| Anderson, E; Armer, T; Baildam, AD; Bramley, M; Clarke, RB; Evans, DG; Howell, A | 1 |
| Aguilar, R; Alonso, R; Bellido, C; Garrido-Gracia, JC; Sánchez-Criado, JE | 1 |
| Cheung, KL; Owers, R; Robertson, JF | 1 |
| Clarke, R; Dai, P; Lou, MA; Lu, JF; Nazarov, V; Wong, LJ | 1 |
| Ayala, GE; Hsieh, JT; Jian, W; Kim, IY; Lerner, SP; Shen, SS; Smith, CL; Sonpavde, G; Younes, M; Yu, J | 1 |
| Frye, CA; Harney, JP; Meade, JR; Rhodes, ME; Walf, AA | 1 |
| Castillo, C; Castillo, EF; Ceballos, G; López, J; Medina, R; Méndez, E; Rodríguez, D; Villanueva, C | 1 |
| Espelund, U; Jepsen, JS; Juncker-Jensen, A; Lykkesfeldt, AE; Ralfkiaer, U; Worm, J | 1 |
| Dodwell, D; Pippen, J | 1 |
| Kofoed, EM; Li, L; Padron, A; Schaufele, F | 1 |
| Ikeda, T; Matsuki, N; Yamada, MK | 1 |
| Cochrum, RK; Klinge, CM; Riggs, KA; Watts, MB; Wickramasinghe, NS | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Brodie, A; Jelovac, D; Sabnis, G | 1 |
| Hardel, V; Jaehde, U; Roth, S; Schaad, S | 1 |
| Cameron, DA; Clarke, R; Kuske, B; Langdon, SP; Macleod, KG; Miller, WR; Moore, K; Naughton, C | 1 |
| Borowiec, AS; Coiret, G; Mariot, P; Matifat, F; Ouadid-Ahidouch, H | 1 |
| Bahr, SJ; Pento, JT; Rajah, TT; Tong, GM; Zang, XP | 1 |
| Fritah, A; Redeuilh, G; Sabbah, M | 1 |
| Abbosh, PH; Chen, L; Cheng, AS; Fan, M; Hartman-Frey, C; Huang, TH; Li, L; Nephew, KP; Oyer, SL; Paik, H; Salisbury, JD; Yan, PS | 1 |
| Asselin, E; Bélanger, G; Boucher, V; Déry, MC; Leblanc, K; Parent, S; Sexton, E | 1 |
| Bertucci, A; Cheng, D; Jordan, VC; Liu, H; Meeke, K; Osipo, C; Weichel, A | 1 |
| Lykkesfeldt, AE; Peters, RH; Rasmussen, LM; Stenvang, J; Zaveri, NT | 1 |
| Aschner, M; Feustel, PJ; Kimelberg, HK; Milatovic, D; Zhang, Y | 1 |
| Han, SY; Hong, JT; Kim, DJ; Kim, TM; Kim, TS; Lee, JW; Lee, YK; Lee, YM; Nam, SY; Seong, MJ; Yun, YW | 1 |
| Altobelli, G; Biglia, N; Cicatiello, L; Cimino, D; De Bortoli, M; Friard, O; Fuso, L; Ponzone, R; Ravo, M; Scafoglio, C; Sismondi, P; Weisz, A | 1 |
| Helmstaedter, V; Lage, H; Moreau, C; Nelson, K | 1 |
| Härkönen, PL; Hentunen, TA; Kangas, L; Michael, H; Väänänen, HK | 1 |
| Bracke, M; Comhaire, F; De Wever, O; Dhooge, W; Eertmans, F; Kaufman, JM | 1 |
| Griekspoor, A; Michalides, R; Neefjes, J; Rondaij, M; Verwoerd, D; Zwart, W | 1 |
| Alonso, R; Diaz, M; Gonzalez, M; Marin, R; Morales, A | 1 |
| Behrens, D; Fichtner, I; Gill, JH | 1 |
| Fichtner, I; Frogne, T; Issinger, OG; Lykkesfeldt, AE; Stenvang, J; Yde, CW | 1 |
| Leaños-Castañeda, O; Van Der Kraak, G | 1 |
| Cheng, J; Shapiro, DJ; Yu, DV; Zhou, JH | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| Eucker, J; Kühnl, A; Possinger, K | 1 |
| Brochu, M; Scott, PA; St-Louis, J; Tremblay, A | 1 |
| Carcel-Trullols, J; Evans, TT; Higuchi, M; Mizumachi, T; Naito, A; Xie, CH | 1 |
| Jankevics, H; Pick, H; Vogel, H | 1 |
| Adamson, AD; Davis, JR; Friedrichsen, S; Harper, CV; Mullins, JJ; Semprini, S; White, MR | 1 |
| Blackmore, PF; Chatterjie, N; Dobrydneva, Y; Fichandler, CE; Fitzgerald, MC; Morrell, MM; Trebley, JP; Weatherman, RV | 1 |
| Bayliss, J; Diehl, K; El-Ashry, D; Hilger, A; Vishnu, P | 1 |
| Dixon, JM; Faratian, D; Macaskill, EJ; Renshaw, L; Thomas, JS; White, S; Young, OE | 1 |
| Kaufmann, M | 1 |
| Bielawski, T; Miltyk, W; Palka, J; Surazynski, A; Wolczynski, S; Zbucka, M | 1 |
| Body, JJ; Journé, F; Laurent, G; Leclercq, G | 1 |
| Brentani, MM; Nagai, MA | 1 |
| Chen, DB; Chow, J; Contreras, C; Dong, H; Dong, X; Ko, KH; Smith, A; Tuo, B; Zhang, HH | 1 |
| Buijs, C; de Vries, EG; Mourits, MJ; Willemse, PH | 1 |
| Kabil, A; Kortenkamp, A; Silva, E | 1 |
| Chen, S; Lui, K; Mori, T; Tamura, T; Zhou, D | 1 |
| Bernoulli, J; Lammintausta, R; Santti, R; Yatkin, E | 1 |
| Ben-Yosef, R; Greenberg, J; Inbar, M; Ron, IG; Safra, T; Sarid, D; Yaal-Hahoshen, N | 1 |
| Creighton, CJ; Hilsenbeck, SG; Huang, S; Malorni, L; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Tsimelzon, A | 1 |
| Banerjee, S; Dowsett, M; Drury, S; Hilmi, C; Johnston, S; Leary, A; Lykkesfeldt, AE; Martin, LA; Pancholi, S | 1 |
| Pang, Y; Thomas, P | 1 |
| Bieche, I; Cohen, PA; Dumontet, C; Ghayad, SE; Lidereau, R; Spyratos, F; Treilleux, I; Vendrell, JA | 1 |
| Cheng, HH; Cheng, JS; Fang, YC; Huang, CC; Jan, CR; Liao, WC; Lin, KL; Tsai, JY | 1 |
| Aktary, Z; Andrews, DW; Hu, X; Lam, L; Pasdar, M | 1 |
| Aiyar, S; Fan, P; Kim, TH; Li, Y; Santen, RJ; Wang, JP; Yue, W | 1 |
| Aleskandarany, M; Ball, G; Douglas Macmillan, R; Ellis, IO; Gee, JM; Green, AR; Habashy, HO; Nicholson, RI; Paish, EC; Powe, DG; Rakha, EA; Staka, CM | 1 |
| Dougherty, SM; Klinge, CM; Li, Y; Manavalan, TT; Riggs, KA; Wickramasinghe, NS | 1 |
| Büssemaker, E; Hagedorn, C; Hausberg, M; Hillebrand, U; Kliche, K; Lang, D; Oberleithner, H; Pavenstädt, H; Reuter, S; Stock, CM; Telgmann, RG | 1 |
| Janssen-Megens, EM; Span, PN; Stunnenberg, HG; Sweep, FC; van Driel, MA; van Heeringen, SJ; Welboren, WJ | 1 |
| Hatae, J; Honda, A; Inoue, R; Lin, H; Takami, N | 1 |
| Casazza, G; Georgoulias, V; Mauri, D; Mavroudis, D; Polyzos, NP; Valachis, A | 1 |
| Greene, AL; Kundel, DW; Kundel, KD; Regal, RR; Rose-Hellekant, TA; Skildum, AJ; Zhdankin, O | 1 |
| Dumontet, C; Ferlini, C; Matera, EL; Saussede-Aim, J | 1 |
| Lianidou, E; Moutsatsou, P; Papoutsi, Z; Strati, A | 1 |
| Cheng, P; Hershberger, PA; Kanterewicz, B; Liu, Y; McCarty, KS; Nichols, M | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P | 1 |
| Dougherty, SM; Ivanova, MM; Klinge, CM; Mazhawidza, W | 1 |
| Collins, SC; Coser, KR; Isselbacher, KJ; Mahoney, CJ; Melas, A; Ramaswamy, S; Rosenthal, NF; Shioda, K; Shioda, T; Smith, SL; Wittner, BS | 1 |
| Goerse, R; Haselberger, M; Konwisorz, A; Ortmann, O; Springwald, A; Treeck, O | 1 |
| Baumann, CK; Castiglione-Gertsch, M | 1 |
| Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P | 1 |
| El Gebeily, G; Fiset, C | 1 |
| Fan, M; Long, X; Nephew, KP | 1 |
| Badve, S; Bhat-Nakshatri, P; McCune, K; Nakshatri, H; Nephew, KP; Thorat, MA | 1 |
| Byrne, C; Donley, C; Hirst, DG; Jithesh, PV; McCarthy, HO; McKeen, HD; O'Rourke, M; Robson, T; Swanton, C; Valentine, A; Yakkundi, A | 1 |
| Buck, MB; Joffroy, CM; Knabbe, C; Pfizenmaier, K; Popp, SL; Stope, MB | 1 |
| Childs, EW; Hunter, FA; Smythe, WR; Tharakan, B | 1 |
| Ashworth, A; Geyer, F; Gillett, C; Grigoriadis, A; Iorns, E; Lambros, M; Lopez-Garcia, MA; Mackay, A; Marchio, C; Natrajan, R; Pearson, A; Reis-Filho, JS; Sharpe, R; Turner, N; Tutt, A | 1 |
| Birnbaumer, L; Li, Y; Teng, CT | 1 |
| Kawabata, L; Louie, MC; McClellan, A; Siewit, C | 1 |
| Barnfather, P; Barrett-Lee, P; Bramble, P; Christensen, J; Hayes, E; Hiscox, S; Nicholson, RI | 1 |
| Brandi, ML; Cavalli, L; Cavalli, T; Colli, E; Galli, G; Gozzini, A; Marini, F; Martineti, V; Nesi, G; Paglierani, M; Sorace, S; Tanini, A; Tognarini, I; Tonelli, F; Zonefrati, R | 1 |
| Goldstein, RE; Klinge, CM; Kumar, A | 1 |
| Brown, JQ; Lem, S; McMahon, CM; Millon, SR; Ostrander, JH; Ramanujam, N; Seewaldt, VL | 1 |
| Bald, L; Fayadat-Dilman, L; Grein, J; Hudak, S; Janatpour, MJ; Sathe, M; Vanderlaag, KE | 1 |
| Bystricky, K; Dalvai, M | 1 |
| Anaganti, S; Fernandez-Cuesta, L; Hainaut, P; Olivier, M | 1 |
| Doihara, H; Fujita, T; Hara, F; Ikeda, H; Miyoshi, S; Nogami, T; Shien, T; Soh, J; Taira, N; Toyooka, S; Yamamoto, H | 1 |
| Dye, WW; Elias, A; Finlayson, C; Haughian, JM; Horwitz, KB; Kabos, P; Sartorius, CA; Wang, X | 1 |
| Alvarez, EA; Azzam, D; Chen, Y; Guggisberg, N; Hennessy, BT; Jordà, M; Ju, Z; Slingerland, JM; Wander, SA | 1 |
| Babus, JK; Bae, I; Jones, LP; Kang, HJ; Kim, HJ; Kwon, SY; Sampson, A; Wang, A; Yi, YW | 1 |
| Galea, GL; Lanyon, LE; Price, JS; Sugiyama, T | 1 |
| Blackmore, JK; Foster, EA; Karmakar, S; Smith, CL | 1 |
| Bystricky, K; Caze-Subra, S; Kocanova, S; Mazaheri, M | 1 |
| Grandison, PM; Kang, J; Kannan, N; Kong, X; Liu, DX; Liu, ET; Lobie, PE; Mertani, HC; Miller, LD; Mohankumar, KM; Perry, JK; Tang, J; Zhu, T | 1 |
| Ashcroft, FJ; Jones, ED; Mancini, MA; Mikic, I; Newberg, JY | 1 |
| Aguirre-Ghiso, J; Bahadur, U; Germain, D; Ishii, Y; Papa, L; Shioda, T; Waxman, S; Yue, Z | 1 |
| Coombes, RC; Januszewski, A; Palmieri, C; Stanway, S | 1 |
| Gandini, C; Lutman, FR; Masci, G; Pedrazzoli, P; Santoro, A; Torrisi, R; Zuradelli, M | 1 |
| Fitts, JM; Klein, RM; Powers, CA | 1 |
| Ao, A; López, JA; Lu, J; Morrison, BJ; Reynolds, BA; Wang, H | 1 |
| de Bont, H; Meerman, J; Moerkens, M; Price, L; Ramaiahgari, S; van de Water, B; Zhang, Y | 1 |
| Ellis, GK; Gralow, JR; Krohn, KA; Kurland, BF; Lawton, TJ; Linden, HM; Link, JM; Livingston, RB; Mankoff, DA; Peterson, LM; Petra, PH; Schubert, EK; Specht, JM | 1 |
| Knowles, MA; Speirs, V; Tomlinson, DC | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Amano, J; Ito, K; Ito, T; Izumi, H; Kamijo, S; Kohno, K | 1 |
| Ceron, CS; Desta, Z; Flockhart, DA; Montenegro, MF; Salgado, MC; Tanus-Santos, JE | 1 |
| Arteaga, CL; Balko, JM; Buck, E; Fox, EM; González-Angulo, AM; Kuba, MG; Liu, S; Manning, HC; Miller, TW; Mills, GB; Sánchez, V; Shyr, Y; Smith, RA; Ye, F | 1 |
| de Cremoux, P | 1 |
| Flomenberg, N; Goldberg, A; Howell, A; Ko, YH; Lin, Z; Lisanti, MP; Martinez-Outschoorn, UE; Pavlides, S; Pestell, RG; Sotgia, F; Wang, C | 1 |
| Brodie, A; Carboni, JM; Finckenstein, FG; Gottardis, MM; Greer, A; Haluska, P; Harrington, SC; Hou, X; Huang, F; Macedo, LF; Reeves, KA | 1 |
| Oliver, J; Roca, P; Sastre-Serra, J; Valle, A | 1 |
| Hojo, Y; Kawato, S; Kimoto, T; Ogiue-Ikeda, M; Shimohigashi, Y; Tanabe, N; Yoshino, H | 1 |
| DeMichele, A; Gogineni, K | 1 |
| Emdal, KB; Guerra, B; Lykkesfeldt, AE; Yde, CW | 1 |
| Kazmin, D; McDonnell, DP; Wardell, SE | 1 |
| Badia, E; Balaguer, P; Busson, M; Cavailles, V; Docquier, A; Lapierre, M; Pujol, P | 1 |
| Belleau, P; Calvo, E; Labrie, F; Luu-The, V; Martel, C | 1 |
| Harada, A; Li, C; Oh, Y | 1 |
| Aapro, M; Bischoff, J; Brain, E; Cardoso, F; Lück, HJ; Tanner, M; Tjan-Heijnen, VC; Zotano, ÁG | 1 |
| Aboagye, EO; Ali, S; Lake, MC; Nguyen, QD | 1 |
| Christensen, IJ; Larsen, MS; Lykkesfeldt, AE; Yde, CW | 1 |
| Hoffman, KL; Lerner, SP; Smith, CL | 1 |
| Hoffmann, F; Kloas, W | 1 |
| Brennan, DJ; Crown, JP; Gallagher, WM; Gremel, G; Higgins, DG; Jirström, K; Madden, SF; Martin, F; McGee, SF; McNally, S; Mulrane, L; O'Connor, DP | 1 |
| Avila, ME; Canchola, E; Cruz-Lemini, P; Lemini, C; Lemus, AE; Medina, M; Santillan, R | 1 |
| Arao, Y; Eddy, EM; Goulding, EH; Hamilton, KJ; Janardhan, KS; Korach, KS | 1 |
| Bernhardt, G; Buschauer, A; Keller, M; Lopuch, M; Memminger, M; Pop, N; von Angerer, E | 1 |
| Ball, GF; Balthazart, J; Christophe, VJ; Cornil, CA; Seredynski, AL | 1 |
| Howell, SJ | 1 |
| Ishitobi, M; Yagi, T; Yoshinami, T | 1 |
| Han, SJ; Liu, S; Smith, CL | 1 |
| Coser, KR; McSweeney, KR; Rivizzigno, D; Shioda, K; Shioda, T; Yeh, WL | 1 |
| Buck, MB; Fritz, P; Joffroy, C; Knabbe, C; Popp, SL; Stope, MB | 1 |
| Axelman, E; Brenner, B; Matan, M; Nadir, Y | 1 |
| Hima, L; Krishnan, HC; Priyanka, HP; Singh, RV; Thyagarajan, S | 1 |
| Giannopoulou, E; Kalofonos, HP; Koutras, AK; Lymperatou, D | 1 |
| Biswas, PK; Chakraborty, S; Levenson, AS | 1 |
| Mehta, A; Tripathy, D | 1 |
| Crippa, V; Messi, E; Piccolella, M; Poletti, A; Tetel, MJ | 1 |
| Harris, LN; Williams, N | 1 |
| Barrow, D; Dutkowski, CM; Gee, JM; Guichard, SM; Hutcheson, IR; Jordan, NJ; Mottram, HJ; Nicholson, RI | 1 |
| Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T | 1 |
| Bradner, J; Coarfa, C; Creighton, CJ; Feng, Q; Fu, X; He, B; Hilsenbeck, SG; Lanz, R; Mitsiades, CS; Mitsiades, N; Nardone, A; O'Malley, BW; Osborne, CK; Schiff, R; Shea, MJ; Song, Y; Wang, L; Zhang, Z | 1 |
| Clarke, PA; Clarke, R; Cook, KL; Cruz, MI; Soto-Pantoja, DR; Wärri, A; Zwart, A | 1 |
| Han, A; Kim, K; Lokich, E; Moore, RG; Romano, N; Singh, RK; Yano, N | 1 |
| Cheung, V; Clyne, CD; Knower, KC; Lazarus, KA; To, SQ | 1 |
| de Haan, LH; Ederveen, AG; Evers, NM; Groten, JP; Houtman, R; Melchers, D; Rietjens, IM; van den Berg, JH; Wang, S | 1 |
| Deng, H; Liu, LJ; Wang, ML; Wang, ZY; Yin, L; Zhang, XT | 1 |
| Andò, S; Barone, I; Brown, PH; Fuqua, SA; Iacopetta, D; O'Malley, BW; Rechoum, Y; Rovito, D; Weigel, NL | 1 |
| Anur, P; Biswal, NC; Contreras, A; Creighton, CJ; Davies, BR; Fu, X; Giuliano, M; Gray, JW; Guichard, SM; Gutierrez, C; Heiser, LM; Herrera, S; Hilsenbeck, SG; Joshi, A; Karlin, KL; Klinowska, T; Kumar, V; Lee, AV; Mills, GB; Morrison, G; Nanda, S; Nardone, A; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Smith, PD; Spellman, P; Wang, T; Westbrook, TF | 1 |
| Auclair, C; Bièche, I; Karam, M; Legay, C; Ricort, JM; Vacher, S | 1 |
| Ishida, A; Ishihara, Y; Itoh, K; Yamazaki, T | 1 |
| Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ | 1 |
| Bak, M; Duun-Henriksen, AK; Kirkegaard, T; Lykkesfeldt, AE; Lænkholm, AV; Pedersen, AM; Rasmussen, BB; Thomsen, MB; Thrane, S; Yde, CW | 1 |
| Brown, M; de Vries, EF; de Vries, EG; Glaudemans, AW; Hospers, GA; Kema, IP; Schröder, CP; van Faassen, M; van Kruchten, M; van Lanschot, MC | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Chrysikos, D; Dimopoulos, MA; Psaltopoulou, T; Sergentanis, TN; Zagouri, F | 1 |
| Kanomata, N; Kurebayashi, J; Moriya, T; Shimo, T; Yamashita, T | 1 |
| Ceballos-Reyes, G; Correa-Basurto, J; Fragoso-Vázquez, MJ; González-Juárez, DE; Maroun, RC; Martínez-Archundia, M; Méndez-Luna, D | 1 |
| Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW | 1 |
| Anzeneder, T; Benes, V; Burwinkel, B; Büttner, R; Deuschle, U; Heck, S; Lichter, P; Nicholson, RI; Sauter, G; Schlotter, M; Schneeweiss, A; Schroeter, P; Simon, R; Sinn, HP; Thewes, V; Zapatka, M | 1 |
| Anderson, L; Chen, D; Conklin, D; Dering, J; Desai, AJ; Finn, RS; Hurvitz, SA; Kalous, O; Kolarova, T; Linnartz, R; O'Brien, NA; Slamon, DJ | 1 |
| Iwase, H; Yamamoto, Y | 1 |
| Munster, PN; Park, J; Raha, P; Thomas, S; Thurn, KT | 1 |
| Di Leo, A; Guarducci, C; Hart, CD; Malorni, L; Migliaccio, I | 1 |
| Bak, M; Duun-Henriksen, AK; Kirkegaard, T; Laenkholm, AV; Larsen, SL; Lykkesfeldt, AE; Rasmussen, BB; Yde, CW | 1 |
| Alley, HM; Arndt, KT; Crowder, R; Dann, SG; Eisele, K; Ellis, MJ; Griffin, E; Lai, JP; Li, S; McDonnell, DP; Norris, JD; Primeau, T; Shao, J; VanArsdale, T; Wardell, SE | 1 |
| Hui, Y; Kurogi, K; Liu, MC; Luo, L; Sakakibara, Y; Suiko, M; Zhang, L; Zhou, C | 1 |
| Alnæs, GI; Bhanot, G; Bjørklund, SS; Børresen-Dale, AL; Ganesan, S; Kerrigan, J; Kristensen, VN; Kumar, S; Ming, Y; Naume, B; Sachidanandam, R; Seiler, M | 1 |
| Badia, E; Balaguer, P; Boulahtouf, A; Boulle, N; Cavaillès, V; Cristol, JP; Lauret, C; Morena, M | 1 |
| Cygankiewicz, AI; Jacenik, D; Krajewska, WM | 1 |
| Komm, BS; Pickar, JH | 1 |
| Acar, A; Alférez, DG; Andó, S; Brennan, K; Catalano, S; Chemi, F; Clarke, RB; Eyre, R; Farnie, G; Gandhi, A; Gee, J; Howell, A; Howell, SJ; Landberg, G; Marangoni, E; O'Brien, CS; Rydén, L; Santiago-Gómez, A; Sarmiento-Castro, A; Silva, A; Simões, BM; Sims, AH; Spence, K; Ucar, A; Yu, L | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Hua, Y; Keep, RF; Xi, G; Xie, Q | 1 |
| Kimura-Tsuchiya, R; Saji, S; Sasaki, E | 1 |
| Andrews, P; Carter, B; Gai, L; Kao, KR; Popadiuk, C; Tzenov, YR; Voisey, K; Whelan, K | 1 |
| Cazzulino, AS; Denny, CA; Martinez, R; Tomm, NK | 1 |
| Li, Y; Liu, Y; Liu, Z; Luo, A; Qu, X; Shi, W; Wang, S; Yu, X | 1 |
| Jiang, T; Li, C; Li, R; Qu, X; Shi, W; Wang, Y; Yu, X | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Bayliss, AL; Evans, NJ; Evans, PD; Reale, V | 1 |
| Hunt, KK; JavanMoghadam, S; Keyomarsi, K; Weihua, Z | 1 |
| Hirakawa, H; Ishida, T; Iwabuchi, E; Miki, Y; Ohuchi, N; Ono, K; Onodera, Y; Sasano, H; Suzuki, T | 1 |
| Dowsett, M; Guest, SK; Johnston, SR; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Ribas, R; Simigdala, N | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Basile, I; Gallud, A; Garcia, M; Gary-Bobo, M; Maynadier, M | 1 |
| Abrahamsson, A; Dabrosin, C; Mishra, AK | 1 |
| Demizu, Y; Fujisato, T; Inoue, H; Kato, M; Kurihara, M; Naito, M; Shoda, T | 1 |
| Blanco-Vaca, F; Dávalos, A; Escolà-Gil, JC; Fernández-Suárez, ME; Gómez-Coronado, D; Lasunción, MA; Martínez-Botas, J; Pastor, O | 1 |
| Asari, Y; Gohno, T; Hayashi, SI; Niwa, T; Shinagawa, Y; Suzuki, K; Takanobu, J; Yamaguchi, Y | 1 |
| Katzenellenbogen, BS; Piccart, M; Tryfonidis, K; Zardavas, D | 1 |
| Kim, JE; Livezey, M; Mao, C; Shapiro, DJ | 1 |
| Fukumitsu, C; Hattori, S; Ito, KI; Izumi, H; Kage, M; Kawahara, A; Kuwano, M; Murakami, Y; Ohdo, S; Ono, M; Shibata, T; Takahashi, R; Tanaka, M; Toh, U; Watari, K | 1 |
| Berger, K; Gligorov, J; Lewis, J; Maass, N; MacDougall, F; Marchetti, P; Montonen, J | 1 |
| Chokr, S; Le, D; Long, B; Long, N; Mana, A; Nguyen, L; Sinchak, K | 1 |
| Bruzzone, A; Copsel, S; Davio, C; Gargiulo, L; Lamb, C; Lanari, C; Lüthy, IA; Lydon, J; May, M; Rivero, EM | 1 |
| Brown, M; De Angelis, C; Jeselsohn, R; Schiff, R | 1 |
| Fredriksson, I; Frisell, J; Haglund, F; Hartman, J; Karthik, GM; Katchy, A; Linder, S; Lövrot, J; Ma, R; Rosin, G; Viberg, L; Williams, C; Zhang, X | 1 |
| Caramia, F; Joshi, S; Loi, S; Moodie, K; Savas, P; Van Geelen, C; Wein, L | 1 |
| Dalmau, E; Fernández-Morales, LA; Marín, M; Martinez Vila, C; Oliveres, H; Pardo, JC; Ribera, P; Segui, MA | 1 |
| Cai, X; Chai, R; Chen, J; Chen, L; Gong, X; Gu, J; Liu, Y; Mo, L; Thiery, JP; Wang, X; Wu, C; Wu, X; Yu, S; Yu, Z; Zhang, J; Zhu, T | 1 |
| Austin, ED; Brittain, EL; Chen, X; Farber-Eger, EH; Fessel, JP; Hemnes, AR; Loyd, JE; Talati, M; West, J | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Adjei, AA; Ames, MM; Black, J; Buhrow, SA; Chalmers, ZR; Collins, JM; Dockter, T; Doroshow, JH; Erlichman, C; Frampton, G; Goetz, MP; Haddad, T; Hawse, JR; Ingle, JN; Kipp, BR; Kuffel, M; Liu, MC; Mahr, MA; McGovern, RM; Northfelt, DW; Ralya, AT; Reid, JM; Safgren, SL; Streicher, H; Suman, VJ; Visscher, D | 1 |
| Abenhardt, W; Beckmann, MW; Belleville, E; Brucker, SY; Ettl, J; Fasching, PA; Fehm, TN; Fersis, N; Geberth, M; Häberle, L; Hadji, P; Hartkopf, AD; Hielscher, C; Huober, J; Janni, W; Kolberg, HC; Kurbacher, C; Lüftner, D; Lux, MP; Müller, V; Nabieva, N; Overkamp, F; Schneeweiss, A; Schwitulla, J; Taran, FA; Tesch, H; Thomssen, C; Untch, M; Volz, B; Wallwiener, D; Wallwiener, M; Wimberger, P; Wuerstlein, R | 1 |
| Ali, S; Bhamra, A; Buluwela, L; Carroll, J; Dowsett, M; Fribbens, C; Gao, Q; Garcia-Murillas, I; Gellert, P; Harrod, A; Hills, M; Li, Z; Martin, LA; Martins, V; Nikitorowicz-Buniak, J; Oesterreich, S; Pancholi, S; Patani, N; Poulogiannis, G; Ribas, R; Schuster, E; Sikora, MJ; Simigdala, N; Tenev, T; Thornhill, A; Turgeon, MO; Turner, N; Zwart, W | 1 |
| Guo, J; Long, X; Shi, Y; Ye, P; Zeng, H; Zhou, Q | 1 |
| Avogadri-Connors, F; Cutler, RE; Dowsett, M; Guest, SK; Johnston, SR; Lalani, AS; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Rani, A; Ribas, R; Schuster, E; Simigdala, N; Thornhill, A | 1 |
| Carpenter, E; Farfus, A; Filkowski, J; Kovalchuk, O; Li, D; Lykkesfeldt, AE; Malach, M; Rodriguez-Juarez, R; Storozynsky, Q; Wang, B | 1 |
| Acconcia, F; Bianchi, F; Busonero, C; Leone, S | 1 |
| Audemard, E; Dumeaux, V; El Ezzy, M; Mader, S; Traboulsi, T | 1 |
| Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J | 1 |
| Alvarez, P; Folch, H; Henriquez, C; Morales, N; Moran, G; Olave, C; Sarmiento, J; Uberti, B | 1 |
| Brown, M; Buchwalter, G; Carlson, KE; Chandarlapaty, S; Dharmarajan, V; Fanning, SW; Fowler, CE; Greene, GL; Griffin, PR; Han, R; Hosfield, DJ; Houtman, R; Jeselsohn, R; Karimi, M; Katzenellenbogen, JA; Lainé, M; Martin, TA; Mayne, CG; Nettles, KW; Nowak, J; Nwachukwu, JC; Shen, Y; Tajkhorshid, E; Toy, W | 1 |
| Basak, P; Bhat, V; Chatterjee, S; Hu, P; Jin, H; Lee-Wing, V; Liu, Q; Murphy, LC; Raouf, A; Su, A | 1 |
| Cohen, O; Cuoco, MS; Freeman, S; Helvie, K; Kapstad, C; Lin, NU; Ma, CX; Marini, L; Nayar, U; Oliver, N; Painter, C; Persky, NS; Regev, A; Rozenblatt-Rosen, O; Wagle, N; Waks, AG; Wander, SA; Winer, EP | 1 |
| Brown, H; Cataldo, ML; Chamness, GC; De Angelis, C; Delpuech, O; Fu, X; Hilsenbeck, SG; Jeselsohn, R; Mitchell, T; Nagi, C; Nardone, A; Osborne, CK; Pilling, M; Rimawi, MF; Schiff, R; Shea, MJ; Trivedi, M; Veeraraghavan, J; Weir, H | 1 |
| Armstrong, DK; Button, B; Christenson, ES; Chu, D; Cravero, K; Croessmann, S; Dalton, WB; Dennison, L; Donaldson, J; Hunter, T; Karthikeyan, S; Kyker-Snowman, K; May, B; Park, BH; Petry, D; Ramin, C; Roden, R; Rosen, DM; Visvanathan, K; Waters, I; Zabransky, DJ | 1 |
| Anderson, D; Bagu, E; Dai, C; Davies, G; Goel, R; Lukong, KE; Miah, S; Ogunbolude, Y; Vizeacoumar, FJ; Vizeacoumar, FS; Ward, A | 1 |
| Chae, YS; Jeong, JH; Jung, JH; Lee, DH; Lee, IH; Lee, J; Lee, SJ; Park, HY | 1 |
| Kitahara, J; Komatsu, M; Miyamoto, T; Nishio, SI; Ohkubo, Y; Sekido, K; Sekido, T | 1 |
| Clarke, RB; Dragoni, I; Gee, JM; Howell, SJ; Kedward, T; NicAmhlaoibh, R; Sabin, V; Santiago-Gómez, A; Simões, BM; Sims, AH; Trivier, E | 1 |
| Aktas, B; Barry, WT; Carey, LA; Carrasco, E; Casas, M; Cirrincione, CT; De la Haba-Rodríguez, J; Dickler, MN; Furlanetto, J; Garcia-Saenz, JA; Guerrero-Zotano, A; Hahn, O; Hudis, C; Hyslop, T; Loibl, S; Martín, M; Martinez-Jañez, N; Mehta, K; Morales, S; Partridge, A; Rodriguez-Martin, C; Winer, E | 1 |
| Yardley, DA | 1 |
| Huizing, MT; Najim, O; Papadimitriou, K; Seghers, S; Sergoynne, L; Tjalma, W; Trinh, XB; Van Gaver, H; Wouters, K | 1 |
| Berger, M; Billard, H; Bougaret, L; Bourgne, C; Caldefie-Chezet, F; Cholet, J; Decombat, C; Delort, L; Dumontet, C; Vermerie, M | 1 |
| Chasen, BA; Damodaran, S; Fujii, T; Gao, H; Hortobagyi, GN; Ibrahim, NK; Iwase, T; Lim, B; Liu, DD; Lucci, A; Reuben, JM; Saigal, B; Shen, Y; Tahara, RK; Tripathy, D; Ueno, NT | 1 |
| Chen, CS; Chen, XS; Cheng, Y; Ding, BN; Guan, YD; Guo, W; Li, LY; Ren, XC; Sun, XY; Tao, YG; Wang, HY; Wang, KS; Yang, JM; Ye, YC; Yin, MZ; Yu, P; Zhang, Y | 1 |
| Buisseret, L; de Azambuja, E; Eiger, D; Nogueira, MS; Pondé, NF; Wagner, M | 1 |
| Altelaar, M; Bhamra, A; Dowsett, M; Fitzpatrick, M; Gao, Q; Johnston, SR; Leal, MF; Marangoni, E; Martin, LA; Montaudon, E; Morisset, L; Nikitorowicz-Buniak, J; Pancholi, S; Ressa, A; Ribas, R; Schuster, E; Simigdala, N; Sourd, L; Thornhill, A | 1 |
| Amaral, C; Fernandes, PA; Ferreira Almeida, C; João Ramos, M; Oliveira, A; Teixeira, N | 1 |
| Cornella-Taracido, I; Garcia-Echeverria, C | 1 |
| Guan, X; Li, C; Li, H; Li, L; Liu, B; Ma, F; Qian, H; Rong, G; Sun, X; Wang, W; Xu, B; Yi, Z; Zhai, J | 1 |
| Li, DQ; Liu, HY; Shao, ZM; Xie, HY; Yang, F; Yang, LF; Zhang, FL; Zhang, L | 1 |
| He, J; Hu, T; Huang, H; Liao, Y; Liu, B; Liu, N; Liu, X; Shao, Z; Xia, X; Xu, Q; Yu, C | 1 |
| Arrighi, A; Ballestrero, A; Becherini, P; Brandhorst, S; Caffa, I; Cea, M; Cilli, M; Clevers, H; Cortellino, S; Cremonini, AL; De Braud, F; Driehuis, E; Ferrando, L; Gradaschi, R; Longo, VD; Mantero, C; Mastracci, L; Monacelli, F; Nencioni, A; Odetti, P; Passalacqua, M; Piacente, F; Piazza, S; Provenzani, A; Salvadori, G; Spagnolo, V; Sukkar, SG; Tagliafico, A; Valdemarin, F; Vellone, VG; Vernieri, C; Wei, M; Zoppoli, G; Zucal, C | 1 |
| Hu, Y; Lee, S; Li, L; Lin, L; Schiff, R; Tan, Y; Veeraraghavan, J; Wang, X; Wang, XS | 1 |
| Abrahamsson, A; Dabrosin, C; Rodriguez, GV | 1 |
| Gigantino, V; Giurato, G; Nassa, G; Nyman, TA; Palumbo, D; Rizzo, F; Salvati, A; Strianese, O; Tarallo, R; Weisz, A | 1 |
| Bergqvist, M; Bethune, A; Bidard, FC; Brain, E; Cabel, L; Cottu, P; Donnadieu, A; Kiavue, N; Lerebours, F; Loirat, D; Pierga, JY; Rodrigues, M; Rosenblum, D; Tanguy, ML | 1 |
| Baird, RD; Batra, AS; Brindle, KM; Bruna, A; Caldas, C; Couturier, DL; D'Santos, P; de Boo, LW; Georgopoulou, D; Hesketh, RL; Hu, DE; Lerda, G; Lewis, DY; Linn, SC; Lubling, Y; Mannion, E; Martin, A; Oliveira, M; Pelossof, R; Razavi, P; Ros, S; Rueda, OM; Scaltriti, M; Wright, AJ | 1 |
| Cavadias, I; Héquet, D; Lerebours, F; Rouzier, R | 1 |
| Atlas, E; Cuyàs, E; Espinoza, I; Lupu, R; Mehmi, I; Menendez, JA; Papadimitropoulou, A; Vander Steen, T; Vellon, L; Verdura, S | 1 |
| Alhusban, A; Alkhalifa, AE; Ayoub, NM; Ibrahim, DR | 1 |
| Bruinsma, ES; Emch, MJ; Goetz, MP; Hawse, JR; Ingle, JN; Jones, CJ; Subramaniam, M | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| Cook, RS; Elion, DL; Stauffer, KM; Stricker, T | 1 |
| Ala-Hongisto, H; Bertula, K; Elo, LL; Euro, L; Heikkilä, P; Hollmann, B; Hukkinen, K; Ikkala, O; Joensuu, H; Junttila, MR; Kivento, M; Klefström, J; Kovanen, P; Leidenius, M; Martikainen, L; Mattson, J; Meretoja, T; Metcalfe, C; Monni, O; Munne, PM; Mutka, M; Nevalaita, L; Patrikainen, L; Peura, A; Pokki, J; Pouwels, J; Räty, I; Ruuska, J; Sahu, B; Salmela, M; Suomi, T; Väänänen, J; Yavuz, K | 1 |
| Abdulkareem, NM; Bae, L; Bhat, R; Cataldo, ML; De Angelis, C; Fu, X; Nanda, S; Schiff, R; Thangavel, H; Trivedi, MV; Vasaikar, S; Zhang, B | 1 |
| Eisner, JR; Lerner, LM; Michmerhuizen, AR; Pesch, AM; Pierce, LJ; Rae, JM; Schwartz, R; Speers, CW; Ward, C; Wilder-Romans, K; Zhang, A | 1 |
| Lauchle, JO; Metcalfe, C | 1 |
| Aimi, J; Bacarro, N; Bellet, M; Chang, CW; Daemen, A; Eng-Wong, J; Gates, MR; Giltnane, J; Hafner, M; Ingalla, ER; Liang, J; Liang, Y; Metcalfe, C; Moore, HM; Roose-Girma, M; Tai, L; Tam, L; Wang, BE; Yao, X | 1 |
| Eckardt, L; Ellermann, C; Frommeyer, G; Kirchner, LM; Leitz, PR; Rath, B; Willy, K; Wolfes, J | 1 |
| Acconcia, F | 1 |
| Bouvier, M; Diennet, M; El Ezzy, M; Haidar, S; Mader, S; Vallet, A | 1 |
| Alexis, MN; Chatziioannou, A; Ganou, V; Gkotsi, EF; Meligova, AK; Mitsiou, DJ; Papadodima, O; Pilalis, E; Siakouli, D; Stasinopoulou, S; Xenopoulou, DS; Zoumpouli, M | 1 |
| Bazgier, V; Berka, K; Holcakova, J; Hrstka, R; Kolarova, T; Kudova, E; Kvasnica, M; Oklestkova, J; Rarova, L; Strnad, M; Tichy, V; Vonka, P | 1 |
| Alzahrani, FM; Fasseas, K; Giannopoulou, E; Kalofonos, HP; Karamouzis, MV; Manou, D; Raftopoulou, S; Sarantis, P; Siatis, KE; Theocharis, AD | 1 |
59 review(s) available for fulvestrant and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Development of novel oestrogen-receptor antagonists.
Topics: Animals; Breast Neoplasms; Drug Design; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Receptors, Estrogen; Tamoxifen | 1991 |
Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer.
Topics: Breast Neoplasms; Drug Resistance; Estradiol; Estradiol Congeners; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Polyunsaturated Alkamides; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1995 |
Clinical potential of new antiestrogens.
Topics: Antineoplastic Agents, Hormonal; Bone Density; Drugs, Investigational; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene | 1997 |
Modern antioestrogens and the coming revolution in women's health care.
Topics: Bone and Bones; Breast Neoplasms; Clomiphene; Estradiol; Estrogen Receptor Modulators; Estrogens, Non-Steroidal; Female; Fulvestrant; Genital Diseases, Female; Humans; Isoflavones; Osteoporosis; Phytoestrogens; Plant Preparations; Plants; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health | 1999 |
Clinical studies of apoptosis and proliferation in breast cancer.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Biomarkers; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Pregnancy; Tamoxifen; Tumor Cells, Cultured | 1999 |
Selective estrogen receptor modulators in reproductive medicine and biology.
Topics: Estradiol; Estrogen Replacement Therapy; Fulvestrant; Genistein; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
[Pure antiestrogen for treatment of advanced breast cancers].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Tamoxifen; Treatment Outcome | 2000 |
Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2001 |
Fulvestrant.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Contraindications; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Tamoxifen | 2002 |
Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients.
Topics: Adaptation, Physiological; Animals; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Models, Biological; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Proteins; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transplantation, Heterologous; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2001 |
Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Down-Regulation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen | 2001 |
A vision for the future?
Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitriles; Tamoxifen; Triazoles | 2001 |
Prospects for combining hormonal and nonhormonal growth factor inhibition.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Quinazolines; Tamoxifen | 2001 |
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes | 2002 |
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Megestrol Acetate; Middle Aged; Postmenopause; Prognosis; Quality of Life; Receptors, Estrogen; Tamoxifen | 2003 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Tamoxifen--what next?
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Fulvestrant; Humans; Tamoxifen | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Staging; Postmenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; United Kingdom | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Neoplasm Staging; Nitriles; Postmenopause; Quality of Life; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Postmenopause; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause; Raloxifene Hydrochloride; Tamoxifen | 2006 |
Time to response: comparison of fulvestrant and oral endocrine agents.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen | 2008 |
Gene expression profiles in breast cancer to identify estrogen receptor target genes.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen | 2008 |
The influence of endocrine treatments for breast cancer on health-related quality of life.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Mastectomy; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome | 2008 |
Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Tamoxifen | 2010 |
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genotype; Humans; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2009 |
Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Dehydroepiandrosterone Sulfate; Estradiol; Estrone; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Steryl-Sulfatase; Sulfonic Acids; Tamoxifen | 2011 |
[Hormone therapy and breast cancer].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Current approaches to the management of Her2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Deoxycytidine; Doxorubicin; Estradiol; Female; Fulvestrant; Gemcitabine; Humans; Megestrol; Ovary; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases | 2012 |
A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Tamoxifen | 2013 |
Advances in the treatment of luminal breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
The renaissance of endocrine therapy in breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Ovariectomy; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome | 2014 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2014 |
Fulvestrant and male breast cancer: a pooled analysis.
Topics: Adult; Aged; Breast Neoplasms, Male; Disease-Free Survival; Estradiol; Estrogen Antagonists; Fulvestrant; Hormones; Humans; Male; Middle Aged; Tamoxifen | 2015 |
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone Acetate; Neoplasm Metastasis; Ovariectomy; Postmenopause; Premenopause; Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Fulvestrant; Humans; Postmenopause; Receptor, ErbB-2; Tamoxifen | 2015 |
[GPER receptor - the new player in estrogen signaling].
Topics: Animals; Autocrine Communication; Breast Neoplasms; Connective Tissue Growth Factor; Dual Specificity Phosphatase 1; Estradiol; Female; Fulvestrant; Gene Expression Regulation; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-fos; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Tamoxifen; Transcriptional Activation | 2015 |
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Topics: Animals; Breast; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Estrogens; Estrogens, Conjugated (USP); Female; Fulvestrant; Humans; Indoles; Osteoporosis; Postmenopause; Protective Factors; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene | 2015 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Endocrine treatment in breast cancer: Cure, resistance and beyond.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Pyridines; Receptors, Estrogen; Tamoxifen | 2016 |
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mutation; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prognosis; Tamoxifen | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mutation; Non-Randomized Controlled Trials as Topic; Randomized Controlled Trials as Topic; Tamoxifen | 2019 |
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Topics: Alopecia; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Fulvestrant; Germany; Humans; Incidence; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Survival Rate; Tamoxifen | 2020 |
Estrogen receptor-positive (ER
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Fulvestrant; Gene Expression; Humans; Molecular Targeted Therapy; Tamoxifen | 2020 |
Monovalent protein-degraders - Insights and future perspectives.
Topics: Biosensing Techniques; Cinnamates; Drug Discovery; Fulvestrant; Humans; Indoles; Ligands; Protein Binding; Proteolysis; Receptors, Estrogen; Stilbenes; Tamoxifen; Ubiquitin-Protein Ligases | 2020 |
[Hot flushes and breast cancer with positive hormone receptors: Mechanisms and management].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Contraindications, Drug; Estrogen Replacement Therapy; Female; Fulvestrant; Hot Flashes; Humans; Kisspeptins; Ovary; Receptors, Neurokinin-3; Selective Estrogen Receptor Modulators; Tamoxifen | 2020 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
13 trial(s) available for fulvestrant and tamoxifen
| Article | Year |
|---|---|
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Tolerance; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Tamoxifen | 1995 |
Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Tamoxifen | 1995 |
Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Biopsy; Breast Neoplasms; Combined Modality Therapy; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Longitudinal Studies; Middle Aged; Paraffin Embedding; Placebos; Receptors, Estrogen; Tamoxifen | 1997 |
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Ki-67 Antigen; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2001 |
Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Area Under Curve; Breast Neoplasms; Chemistry, Pharmaceutical; Delayed-Action Preparations; Estradiol; Female; Fulvestrant; Half-Life; Humans; Injections, Intramuscular; Postmenopause; Tamoxifen | 2003 |
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2004 |
Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Postmenopause; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Tamoxifen; Treatment Outcome | 2006 |
Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Ki-67 Antigen; Middle Aged; Neoplasms, Hormone-Dependent; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2008 |
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Aromatase Inhibitors; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cytochrome P-450 CYP2D6; Disease-Free Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Tamoxifen | 2017 |
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Goserelin; Humans; Neoplasm Metastasis; Premenopause; Tamoxifen | 2018 |
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Evaluation Studies as Topic; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Tamoxifen | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Tamoxifen; Young Adult | 2019 |
Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.
Topics: Adult; Aged; Alpha Particles; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy; Denosumab; Female; Fulvestrant; Humans; Injections, Intravenous; Middle Aged; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Radioisotopes; Radium; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2020 |
513 other study(ies) available for fulvestrant and tamoxifen
| Article | Year |
|---|---|
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Topics: Animals; Breast Neoplasms; Cell Division; Estrogen Antagonists; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tumor Cells, Cultured | 1997 |
(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.
Topics: Administration, Oral; Animals; Benzopyrans; Binding, Competitive; Breast Neoplasms; Cytosol; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Female; Humans; Mice; Molecular Structure; Ovariectomy; Piperidines; Propionates; Raloxifene Hydrochloride; Receptors, Estrogen; Stereoisomerism; Structure-Activity Relationship; Uterus | 1997 |
Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells.
Topics: Adenylyl Cyclases; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Estrogens; GTP-Binding Protein alpha Subunits, Gs; Humans; Kidney; Membrane Proteins; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Sulfur Radioisotopes; Transfection | 2005 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Genes, Reporter; Humans; Inhibitory Concentration 50; Molecular Conformation; Protein Binding; Receptors, Estrogen; Receptors, Progesterone; Tetrahydroisoquinolines | 2007 |
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Topics: 17-Hydroxysteroid Dehydrogenases; Androstane-3,17-diol; Androstanes; Biocatalysis; Cell Line; Dihydrotestosterone; Enzyme Inhibitors; Estradiol; Estrone; Humans; Inhibitory Concentration 50; Oxidation-Reduction; Substrate Specificity | 2009 |
Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Crystallography, X-Ray; Estrogen Receptor alpha; Humans; Molecular Conformation; Protein Binding; Structure-Activity Relationship; Tamoxifen; Transcription, Genetic | 2010 |
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Humans; Hydrophobic and Hydrophilic Interactions; Isoflavones; Mice; Mice, Nude; Models, Molecular; Receptors, Progesterone; Response Elements; Structure-Activity Relationship; Transcription, Genetic; Xenograft Model Antitumor Assays | 2010 |
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
Topics: Antineoplastic Agents; Biomimetics; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Screening Assays, Antitumor; Female; Humans; Magnetic Resonance Spectroscopy; Male; Models, Chemical; Ovarian Neoplasms; Prostatic Neoplasms; Pterocarpans; Receptors, Estrogen; Stereoisomerism | 2011 |
Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.
Topics: Breast Neoplasms; Catalysis; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Models, Molecular; Transcription, Genetic | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Dogs; Drug Discovery; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Heterografts; Humans; Mice; Proteolysis; Rats; Selective Estrogen Receptor Modulators; Small Molecule Libraries; Tamoxifen | 2015 |
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregu
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cinnamates; Clinical Trials, Phase I as Topic; Down-Regulation; Drug Design; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Humans; Indoles; Injections, Intramuscular; X-Ray Diffraction | 2015 |
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
Topics: Animals; Cell Line; Dehydrocholesterols; Dose-Response Relationship, Drug; Fibroblasts; Homeostasis; Humans; Mice; Molecular Conformation; Neurons; Oxidoreductases Acting on CH-CH Group Donors; Small Molecule Libraries; Sterols; Structure-Activity Relationship | 2016 |
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice, Nude; Models, Molecular; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Thiophenes | 2017 |
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
Topics: Acrylates; Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Dogs; Drug Discovery; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Mice, Inbred C57BL; Molecular Docking Simulation; Proteolysis; Tetrahydroisoquinolines | 2017 |
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
Topics: Antineoplastic Agents; Benzoxepins; Crystallography, X-Ray; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Ligands; MCF-7 Cells; Models, Molecular; Molecular Docking Simulation; Proteolysis; Selective Estrogen Receptor Modulators; Structure-Activity Relationship | 2018 |
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Drug Design; Drug Discovery; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Mice; Mice, Nude; Rats; Rats, Sprague-Dawley; Rats, Wistar; Selective Estrogen Receptor Modulators; Thiophenes; Xenograft Model Antitumor Assays | 2018 |
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzopyrans; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Mice; Rats; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.
Topics: | 2019 |
Structure-based drug design, synthesis, In vitro, and In vivo biological evaluation of indole-based biomimetic analogs targeting estrogen receptor-α inhibition.
Topics: Antineoplastic Agents; Biomimetic Materials; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Design; Estrogen Receptor alpha; Humans; Indoles; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Conformation | 2019 |
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Topics: Animals; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation; Proteolysis; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Thiophenes; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models, Molecular; Piperazines; Protein Domains; Pyridines; Pyridones; Receptors, Estrogen; Tissue Distribution; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Estrogen Receptor Antagonists; Female; Humans; MCF-7 Cells; Molecular Structure; Receptors, Estrogen; Structure-Activity Relationship; Thiophenes; Tumor Cells, Cultured | 2021 |
A potent specific pure antiestrogen with clinical potential.
Topics: Animals; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Macaca nemestrina; Mice; Mice, Nude; Neoplasm Transplantation; Ovariectomy; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterus | 1991 |
A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
Topics: Amino Acid Sequence; Cell Division; Estradiol; Estradiol Congeners; Estrogen Antagonists; Fulvestrant; Growth Inhibitors; Humans; Molecular Sequence Data; Point Mutation; Polymorphism, Single-Stranded Conformational; Receptors, Estrogen; Recombinant Proteins; Structure-Activity Relationship; Tamoxifen; Transcriptional Activation; Transfection | 1995 |
Biphasic effect of estrogen on neuronal constitutive nitric oxide synthase via Ca(2+)-calmodulin dependent mechanism.
Topics: Amino Acid Oxidoreductases; Animals; Calcium; Calmodulin; Cerebellum; Clomiphene; Cytosol; Estradiol; Fulvestrant; Imidazoles; Neurons; Nitric Oxide Synthase; Progesterone; Rabbits; Receptors, Estrogen; Spectrometry, Fluorescence; Sulfonamides; Tamoxifen | 1994 |
In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate.
Topics: Animals; Arylsulfatases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Estrone; Female; Fulvestrant; Liver; Mammary Neoplasms, Experimental; Rats; Rats, Wistar; Steryl-Sulfatase; Sulfatases; Tamoxifen; Time Factors | 1995 |
Yeast two-hybrid system demonstrates that estrogen receptor dimerization is ligand-dependent in vivo.
Topics: Base Sequence; Binding Sites; DNA Primers; DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Fulvestrant; Fungal Proteins; Humans; Molecular Sequence Data; Protein Conformation; Receptors, Estrogen; Recombinant Fusion Proteins; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Tamoxifen; Transcription Factors; Transcriptional Activation | 1995 |
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Breast Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Tamoxifen | 1995 |
Estrogen increases endothelial nitric oxide by a receptor-mediated system.
Topics: Animals; Aorta; Blotting, Western; Cattle; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Immunohistochemistry; Isoenzymes; Kinetics; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Receptors, Estrogen; Tamoxifen; Umbilical Veins | 1995 |
Contrasting effects of tamoxifen and ICI 182 780 on estrogen-induced calbindin-D 9k gene expression in the uterus and in primary culture of myometrial cells.
Topics: Animals; Calbindins; Cells, Cultured; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Myometrium; Ovariectomy; Rats; Rats, Sprague-Dawley; Receptors, Estradiol; RNA, Messenger; S100 Calcium Binding Protein G; Tamoxifen; Transcriptional Activation; Uterus | 1995 |
The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor.
Topics: Binding Sites; Binding, Competitive; Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1995 |
Inhibition of angiogenesis by antiestrogens.
Topics: Animals; Chick Embryo; Clomiphene; Dimethyl Sulfoxide; Dimethylformamide; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Fulvestrant; Heparin; Hydrocortisone; Nafoxidine; Neovascularization, Pathologic; Polyunsaturated Alkamides; Solubility; Tamoxifen | 1993 |
Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media.
Topics: Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Cell Division; Cell Line; Culture Media, Conditioned; DNA, Bacterial; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Protein 4; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Molecular Weight; Tamoxifen; Thymidine; Tumor Cells, Cultured | 1993 |
Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1995 |
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Resistance; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Tamoxifen | 1995 |
Estrogen receptor-mediated direct stimulation of colon cancer cell growth in vitro.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Base Sequence; Blotting, Northern; Cell Division; Colonic Neoplasms; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Mice; Molecular Sequence Data; Oligonucleotides, Antisense; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured | 1994 |
Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Doxorubicin; Drug Resistance; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Leukemia; Membrane Glycoproteins; Neoplasm Proteins; Tamoxifen; Time Factors; Tumor Cells, Cultured | 1993 |
Interaction of proteins with transcriptionally active estrogen receptors.
Topics: Animals; Base Sequence; Blotting, Western; Cell Line; Cell Nucleus; Cell-Free System; Chlorocebus aethiops; DNA Primers; DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Fulvestrant; Glutathione Transferase; HeLa Cells; Humans; Kidney; Molecular Sequence Data; Nuclear Proteins; Polyunsaturated Alkamides; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Transcription, Genetic | 1994 |
New antiestrogen shows promise in ER-positive breast cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen | 1994 |
Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Division; Clone Cells; Culture Media, Serum-Free; Drug Resistance; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Pleural Effusion, Malignant; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1994 |
Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model.
Topics: Adenocarcinoma; Animals; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Polyunsaturated Alkamides; Receptors, Estrogen; Tamoxifen; Transplantation, Heterologous; Tumor Cells, Cultured | 1994 |
The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling.
Topics: Amino Acid Sequence; Animals; Biological Transport; Cell Compartmentation; Cell Nucleus; Cells, Cultured; Chlorocebus aethiops; Cytoplasm; Estradiol; Estrogen Antagonists; Fulvestrant; Hybrid Cells; Mice; Molecular Sequence Data; Oligomycins; Polyunsaturated Alkamides; Receptors, Estrogen; Recombinant Proteins; Sequence Homology, Amino Acid; Tamoxifen; Transfection | 1993 |
Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Topics: Animals; Base Sequence; Breast Neoplasms; Cell Division; Chloramphenicol O-Acetyltransferase; Culture Media; Drug Resistance; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Molecular Sequence Data; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tamoxifen; Time Factors; Transfection; Tumor Cells, Cultured | 1994 |
RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice.
Topics: Animals; Antineoplastic Agents; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Progesterone; Rabbits; Rats; Receptors, Estrogen; Tamoxifen; Thymus Gland; Tumor Cells, Cultured; Uterus | 1994 |
Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Insulin-Like Growth Factor I; Organ Size; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1993 |
Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.
Topics: Binding Sites; Breast Neoplasms; Cell Division; Drug Resistance; Estradiol; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1993 |
ICI 182,780: a pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain.
Topics: Animals; Behavior, Animal; Brain; Energy Metabolism; Estradiol; Estrogen Antagonists; Estrus; Female; Fulvestrant; Ovariectomy; Rats; Tamoxifen | 1993 |
Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells.
Topics: Cell Division; Dose-Response Relationship, Drug; Estradiol; Fulvestrant; Humans; Oleic Acid; Oleic Acids; Receptors, Estrogen; Stearic Acids; Tamoxifen; Tumor Cells, Cultured | 1994 |
Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cathepsin D; Cell Division; Drug Resistance; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Proteins; Receptors, Estrogen; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1994 |
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Resistance; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Mice; Mice, Nude; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1993 |
Effects of onapristone, tamoxifen and ICI 182780 on uterine prostaglandin production and luteal function in nonpregnant guinea-pigs.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Dinoprost; Dinoprostone; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gonanes; Guinea Pigs; Luteolysis; Progesterone; Tamoxifen; Uterus | 1993 |
Isolation of pMGT1: a gene that is repressed by oestrogen and increased by antioestrogens and antiprogestins.
Topics: Breast Neoplasms; DNA, Neoplasm; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mifepristone; Polyunsaturated Alkamides; Progestins; Tamoxifen; Tumor Cells, Cultured | 1993 |
Lens opacification by antioestrogens: tamoxifen vs ICI 182,780.
Topics: Animals; Cataract; Cattle; Chloride Channels; Disease Models, Animal; Estradiol; Estrogen Antagonists; Fulvestrant; In Vitro Techniques; Neuroblastoma; Patch-Clamp Techniques; Tamoxifen; Tumor Cells, Cultured | 1995 |
Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells.
Topics: Base Sequence; Blotting, Western; Breast Neoplasms; Cell Division; Culture Media, Conditioned; DNA; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Insulin-Like Growth Factor I; Molecular Sequence Data; Polyunsaturated Alkamides; RNA, Messenger; Steroids; Tamoxifen; Tumor Cells, Cultured | 1995 |
Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors.
Topics: Breast Neoplasms; Cell Cycle; Cell Line; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Estradiol; Estradiol Congeners; Estrogen Antagonists; Female; Fulvestrant; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; RNA, Messenger; Simvastatin; Tamoxifen; Tumor Cells, Cultured | 1996 |
Regulation of avian osteoclastic H+ -ATPase and bone resorption by tamoxifen and calmodulin antagonists. Effects independent of steroid receptors.
Topics: Animals; Biological Transport; Bone Resorption; Calmodulin; Cell Membrane; Cells, Cultured; Chickens; Diethylstilbestrol; Drug Synergism; Estradiol; Female; Fulvestrant; Hydrochloric Acid; Osteoclasts; Proton-Translocating ATPases; Tamoxifen; Trifluoperazine | 1996 |
Chemosensitizing effect of tamoxifen and ICI 182,780 on parental and adriamycin-resistant MCF-7 human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Antagonists; Female; Flow Cytometry; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Phenotype; Progesterone; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1996 |
Changes in the subcellular distribution of the rat uterus oestrogen receptor as induced by oestradiol, tamoxifen and ZD 182,780.
Topics: Animals; DNA; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Rats; Rats, Wistar; Receptors, Estrogen; Subcellular Fractions; Tamoxifen; Uterus | 1996 |
2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumor activity.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cattle; Cell Division; Estradiol; Estrogen Antagonists; Estrone; Female; Fulvestrant; HeLa Cells; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Organ Size; Receptors, Estrogen; Sulfur; Tamoxifen; Transcriptional Activation; Tumor Cells, Cultured; Uterus; Vitellogenins | 1996 |
ICI 182,780 inhibits endogenous estrogen-dependent rat uterine growth and tamoxifen-induced developmental toxicity.
Topics: Animals; Epithelium; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Immunohistochemistry; Organ Size; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen; Uterus | 1996 |
Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity.
Topics: Animals; Breast Neoplasms; Cell Division; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Fulvestrant; Gelatinases; Humans; Mice; Mice, Nude; Phenotype; Protein Binding; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tamoxifen; Transcription Factor AP-1; Tumor Cells, Cultured | 1996 |
Inhibition of endothelial adhesion and invasion by breast carcinoma cells may contribute towards the anti-metastatic effects of tamoxifen.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Chemotherapy, Adjuvant; Collagen; Disease-Free Survival; Drug Combinations; Endothelium; Estradiol; Estrogen Antagonists; Extracellular Matrix; Female; Fulvestrant; Humans; Laminin; Proteoglycans; Tamoxifen; Tumor Cells, Cultured | 1996 |
Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Cycle; DNA, Neoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Antagonists; Flow Cytometry; Fulvestrant; Humans; Phenotype; Ploidies; Receptors, Estrogen; Rhodamine 123; Rhodamines; Tamoxifen; Tumor Cells, Cultured | 1996 |
Anti-implantation activity of antiestrogens and mifepristone.
Topics: Administration, Oral; Animals; Contraceptives, Postcoital; Embryo Implantation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Injections, Subcutaneous; Male; Mifepristone; Norandrostanes; Pregnancy; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1996 |
Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proteins; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins | 1996 |
Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells.
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Receptors, Somatostatin; RNA, Messenger; Tamoxifen; Time Factors; Tumor Cells, Cultured | 1996 |
Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
Topics: Animals; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Leiomyoma; Phenotype; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterine Neoplasms | 1996 |
RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinogenicity Tests; Cell Cycle; Cell Division; Chick Embryo; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Genes, ras; Heart; Humans; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Myocardium; Neoplasm Invasiveness; Tamoxifen; Tumor Cells, Cultured | 1996 |
Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Genetic Vectors; Humans; Polyunsaturated Alkamides; Receptors, Estrogen; RNA Splicing; RNA, Messenger; RNA, Neoplasm; Tamoxifen; Transfection; Tumor Cells, Cultured | 1997 |
Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Estradiol; Fibronectins; Fulvestrant; Humans; Melanoma; Naphthalenes; Neoplasm Invasiveness; Receptors, Progesterone; Skin Neoplasms; Sulfonamides; Tamoxifen; Uveal Neoplasms | 1997 |
Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels.
Topics: Animals; Cholesterol; Dexamethasone; Disease Models, Animal; Estradiol; Estrogen Antagonists; Estrogens; Ethinyl Estradiol; Female; Fulvestrant; Lipids; Ovariectomy; Piperidines; Progesterone; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1997 |
The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Binding, Competitive; Dimerization; DNA-Binding Proteins; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Flavones; Flavonoids; Fulvestrant; Fungal Proteins; Genistein; Humans; Isoflavones; Lac Operon; Plant Extracts; Receptors, Estrogen; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Tamoxifen; Transcription Factors | 1997 |
Tamoxifen and ICI 182,780 interactions with thyroid hormone in the ovariectomized-thyroidectomized rat.
Topics: Animals; Body Weight; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Malate Dehydrogenase; Organ Size; Ovariectomy; Rats; Receptors, Estrogen; Receptors, Thyroid Hormone; Tamoxifen; Thyroidectomy; Triglycerides; Triiodothyronine; Uterus | 1997 |
Estrogen receptor ligands modulate its interaction with DNA.
Topics: DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Ethinyl Estradiol; Fulvestrant; Humans; Ligands; Piperidines; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Tamoxifen; Transcription Factors | 1997 |
The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens.
Topics: Animals; Base Sequence; Binding Sites; Breast Neoplasms; Cell Line; DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Enzymologic; Genes, Reporter; Genetic Vectors; Glutathione Transferase; Growth Hormone; Humans; Kinetics; Mice; Molecular Sequence Data; NAD(P)H Dehydrogenase (Quinone); Oligodeoxyribonucleotides; Promoter Regions, Genetic; Receptors, Estrogen; Recombinant Proteins; Tamoxifen; Transfection | 1997 |
FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
Topics: Amino Acid Sequence; Bacterial Outer Membrane Proteins; Diethylstilbestrol; DNA Nucleotidyltransferases; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Fulvestrant; Hexestrol; HSP90 Heat-Shock Proteins; Humans; Ligands; Molecular Sequence Data; Nafoxidine; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Time Factors; Yeasts | 1997 |
Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780.
Topics: Animals; Dose-Response Relationship, Drug; Endothelial Growth Factors; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Lymphokines; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1997 |
Effect of mifepristone and antiestrogens on uterine PGF2 alpha and PGE2 concentrations in ovariectomized and pregnant rats.
Topics: Abortifacient Agents, Steroidal; Animals; Contraceptives, Postcoital, Synthetic; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Embryonic Development; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Mifepristone; Norandrostanes; Organ Size; Ovariectomy; Pregnancy; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1997 |
Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182,780.
Topics: Acids; Antigens, Neoplasm; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cathepsin D; Culture Media, Serum-Free; Enzyme Activation; Enzyme Precursors; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Immunoblotting; Neoplasm Invasiveness; Tamoxifen; Tumor Cells, Cultured | 1997 |
Influence of antiestrogens on the migration of breast cancer cells using an in vitro wound model.
Topics: Breast Neoplasms; Cell Movement; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Neoplasm Invasiveness; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 1997 |
Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Collagenases; Electrophoresis, Polyacrylamide Gel; Estradiol; Estrogen Antagonists; Fulvestrant; Gelatinases; Glycoproteins; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metalloendopeptidases; Neoplasm Invasiveness; Protease Inhibitors; Receptors, Estrogen; Tamoxifen; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 1997 |
Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium.
Topics: Acetylcholine; Animals; Calcimycin; Calcium; Cells, Cultured; DNA Primers; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Fetus; Fulvestrant; Gestational Age; Isoenzymes; Kinetics; Nitric Oxide Synthase; Polymerase Chain Reaction; Pulmonary Artery; Sheep; Tamoxifen | 1997 |
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Genetic Markers; Humans; Mice; Mice, Nude; Phenotype; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1997 |
Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
Topics: Adenocarcinoma; Alkaline Phosphatase; Benzopyrans; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Proteins; Piperidines; Propionates; Raloxifene Hydrochloride; Tamoxifen; Toremifene; Tumor Cells, Cultured | 1997 |
Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.
Topics: Biomarkers, Tumor; Cell Differentiation; Cell Division; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Cyclins; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Oncogene Proteins; Pregnancy; Proto-Oncogene Proteins; Receptors, Estrogen; Tamoxifen; Transcription, Genetic | 1997 |
Cloning and characterization of the type I inositol 1,4,5-trisphosphate receptor gene promoter. Regulation by 17beta-estradiol in osteoblasts.
Topics: Base Sequence; Calcium Channels; Cloning, Molecular; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression Regulation; Humans; Inositol 1,4,5-Trisphosphate; Inositol 1,4,5-Trisphosphate Receptors; Molecular Sequence Data; Osteoblasts; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 1997 |
Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding Sites; Enzyme Induction; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Integrases; Kinetics; Mice; Molecular Sequence Data; Mutagenesis, Insertional; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Point Mutation; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Teratoma; Tumor Cells, Cultured; Viral Proteins | 1997 |
Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha.
Topics: Animals; Cloning, Molecular; COS Cells; Dimerization; DNA; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Ligands; Polymerase Chain Reaction; Receptors, Estrogen; Tamoxifen; Temperature | 1997 |
Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: an in situ hybridization study.
Topics: Animals; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; In Situ Hybridization; Piperidines; Preoptic Area; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Progesterone; RNA, Messenger; Sensitivity and Specificity; Tamoxifen; Time Factors | 1997 |
Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen.
Topics: Blotting, Northern; Blotting, Western; Bone Morphogenetic Protein 6; Bone Morphogenetic Proteins; Cell Line; Estradiol; Estrogens; Fulvestrant; Humans; Osteoblasts; Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Transforming Growth Factor beta | 1998 |
Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transforming Growth Factor beta; Tumor Cells, Cultured | 1998 |
Physiological concentrations of 17beta-estradiol inhibit the synthesis of nitric oxide synthase in macrophages via a receptor-mediated system.
Topics: Animals; Antibodies, Monoclonal; Blotting, Western; Cell Line; Edetic Acid; Estradiol; Estrogen Antagonists; Fulvestrant; Immunohistochemistry; Interferon-gamma; Lipopolysaccharides; Macrophages; Mice; Microelectrodes; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Tamoxifen | 1998 |
Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line; Chloramphenicol O-Acetyltransferase; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factors; Fulvestrant; Humans; Letrozole; Luciferases; Mice; Mice, Nude; Nitriles; Ovariectomy; Polymerase Chain Reaction; Receptors, Progesterone; Recombinant Fusion Proteins; RNA, Messenger; Tamoxifen; Transcription, Genetic; Transfection; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured | 1998 |
Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Division; Cell Nucleus; DNA Fragmentation; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Ovarian Neoplasms; Receptors, Estrogen; Tamoxifen; Time Factors; Tumor Cells, Cultured | 1998 |
Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an breast tumor.
Topics: Animals; Binding Sites; Breast Neoplasms; Cell Division; DNA Primers; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Glycine; Humans; Luciferases; Mice; Mice, Nude; Ovariectomy; Point Mutation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Valine | 1998 |
The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fibronectins; Fulvestrant; Humans; Neoplasm Invasiveness; Tamoxifen; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1998 |
17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells.
Topics: Arteriosclerosis; Coronary Vessels; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Fulvestrant; Gelatinases; Humans; Matrix Metalloproteinase 2; Metalloendopeptidases; Muscle, Smooth, Vascular; Tamoxifen; Umbilical Arteries | 1998 |
Estrogen- and antiestrogen-responsiveness of HEC1A endometrial adenocarcinoma cells in culture.
Topics: Cell Division; Chloramphenicol O-Acetyltransferase; Endometrium; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Luciferases; Nuclear Proteins; Receptors, Estrogen; Tamoxifen; Transfection; Tumor Cells, Cultured | 1998 |
The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Humans; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Transforming Growth Factor alpha | 1998 |
Classification of breast cancer cells on the basis of a functional assay for estrogen receptor.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Survival; DNA-Binding Proteins; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Promoter Regions, Genetic; Receptors, Estrogen; Regulatory Sequences, Nucleic Acid; Tamoxifen; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 1998 |
Anti-estrogens induce apoptosis of multiple myeloma cells.
Topics: Apoptosis; Breast Neoplasms; Cell Division; Cell Survival; Coloring Agents; Estradiol; Estrogen Antagonists; Flow Cytometry; Fulvestrant; Hematopoietic Stem Cells; Humans; Immunoblotting; Multiple Myeloma; Propidium; Receptors, Estrogen; Tamoxifen; Toremifene; Tumor Cells, Cultured | 1998 |
Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins.
Topics: Diethylstilbestrol; Dimerization; DNA Nucleotidyltransferases; Estradiol; Estrogen Antagonists; Fulvestrant; Hexestrol; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen | 1998 |
The estrogen receptor's involvement in osteoblasts' adaptive response to mechanical strain.
Topics: Animals; Bone Remodeling; Cell Division; Down-Regulation; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factor 2; Fulvestrant; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Male; Osteoblasts; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Stress, Mechanical; Tamoxifen | 1998 |
Estrogen increases the permeability of the cultured human cervical epithelium by modulating cell deformability.
Topics: Actins; Cell Line; Cell Membrane Permeability; Cells, Cultured; Cervix Uteri; Chlorides; Diethylstilbestrol; Egtazic Acid; Epithelial Cells; Estradiol; Estriol; Estrogen Antagonists; Estrogens; Estrone; Female; Fulvestrant; Humans; Kinetics; Progesterone; Sodium; Tamoxifen | 1998 |
Effect of estrogens on IL-1beta promoter activity.
Topics: Animals; Cell Line; Chloramphenicol O-Acetyltransferase; Drug Synergism; Estradiol; Estrogen Antagonists; Exons; Fulvestrant; Genes, Reporter; Humans; Interleukin-1; Lipopolysaccharides; Macrophages; Mice; Progesterone; Promoter Regions, Genetic; Recombinant Fusion Proteins; Tamoxifen; Testosterone; Transcription, Genetic; Transfection | 1998 |
Effects of partial versus pure antiestrogens on ovulation and the pituitary-ovarian axis in the rat.
Topics: Animals; Estradiol; Estrogen Antagonists; Estrus; Female; Follicle Stimulating Hormone; Fulvestrant; Luteinizing Hormone; Ovulation; Pituitary Gland; Prolactin; Rats; Rats, Wistar; Structure-Activity Relationship; Tamoxifen | 1998 |
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Models, Animal; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Mice; Mice, Nude; Ovariectomy; Tamoxifen; Toremifene | 1998 |
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured | 1998 |
Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens.
Topics: Animals; Breast Neoplasms; Carrier Proteins; Cell Nucleus; Estradiol; Estrogen Antagonists; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins; Female; Fulvestrant; Genes, Tumor Suppressor; Growth Inhibitors; Half-Life; Humans; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Organ Culture Techniques; Pregnancy; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tamoxifen; Transcription, Genetic | 1997 |
Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Division; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Polyunsaturated Alkamides; Proto-Oncogene Proteins; S Phase; Tamoxifen; Tumor Cells, Cultured; Zinc Sulfate | 1997 |
A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; DNA Primers; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factors; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tamoxifen; Transforming Growth Factor beta; Tumor Cells, Cultured; Up-Regulation | 1998 |
Effect of tamoxifen on cholesterol synthesis in HepG2 cells and cultured rat hepatocytes.
Topics: Acetates; Animals; Carbon Isotopes; Cells, Cultured; Cholesterol; Estradiol; Estrogen Antagonists; Fulvestrant; Gas Chromatography-Mass Spectrometry; Glucose; Humans; Hydroxycholesterols; Liver; Mevalonic Acid; Progesterone; Rats; Steroids; Tamoxifen; Triglycerides; Tumor Cells, Cultured | 1998 |
Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; beta-Galactosidase; Blotting, Western; Dimerization; DNA; DNA Primers; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Ligands; Molecular Sequence Data; Nuclear Proteins; Nuclear Receptor Interacting Protein 1; Polymerase Chain Reaction; Receptors, Estrogen; Recombinant Fusion Proteins; Saccharomyces cerevisiae; Sequence Alignment; Tamoxifen | 1999 |
Transcriptional regulation by a naturally occurring truncated rat estrogen receptor (ER), truncated ER product-1 (TERP-1).
Topics: Animals; Binding, Competitive; Blotting, Western; Chlorocebus aethiops; COS Cells; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Pituitary Gland; Plasmids; Precipitin Tests; Rats; Receptors, Estrogen; Tamoxifen | 1999 |
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
Topics: Antineoplastic Agents, Hormonal; Cell Division; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Tamoxifen; Toremifene | 1999 |
Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Binding, Competitive; Breast Neoplasms; Cell Count; Cell Division; DNA, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Mice; Rats; Rats, Wistar; Receptors, Estrogen; Tamoxifen; Thymidine; Tumor Cells, Cultured; Uterus | 1999 |
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Transformation, Neoplastic; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mice; Neoplasms, Hormone-Dependent; Tamoxifen; Toremifene | 1999 |
17Beta-estradiol decreases nitric oxide synthase II synthesis in vascular smooth muscle cells.
Topics: Animals; Aorta; Cells, Cultured; Estradiol; Estrogen Antagonists; Fulvestrant; Male; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Progesterone; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; RNA, Messenger; Tamoxifen | 1999 |
Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals.
Topics: DDT; Environmental Pollutants; Estradiol; Estrogens; Ethanol; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Vitellogenins | 1999 |
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Risk; Tamoxifen; Toremifene | 1999 |
Differences in morphology and cytoskeleton of MCF-7 and MX-1 cells after therapy with OH-tamoxifen and the pure estrogen antagonist ZM 182780. An immunofluorescence and scanning electron microscopic study.
Topics: Actins; Antineoplastic Agents; Breast Neoplasms; Cytoskeleton; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Immunohistochemistry; Keratins; Microscopy, Electron, Scanning; Receptors, Estrogen; Tamoxifen; Tubulin; Tumor Cells, Cultured; Vimentin | 1999 |
Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability.
Topics: Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Ligands; Molecular Weight; Peptide Fragments; Polyunsaturated Alkamides; Protein Conformation; Receptors, Estrogen; Tamoxifen; Trypsin | 1999 |
Short-term exposure to physiological levels of 17 beta-estradiol enhances endothelium-independent relaxation in porcine coronary artery.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Coronary Vessels; Cromakalim; Drug Synergism; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Female; Fulvestrant; In Vitro Techniques; Male; Nitroprusside; Swine; Tamoxifen; Time Factors; Vasoconstrictor Agents; Vasodilation | 1999 |
Inhibition of estrogen receptor function promotes porcine coronary artery smooth muscle cell proliferation.
Topics: Animals; Base Sequence; Cell Division; DNA Primers; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Muscle, Smooth, Vascular; Receptors, Estrogen; RNA, Messenger; Swine; Tamoxifen; Tumor Cells, Cultured | 1999 |
Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae.
Topics: Animals; Calcium; Cattle; Cell Membrane; Cells, Cultured; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fluorescein-5-isothiocyanate; Fulvestrant; Humans; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Receptors, Estrogen; Serum Albumin, Bovine; Tamoxifen | 1999 |
Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Iodine Radioisotopes; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured | 1999 |
Estrogen stimulates neuronal nitric oxide synthase protein expression in human neutrophils.
Topics: Adult; Aged; Cardiovascular Diseases; CD18 Antigens; Cell Adhesion; Enzyme Induction; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Luteinizing Hormone; Male; Menstrual Cycle; Middle Aged; Neutrophils; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; omega-N-Methylarginine; Postmenopause; Premenopause; Receptors, Estrogen; Sex Characteristics; Tamoxifen | 1999 |
Comparative analyses of mechanistic differences among antiestrogens.
Topics: Blood Proteins; Breast Neoplasms; Cell Division; Cinnamates; Drug Stability; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression; Humans; Protein Binding; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Stilbenes; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 1999 |
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Tamoxifen; Time Factors; Triazoles; Tumor Cells, Cultured | 1999 |
Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.
Topics: Blotting, Northern; Blotting, Western; Breast Neoplasms; DNA Primers; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Polyunsaturated Alkamides; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Tumor Cells, Cultured | 1999 |
How is tamoxifen's action subverted?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, BRCA1; Humans; Phosphoproteins; Proteins; Receptors, Estrogen; Retinoblastoma-Like Protein p130; Tamoxifen | 2000 |
The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; DNA Primers; Dose-Response Relationship, Drug; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Microscopy, Electron; Microscopy, Fluorescence; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured | 1999 |
Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements.
Topics: Cloning, Molecular; Estradiol; Estrogen Antagonists; Fulvestrant; Glutathione Transferase; HeLa Cells; Humans; Ligands; Models, Biological; Mutagenesis; Plasmids; Promoter Regions, Genetic; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Structure, Tertiary; Receptors, Estrogen; Sp1 Transcription Factor; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 2000 |
Differential cross-talk of estrogen and growth factor receptors in two human mammary tumor cell lines.
Topics: Breast Neoplasms; Cell Division; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Insulin-Like Growth Factor I; Neuregulin-1; Receptors, Estrogen; Signal Transduction; Tamoxifen; Tumor Cells, Cultured | 1999 |
Activation of the human estrogen receptor by the antiestrogens ICI 182,780 and tamoxifen in yeast genetic systems: implications for their mechanism of action.
Topics: Binding Sites; DNA Primers; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Lac Operon; Ligands; Molecular Sequence Data; Receptors, Estrogen; Recombinant Proteins; Saccharomyces cerevisiae; Tamoxifen; Transcription, Genetic | 2000 |
Aromatase inhibitors and their antitumor effects in model systems.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Mice; Mice, Inbred BALB C; Models, Biological; Neoplasms, Hormone-Dependent; Tamoxifen; Transfection | 1999 |
Differential effects of 17beta-estradiol and testosterone on the contractile responses of porcine coronary arteries.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Androgen Antagonists; Androgen Receptor Antagonists; Animals; Coronary Vessels; Cycloheximide; Cyproterone; Dactinomycin; Dose-Response Relationship, Drug; Endothelin-1; Estradiol; Estrogen Antagonists; Female; Flutamide; Fulvestrant; In Vitro Techniques; Isotonic Solutions; Male; Potassium Chloride; Receptors, Estrogen; Serotonin; Swine; Tamoxifen; Testosterone; Vasoconstriction | 2000 |
Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects.
Topics: Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; HeLa Cells; Humans; Ligands; Muscle, Smooth, Vascular; Promoter Regions, Genetic; Receptors, Estrogen; Regression Analysis; RNA; Tamoxifen; Transcription, Genetic | 2000 |
Subnuclear trafficking of estrogen receptor-alpha and steroid receptor coactivator-1.
Topics: Antibodies, Monoclonal; Binding Sites; Biological Transport; Cell Nucleus; Estradiol; Estrogen Receptor alpha; Fulvestrant; Gene Deletion; Green Fluorescent Proteins; HeLa Cells; Histone Acetyltransferases; Humans; Infant; Kinetics; Luminescent Proteins; Mutagenesis; Nuclear Matrix; Nuclear Receptor Coactivator 1; Receptors, Estrogen; Recombinant Fusion Proteins; Tamoxifen; Transcription Factors; Tumor Cells, Cultured | 2000 |
Functional interactions between the estrogen receptor and DRIP205, a subunit of the heteromeric DRIP coactivator complex.
Topics: Animals; Carrier Proteins; Cell Line; COS Cells; Estradiol; Fulvestrant; Humans; Mediator Complex; Mediator Complex Subunit 1; Mutation; Nuclear Proteins; Peptide Fragments; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction; Surface Plasmon Resonance; Tamoxifen; Trans-Activators; Transcription Factors; Transcriptional Activation; Transfection | 2000 |
Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
Topics: Cell Culture Techniques; Cell Division; Cells, Cultured; Diethylstilbestrol; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens, Non-Steroidal; Fulvestrant; Humans; Male; Methylation; Oligonucleotides, Antisense; Prostate; Prostatic Neoplasms; Protein Biosynthesis; Proteins; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |
Putative membrane-bound estrogen receptors possibly stimulate mitogen-activated protein kinase in the rat hippocampus.
Topics: Animals; Cell Membrane; Cell Nucleus; Dose-Response Relationship, Drug; Enzyme Activators; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Hippocampus; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen | 2000 |
Influence of antiestrogens on the invasiveness and laminin attachment of breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Basement Membrane; Breast Neoplasms; Cell Adhesion; Collagen; Drug Combinations; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Laminin; Microscopy, Electron, Scanning; Microvilli; Neoplasm Invasiveness; Neoplasm Metastasis; Proteoglycans; Pseudopodia; Tamoxifen; Tumor Cells, Cultured | 1999 |
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
Topics: Allosteric Regulation; Amino Acid Substitution; Aspartic Acid; Binding Sites; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Glycine; Humans; Kinetics; Ligands; Mutagenesis, Site-Directed; Protein Conformation; Protein Structure, Tertiary; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2000 |
Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells.
Topics: Animals; Cells, Cultured; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Ligands; Mammary Glands, Animal; Osteoblasts; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Response Elements; Tamoxifen | 2000 |
Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain.
Topics: Adenocarcinoma; Antigens, Polyomavirus Transforming; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cyclin D1; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; G1 Phase; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Structure, Tertiary; Recombinant Fusion Proteins; Retinoblastoma Protein; Tamoxifen; Transfection; Tumor Cells, Cultured | 2000 |
Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism.
Topics: Animals; Barium Compounds; Calcium Channel Blockers; Chlorides; Coronary Vessels; Dose-Response Relationship, Drug; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Female; Fulvestrant; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rabbits; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Vasodilation | 2000 |
Differential transcriptional regulation of rat vasopressin gene expression by estrogen receptor alpha and beta.
Topics: Animals; Arginine Vasopressin; Base Sequence; Cell Line; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression Regulation; Humans; Luciferases; Molecular Sequence Data; Mutagenesis, Site-Directed; Rats; Receptors, Estrogen; Response Elements; Tamoxifen; Transcription, Genetic; Transfection | 2000 |
Mechanical strain stimulates osteoblast proliferation through the estrogen receptor in males as well as females.
Topics: Androgen Antagonists; Androstenedione; Animals; Antibodies; Aromatase Inhibitors; Cells, Cultured; Dihydrotestosterone; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens; Flutamide; Fulvestrant; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Male; Osteoblasts; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Stress, Mechanical; Tamoxifen; Testosterone; Thymidine | 2000 |
Increased expression of cytochrome p450 1A1 and 1B1 genes in anti-estrogen-resistant human breast cancer cell lines.
Topics: Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Blotting, Northern; Blotting, Southern; Breast Neoplasms; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Neoplasm Proteins; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured | 2000 |
Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.
Topics: Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Proteins; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger; Tamoxifen; TNF Receptor-Associated Factor 1; Tumor Cells, Cultured | 2000 |
Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats.
Topics: Animals; Apoptosis; Bile Ducts; Bile Ducts, Intrahepatic; Blotting, Western; Cell Division; Epithelial Cells; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Immunohistochemistry; Ligation; Liver; Male; Rats; Rats, Wistar; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2000 |
Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.
Topics: Active Transport, Cell Nucleus; Amino Acid Sequence; Animals; Cell Compartmentation; Cell Line; Cell Nucleus; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Green Fluorescent Proteins; Indicators and Reagents; Kinetics; Ligands; Luminescent Proteins; Macromolecular Substances; Molecular Sequence Data; Nuclear Receptor Coactivator 2; Peptides; Protein Structure, Tertiary; Receptors, Estrogen; Recombinant Fusion Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors | 2000 |
FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent.
Topics: Bacterial Proteins; Biological Transport; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dactinomycin; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; HeLa Cells; Histone Acetyltransferases; Humans; Leupeptins; Ligands; Luminescent Proteins; Microscopy, Fluorescence; Multienzyme Complexes; Nuclear Matrix; Nuclear Receptor Coactivator 1; Proteasome Endopeptidase Complex; Protein Structure, Tertiary; Receptors, Estrogen; Tamoxifen; Transcription Factors; Transcription, Genetic | 2001 |
Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Stilbenes; Tamoxifen; Time Factors; Toremifene; Tumor Cells, Cultured | 2000 |
Regulation of the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Deoxyribonuclease I; DNA; DNA Footprinting; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; Proteins; Response Elements; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |
Dehydroepiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiol.
Topics: Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Chromatography, Thin Layer; Dehydroepiandrosterone; Dexamethasone; Dihydrotestosterone; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunoassay; Mitogens; Tamoxifen; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2001 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Hormonal; Blotting, Northern; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Movement; Cells, Cultured; Cysteine-Rich Protein 61; Disease Progression; DNA, Complementary; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Library; Growth Substances; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; Middle Aged; Multivariate Analysis; Neoplasm Transplantation; Promoter Regions, Genetic; Protein Binding; Receptors, Estrogen; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |
Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Nerve Growth Factor; PC12 Cells; Phosphorylation; Rats; Receptor, trkA; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured | 2001 |
Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway.
Topics: Animals; Blotting, Western; Cell Line; Drug Synergism; Enzyme Activation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fibroblasts; Fulvestrant; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Rats; Receptors, Estrogen; Tamoxifen; Transfection | 2001 |
Induction of UO-44 gene expression by tamoxifen in the rat uterus and ovary.
Topics: Animals; DNA, Complementary; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Humans; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Subcellular Fractions; Tamoxifen; Tissue Distribution; Tumor Cells, Cultured; Uterus | 2001 |
Estrogen protects neuronal cells from amyloid beta-induced apoptotic cell death.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Brain; Calcium; Cell Survival; Cytochrome c Group; DNA Fragmentation; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Fulvestrant; Intracellular Fluid; Menopause; Mitochondria; Nerve Degeneration; Neurons; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Rats; Tamoxifen | 2001 |
S-adenosylmethionine decarboxylase overexpression reduces invasiveness and tumorigenicity in nude mice of MCF-7 breast cancer cells.
Topics: Adenosylmethionine Decarboxylase; Agar; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Collagen; DNA-Binding Proteins; Drug Combinations; Epidermal Growth Factor; Estradiol; Female; Fulvestrant; Humans; Laminin; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Proteoglycans; Sensitivity and Specificity; STAT3 Transcription Factor; Tamoxifen; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
Estrogen downregulates the number of caveolae and the level of caveolin in uterine smooth muscle.
Topics: Animals; Caveolae; Caveolin 1; Caveolin 2; Caveolins; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Microscopy, Electron; Muscle, Smooth; Myometrium; Ovariectomy; Pregnancy; Protein Isoforms; Rats; Rats, Wistar; Tamoxifen; Uterus | 2001 |
Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.
Topics: Animals; Atrophy; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Immunohistochemistry; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Intracellular Signaling Peptides and Proteins; Ki-67 Antigen; Mammary Glands, Animal; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Proto-Oncogene Proteins c-raf; Rats; Rats, Sprague-Dawley; Receptor, IGF Type 1; RNA, Messenger; Signal Transduction; Somatomedins; Tamoxifen | 2001 |
Differential activation of wild-type and variant forms of estrogen receptor alpha by synthetic and natural estrogenic compounds using a promoter containing three estrogen-responsive elements.
Topics: Benzhydryl Compounds; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Estrogens, Non-Steroidal; Fulvestrant; Humans; Phenols; Polychlorinated Biphenyls; Polymorphism, Genetic; Receptors, Estrogen; Response Elements; Tamoxifen; Transfection; Tumor Cells, Cultured | 2001 |
A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Topics: Animals; Binding, Competitive; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Organ Size; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Sensitivity and Specificity; Tamoxifen; Time Factors; Tumor Cells, Cultured; Uterus; Xenograft Model Antitumor Assays | 2001 |
Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2001 |
Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
Topics: Adenylyl Cyclases; Breast Neoplasms; Carbazoles; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Indoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-raf; Pyrroles; Receptors, Cell Surface; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Tumor Cells, Cultured | 2002 |
Expression and regulation of Cyr61 in human breast cancer cell lines.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Breast Neoplasms; Calcitriol; Cysteine-Rich Protein 61; Drug Resistance; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Immediate-Early; Growth Substances; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phenotype; Protein Structure, Tertiary; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Selective Estrogen Receptor Modulators; Tamoxifen; Tetradecanoylphorbol Acetate; Transcriptional Activation; Transfection; Tretinoin; Tumor Cells, Cultured | 2002 |
Comparative effects of testosterone propionate, oestradiol benzoate, ICI 182,780, tamoxifen and raloxifene on hypothalamic differentiation in the female rat.
Topics: Analysis of Variance; Animals; Animals, Newborn; Cell Differentiation; Chi-Square Distribution; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Hypothalamus; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Testosterone | 2002 |
Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer.
Topics: Cell Line; Diethylstilbestrol; Energy Transfer; Estradiol; Estrogen Receptor alpha; Fulvestrant; Green Fluorescent Proteins; Ligands; Luminescent Proteins; Peptides; Protein Structure, Secondary; Receptors, Estrogen; Recombinant Fusion Proteins; Red Fluorescent Protein; Response Elements; Selective Estrogen Receptor Modulators; Spectrometry, Fluorescence; Tamoxifen; Transcription, Genetic | 2002 |
Fulvestrant: clinical application of an estrogen receptor downregulator.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Goserelin; Humans; Tamoxifen | 2002 |
Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade.
Topics: Anisomycin; Anti-Bacterial Agents; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Genes, ras; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-raf; Receptors, Estrogen; Recombinant Proteins; Tamoxifen; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 2002 |
Human osteoblasts' proliferative responses to strain and 17beta-estradiol are mediated by the estrogen receptor and the receptor for insulin-like growth factor I.
Topics: Antibodies, Monoclonal; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Osteoblasts; Receptor, IGF Type 1; Stress, Mechanical; Tamoxifen; Thymidine | 2002 |
Effects of dietary phytoestrogens in vivo and in vitro in rainbow trout and Siberian sturgeon: interests and limits of the in vitro studies of interspecies differences.
Topics: Animals; Cells, Cultured; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Ethinyl Estradiol; Female; Fishes; Fulvestrant; Genistein; Hepatocytes; Isoflavones; Male; Phytoestrogens; Plant Preparations; Receptors, Estrogen; Species Specificity; Tamoxifen; Vitellogenins | 2002 |
Tamoxifen elicits its anti-estrogen effects in growth plate chondrocytes by inhibiting protein kinase C.
Topics: Alkaline Phosphatase; Animals; Cell Membrane; Cells, Cultured; Chondrocytes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Male; Protein Kinase C; Protein Transport; Proteoglycans; Rats; Rats, Sprague-Dawley; Sex Factors; Signal Transduction; Tamoxifen; Time Factors | 2002 |
Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone.
Topics: Animals; Blood Vessels; Body Weight; Brain; Dose-Response Relationship, Drug; Drug Implants; Enzyme Activation; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Fulvestrant; In Vitro Techniques; Medroxyprogesterone Acetate; Models, Animal; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Organ Size; Ovariectomy; Progesterone; Rats; Rats, Inbred F344; Receptors, Estrogen; Tamoxifen; Uterus | 2002 |
Direct actions of estradiol on the anterior pituitary gland are required for hypothalamus-dependent lactotrope proliferation and secretory surges of luteinizing hormone but not of prolactin in female rats.
Topics: Animals; Blood-Brain Barrier; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hypothalamus; Lactation; Luteinizing Hormone; Organ Size; Ovariectomy; Ovulation; Pituitary Gland, Anterior; Prolactin; Rats; Rats, Wistar; Receptors, Progesterone; Sucking Behavior; Tamoxifen; Uterus | 2002 |
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Endocrine Glands; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Trastuzumab; Tumor Cells, Cultured | 2002 |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2002 |
Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera.
Topics: Amino Acid Sequence; Animals; Antibodies; Breast Neoplasms; COS Cells; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Humans; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Phosphorylation; Protein Serine-Threonine Kinases; Receptors, Estrogen; Serine; Signal Transduction; Tamoxifen | 2002 |
Interactions of ATP, oestradiol, genistein and the anti-oestrogens, faslodex (ICI 182780) and tamoxifen, with the human erythrocyte glucose transporter, GLUT1.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Binding Sites; Biological Transport; Cytochalasin B; Enzyme Inhibitors; Erythrocyte Membrane; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Fulvestrant; Genistein; Glucose; Glucose Transporter Type 1; Humans; Ligands; Models, Biological; Models, Molecular; Molecular Sequence Data; Monosaccharide Transport Proteins; Phloretin; Protein Structure, Secondary; Protein Structure, Tertiary; Tamoxifen | 2002 |
Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat.
Topics: Animals; Bile Ducts, Intrahepatic; Cell Division; Estradiol; Estrogen Antagonists; Fulvestrant; In Vitro Techniques; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Rats; Rats, Wistar; Tamoxifen | 2002 |
The pure anti-oestrogen ICI 182,780 (Faslodex) activates large conductance Ca(2+)-activated K(+) channels in smooth muscle.
Topics: Animals; Colon; Dogs; Estradiol; Estrogen Antagonists; Fulvestrant; In Vitro Techniques; Ion Channel Gating; Muscle Cells; Muscle, Smooth; Patch-Clamp Techniques; Potassium Channels, Calcium-Activated; Tamoxifen | 2002 |
Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists.
Topics: Amino Acid Motifs; Amino Acid Sequence; Binding Sites; Cell Line; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; HeLa Cells; Humans; In Vitro Techniques; Molecular Sequence Data; Mutagenesis, Site-Directed; Peptide Library; Receptors, Estrogen; Repressor Proteins; Signal Transduction; Tamoxifen; Transcription, Genetic | 2002 |
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Lymphokines; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Fractionation; Cell Size; Estradiol; Estrogen Antagonists; Etoposide; Fulvestrant; Genes, Reporter; HeLa Cells; Humans; Microscopy, Electron; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Transcriptional Activation | 2002 |
Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
Topics: Adaptor Proteins, Signal Transducing; ATPases Associated with Diverse Cellular Activities; Blotting, Northern; Blotting, Western; Breast Neoplasms; Carrier Proteins; Cell Division; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Nuclear Proteins; Nuclear Receptor Co-Repressor 2; Nuclear Receptor Interacting Protein 1; Phosphoproteins; Phosphorylation; Proteasome Endopeptidase Complex; Protozoan Proteins; Receptors, Estrogen; Receptors, Progesterone; Repressor Proteins; RNA, Messenger; Tamoxifen; Transcription Factors; Tumor Cells, Cultured | 2002 |
In vitro antiestrogenic effects of aryl methyl sulfone metabolites of polychlorinated biphenyls and 2,2-bis(4-chlorophenyl)-1,1-dichloroethene on 17beta-estradiol-induced gene expression in several bioassay systems.
Topics: Adenocarcinoma; Animals; Biphenyl Compounds; Breast Neoplasms; Carps; Cell Line; Cell Survival; Cytochrome P-450 CYP1A1; Dichlorodiphenyl Dichloroethylene; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Hepatocytes; Humans; Luciferases; Male; Polychlorinated Biphenyls; Rats; Tamoxifen; Vitellogenins | 2002 |
Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells.
Topics: Blotting, Western; Cell Nucleus; Chromatin; Deoxyribonuclease I; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation; Humans; Immunohistochemistry; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Proteins; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2002 |
Estrogen blocks 3-nitropropionic acid-induced Ca2+i increase and cell damage in cultured rat cerebral endothelial cells.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Bradykinin; Brain; Calcium; Calcium Signaling; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Fulvestrant; Immunohistochemistry; In Situ Nick-End Labeling; Necrosis; Nitro Compounds; Propionates; Rats; Rats, Wistar; Tamoxifen; von Willebrand Factor | 2002 |
Enhancing effects of estrogen on inhibitory avoidance performance may be in part independent of intracellular estrogen receptors in the hippocampus.
Topics: Animals; Avoidance Learning; Cognition; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hippocampus; Ovariectomy; Rats; Rats, Long-Evans; Receptors, Estrogen; Tamoxifen | 2002 |
Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Glutathione Transferase; HeLa Cells; Histone Deacetylases; Humans; Luciferases; Models, Biological; Models, Molecular; Mutation; Plasmids; Precipitin Tests; Progesterone; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transfection; Tumor Cells, Cultured | 2003 |
Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12.
Topics: Aspartic Acid; Blotting, Northern; Blotting, Western; Cell Line; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Humans; Ligands; Luciferases; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Protein Binding; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Time Factors; Transcription, Genetic; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2003 |
Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
Topics: Base Composition; Base Sequence; Binding Sites; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Fulvestrant; Gene Expression Regulation; Molecular Sequence Data; Point Mutation; Promoter Regions, Genetic; Protein Structure, Tertiary; Receptors, Estrogen; Sp1 Transcription Factor; Tamoxifen; Tumor Cells, Cultured; Zinc Fingers | 2003 |
Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Breast Neoplasms; DNA Damage; DNA Repair; DNA-Binding Proteins; Enzyme Activation; Epithelial Cells; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Guanine; Humans; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Xeroderma Pigmentosum Group A Protein | 2003 |
Estradiol inhibits atp-induced intracellular calcium concentration increase in dorsal root ganglia neurons.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Channel Blockers; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Fulvestrant; Ganglia, Spinal; Neurons; Potassium Chloride; Rats; Rats, Sprague-Dawley; Tamoxifen | 2003 |
Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Topics: Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Division; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Humans; Ligands; Membrane Proteins; Piperidines; Presenilin-2; Protein Binding; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Time Factors; Tumor Cells, Cultured | 2003 |
Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation.
Topics: Amino Acid Substitution; Base Sequence; Binding Sites; DNA; Estradiol; Estrogen Receptor alpha; Fulvestrant; HeLa Cells; Humans; In Vitro Techniques; Leucine; Ligands; Models, Molecular; Mutagenesis, Site-Directed; Promoter Regions, Genetic; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Transcription Factor AP-1; Transcriptional Activation; Two-Hybrid System Techniques | 2003 |
Antiestrogens are pro-apoptotic in normal human breast epithelial cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Breast; Breast Neoplasms; Caspase 3; Caspases; Cells, Cultured; Enzyme Induction; Epithelial Cells; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, p53; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Stimulation, Chemical; Tamoxifen; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Idoxifene and estradiol enhance antiapoptotic activity through estrogen receptor-beta in cultured rat hepatocytes.
Topics: Animals; Antioxidants; Apoptosis; Blotting, Western; Cells, Cultured; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Female; Flow Cytometry; Fulvestrant; Hepatocytes; Liver; Male; Microscopy, Confocal; Oxidative Stress; Rats; Rats, Wistar; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2003 |
The effect of estradiol in the striatum is blocked by ICI 182,780 but not tamoxifen: pharmacological and behavioral evidence.
Topics: Amphetamine; Analysis of Variance; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Organ Culture Techniques; Rats; Rats, Sprague-Dawley; Sexual Behavior, Animal; Tamoxifen | 2003 |
Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus.
Topics: Animals; Cell Division; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation; Insulin-Like Growth Factor I; Ki-67 Antigen; Organ Size; Ovariectomy; Proliferating Cell Nuclear Antigen; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Receptors, Somatotropin; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2003 |
Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting.
Topics: Carrier Proteins; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Folate Receptors, GPI-Anchored; Fulvestrant; Gene Silencing; HeLa Cells; Humans; Ovarian Neoplasms; Promoter Regions, Genetic; Receptors, Cell Surface; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2003 |
Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Ligands; MAP Kinase Kinase Kinases; Multienzyme Complexes; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Receptors, Estrogen; Tamoxifen; Transcription, Genetic | 2003 |
p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p27; DNA-Binding Proteins; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Growth Substances; Humans; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Co-Repressor 2; Receptors, Estrogen; Repressor Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo.
Topics: Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Genes, Reporter; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oncogene Proteins; Phosphorylation; Plasmids; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Response Elements; RNA, Messenger; Tamoxifen; Time Factors; Transcription, Genetic; Transfection | 2003 |
Identification of estrogen receptor beta expression in Chinese hamster ovary (CHO) cells and comparison of estrogen-responsive gene transcription in cells adapted to serum-free media.
Topics: Animals; CHO Cells; Cricetinae; Culture Media, Serum-Free; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Ethanol; Fulvestrant; Gene Expression Regulation; Genes, Reporter; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; RNA, Messenger; Tamoxifen; Transcription, Genetic | 2003 |
Effect of estrogen and antiestrogens on the estrogen receptor content in the cochlea of ovariectomized rats.
Topics: Animals; Cochlea; Disease Models, Animal; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Immunohistochemistry; Ovariectomy; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stria Vascularis; Tamoxifen | 2003 |
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Combinations; Drug Resistance; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tamoxifen | 2003 |
The differential effects of tamoxifen and ICI 182,780 on the reduction of Na+/K+ ATPase activity and spontaneous oscillations by 17beta-estradiol.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Oscillometry; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Tamoxifen; Uterine Contraction; Uterus | 2003 |
Future directions in the endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endocrine System; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism.
Topics: Analysis of Variance; Animals; Blotting, Western; Cell Cycle Proteins; Cell Division; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p27; DNA; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fibroblasts; Fulvestrant; In Situ Nick-End Labeling; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; Phosphorylation; Proliferating Cell Nuclear Antigen; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Suppressor Proteins | 2003 |
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth.
Topics: Antineoplastic Agents, Hormonal; Carcinosarcoma; Cell Cycle; Cell Division; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Progesterone; Raloxifene Hydrochloride; Tamoxifen; Triptorelin Pamoate; Uterine Neoplasms | 2003 |
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Fas Ligand Protein; Female; Fulvestrant; Humans; In Situ Nick-End Labeling; Membrane Glycoproteins; Mice; Mice, Nude; Polymerase Chain Reaction; Receptor, ErbB-2; Tamoxifen; Transforming Growth Factor alpha; Transplantation, Heterologous | 2003 |
Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1.
Topics: Breast Neoplasms; Cycloheximide; DNA-Binding Proteins; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Galactosyltransferases; Gene Expression Regulation; Humans; Insulin-Like Growth Factor Binding Protein 4; Neoplasm Proteins; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Pesticides; Phytoestrogens; Protein Synthesis Inhibitors; Puromycin; Receptors, Estrogen; Regulatory Factor X Transcription Factors; Tamoxifen; Transcription Factors; Tumor Cells, Cultured; X-Box Binding Protein 1 | 2004 |
Tamoxifen induces vasorelaxation via inhibition of mitogen-activated protein kinase in rat aortic smooth muscle.
Topics: Animals; Aorta; Blotting, Western; Endothelin-1; Estradiol; Fulvestrant; Imidazoles; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Pyridines; Rats; Tamoxifen; Vasodilation | 2003 |
Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
Topics: Blotting, Western; Breast Neoplasms; Cell Fusion; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Flow Cytometry; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Protein 2; Microscopy, Phase-Contrast; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2003 |
Estrogenic activity of procymidone in rainbow trout (Oncorhynchus mykiss) hepatocytes: a possible mechanism of action.
Topics: alpha-Tocopherol; Animals; Bridged Bicyclo Compounds; Cell Survival; Cells, Cultured; Drug Combinations; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Female; Fulvestrant; Fungicides, Industrial; Hepatocytes; Mitogen-Activated Protein Kinase Kinases; Oncorhynchus mykiss; Reactive Oxygen Species; Tamoxifen; Vitellogenins | 2004 |
Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Progesterone; Progestins; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; RNA, Small Interfering; Tamoxifen; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |
Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses e
Topics: Breast Neoplasms; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; gamma-Linolenic Acid; Humans; Luciferases; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 2004 |
Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Calcitriol; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Genes, bcl-2; Humans; Predictive Value of Tests; Receptors, Calcitriol; Receptors, Estrogen; Tamoxifen; Vitamin D | 2004 |
Isoflavones stimulate estrogen receptor-mediated core histone acetylation.
Topics: Acetylation; Acetyltransferases; Animals; Cell Line; Drosophila; Equol; Estradiol; Estrogen Antagonists; Fulvestrant; Genistein; Histone Acetyltransferases; Histones; Isoflavones; Nuclear Proteins; Nuclear Receptor Coactivator 2; Receptors, Estrogen; Recombinant Proteins; Spodoptera; Tamoxifen; Trans-Activators; Transcription Factors; Transcription, Genetic | 2004 |
Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells.
Topics: Breast Neoplasms; Cell Proliferation; Cyclin A; DNA-Binding Proteins; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Mutation; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Smad2 Protein; Smad3 Protein; Smad4 Protein; Tamoxifen; Trans-Activators; Transforming Growth Factor beta; Tumor Cells, Cultured | 2004 |
Re-expression of estrogen receptor alpha using a tetracycline-regulated gene expression system induced estrogen-mediated growth inhibition of the MDA-MB-231 breast cancer cell line.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Chloramphenicol O-Acetyltransferase; Clone Cells; Doxycycline; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; S Phase; Tamoxifen; Transfection | 2004 |
Re: Playing the old piano: another tune for endocrine therapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation.
Topics: Breast Neoplasms; Cell Proliferation; Cell Transformation, Neoplastic; Cycloheximide; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Time Factors; Tumor Cells, Cultured | 2004 |
Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
Topics: Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrrolidines; Raloxifene Hydrochloride; Response Elements; Tamoxifen; Thiophenes; Transcription, Genetic; Tumor Cells, Cultured | 2004 |
Distinct effects of the antiestrogen Faslodex on the stability of estrogen receptors-alpha and -beta in the breast cancer cell line MCF-7.
Topics: Acetylcysteine; Animals; Breast Neoplasms; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation; Genes, Reporter; Humans; Ligands; Point Mutation; Tamoxifen | 2004 |
Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Binding Sites; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fluorescence Resonance Energy Transfer; Fulvestrant; Humans; Luciferases; Microscopy, Confocal; Models, Biological; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Phosphorylation; Protein Conformation; Protein Structure, Tertiary; Receptors, Estrogen; RNA Interference; Serine; Tamoxifen; Time Factors; Transcriptional Activation; Transfection | 2004 |
A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene.
Topics: Breast Neoplasms; Cathepsin D; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Coactivator 1; Piperidines; Proto-Oncogene Proteins c-bcl-2; Receptors, Progesterone; Repressor Proteins; RNA, Messenger; Tamoxifen; Thiophenes; Transcription Factors | 2004 |
17beta-Estradiol promotes striatal medium size spiny neuronal maturation in vitro.
Topics: Animals; Caudate Nucleus; Cells, Cultured; Dopamine and cAMP-Regulated Phosphoprotein 32; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Female; Fulvestrant; Immunohistochemistry; Male; Mice; Nerve Tissue Proteins; Neurons; Phosphoproteins; Receptors, Estrogen; Sex Factors; Tamoxifen | 2004 |
Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor beta.
Topics: Animals; Cells, Cultured; Cyclooxygenase 2; Enzyme Activation; Estradiol; Estriol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Inflammation Mediators; Isoenzymes; Lipopolysaccharides; MAP Kinase Signaling System; Mice; Microglia; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Prostaglandin-Endoperoxide Synthases; RNA, Messenger; Tamoxifen; Tumor Necrosis Factor-alpha | 2004 |
Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Coloring Agents; DNA Fragmentation; Drug Resistance, Neoplasm; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Fulvestrant; G1 Phase; Hormone Antagonists; Humans; Immunoblotting; Mifepristone; Phosphorylation; Receptors, Estrogen; Receptors, Progesterone; Resting Phase, Cell Cycle; Tamoxifen; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells.
Topics: Androgen Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Male; Mutation; Prostatic Neoplasms; Receptors, Androgen; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Transcriptional Activation | 2004 |
Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation.
Topics: Acetylcholine; Androstadienes; Animals; Aorta; Blotting, Western; Cattle; Cell Line; Cerebral Veins; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitrites; Ovariectomy; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Tamoxifen; Vasodilation; Wortmannin | 2004 |
Understanding the biologic mechanisms responsible for breast-cancer progression during tamoxifen or fulvestrant treatment.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Disease Progression; Estradiol; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Tamoxifen; Treatment Failure; Tumor Cells, Cultured | 2004 |
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
Topics: Antimetabolites; Breast Neoplasms; Cell Division; Clodronic Acid; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors; Tumor Cells, Cultured | 2004 |
Intracellular signaling involved in estrogen regulation of serotonin reuptake.
Topics: Androgens; Animals; Calcium; Cells, Cultured; Cyclic AMP; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Fulvestrant; Gene Expression Regulation; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neurons; Progesterone; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction; Tamoxifen; Testosterone | 2004 |
Tissue-specific effect of estradiol on endothelial cell-dependent lymphocyte recruitment.
Topics: Animals; Autoimmunity; Cell Adhesion; Cells, Cultured; Chemokine CCL2; Chemokine CCL7; Chemokines; Chemotaxis; Cytokines; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogen Receptor beta; Estrogens; Female; Flow Cytometry; Fulvestrant; Intercellular Adhesion Molecule-1; Lymphocytes; Male; Mice; Microcirculation; Monocyte Chemoattractant Proteins; Receptors, Estrogen; RNA, Messenger; Sex Factors; Spleen; Tamoxifen; Time Factors; Vascular Cell Adhesion Molecule-1 | 2004 |
Selective estrogen receptor modulators prevent neointima formation after vascular injury.
Topics: Animals; Aorta; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Estradiol; Estrogens; Female; Fulvestrant; Muscle, Smooth, Vascular; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Tunica Intima | 2004 |
The putative tumor suppressor deleted in malignant brain tumors 1 is an estrogen-regulated gene in rodent and primate endometrial epithelium.
Topics: Agglutinins; Alu Elements; Animals; Blotting, Northern; Calcium-Binding Proteins; Cell Differentiation; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endometrium; Epithelium; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Haplorhini; Humans; Immunohistochemistry; Luciferases; Mucins; Mucous Membrane; Oligonucleotide Array Sequence Analysis; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; RNA; Tamoxifen; Transfection; Tumor Suppressor Proteins; Up-Regulation; Uterus | 2005 |
Tamoxifen exerts agonistic effects on clusterin and complement C3 gene expression in RUCA-I primary xenografts and metastases but not normal uterus.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Complement C3; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Neoplasm Metastasis; Rats; Rats, Inbred Strains; RNA, Messenger; Tamoxifen; Transplantation, Heterologous; Uterus | 2004 |
Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Blotting, Western; Cattle; Cell Nucleus; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Flavonoids; Fulvestrant; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mice; Microcirculation; Models, Biological; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phenols; Phosphorylation; Polyphenols; Resveratrol; Serine; Signal Transduction; Stilbenes; Tamoxifen; Time Factors; Transfection; Umbilical Veins; Wine | 2005 |
Estradiol and endocrine disrupting compounds adversely affect development of sea urchin embryos at environmentally relevant concentrations.
Topics: Age Factors; Analysis of Variance; Animals; Benzhydryl Compounds; California; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Embryonic Development; Estradiol; Estradiol Congeners; Fulvestrant; Pacific Ocean; Phenols; Sea Urchins; Tamoxifen; Toxicity Tests | 2005 |
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Carcinogens; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Humans; Luciferases; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Ovary; Protein Binding; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen; Time Factors; Transcriptional Activation; Treatment Outcome; Uterus | 2005 |
Suppression of ps20 expression in the rat uterus by tamoxifen and estrogens.
Topics: Animals; Culture Media, Conditioned; Epithelial Cells; Estradiol; Estrogen Antagonists; Estrogens; Estrous Cycle; Female; Fulvestrant; Gene Expression; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Lung; Muscle, Smooth; Myocardium; Ovariectomy; Polymerase Chain Reaction; Proteins; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Tamoxifen; Transfection; Uterus | 2005 |
Signal transduction. A new mediator for an old hormone?
Topics: Cell Membrane; Endoplasmic Reticulum; Estradiol; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gene Expression Regulation; Humans; Models, Biological; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Tamoxifen; Time Factors | 2005 |
A nongenomic action of 17beta-estradiol as the mechanism underlying the acute suppression of secretion of luteinizing hormone.
Topics: Animals; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Hormone Antagonists; Kinetics; Luteinizing Hormone; Nitriles; Phenols; Pituitary Gland, Anterior; Propionates; Pyrazoles; Secretory Rate; Sheep; Tamoxifen | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
Topics: Anilides; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Multivariate Analysis; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Tubulin | 2005 |
Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts.
Topics: Arthritis, Rheumatoid; Carrier Proteins; Cells, Cultured; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Fibroblasts; Fulvestrant; Glycoproteins; Humans; Membrane Glycoproteins; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; Synovial Membrane; Tamoxifen; Up-Regulation | 2005 |
Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-alpha expression in the rat uterus.
Topics: Animals; Blotting, Northern; Blotting, Western; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Immunohistochemistry; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2005 |
17beta-estradiol protects SH-SY5Y Cells against HIV-1 gp120-induced cell death: evidence for a role of estrogen receptors.
Topics: Cell Death; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Fulvestrant; HIV Envelope Protein gp120; Humans; Neurons; Neuroprotective Agents; Reactive Oxygen Species; Receptors, Estrogen; Tamoxifen | 2005 |
The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression; Hemodynamics; Hypertension; In Vitro Techniques; Magnetic Resonance Imaging; Models, Animal; Myocardium; Myosin Heavy Chains; Organ Size; Ovariectomy; Papillary Muscles; Random Allocation; Rats; Rats, Inbred SHR; Tamoxifen; Ventricular Myosins | 2005 |
Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Blotting, Northern; Cell Proliferation; Cells, Cultured; CpG Islands; DNA; Dose-Response Relationship, Drug; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Estradiol; Fulvestrant; Hippocampus; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Inflammation; Interleukin-6; L-Lactate Dehydrogenase; Lipopolysaccharides; Mice; Microglia; Nitric Oxide; Oligonucleotides; Protein Binding; Raloxifene Hydrochloride; Rats; Rats, Wistar; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2005 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Gonadal Steroid Hormones; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2005 |
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; GRB2 Adaptor Protein; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Models, Biological; Nitriles; Receptors, Estrogen; Shc Signaling Adaptor Proteins; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Postmenopause; Retrospective Studies; Salvage Therapy; Tamoxifen; Treatment Outcome | 2005 |
A paradoxical inhibitory effect of oestradiol-17beta on GnRH self-priming in pituitaries from tamoxifen-treated rats.
Topics: Animals; Autocrine Communication; Depression, Chemical; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Organ Culture Techniques; Ovariectomy; Phenols; Pituitary Gland; Pyrazoles; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
Evidence that 17alpha-estradiol is biologically active in the uterine tissue: antiuterotonic and antiuterotrophic action.
Topics: Animals; Calcium Chloride; Cycloheximide; Dactinomycin; Estradiol; Estrogens; Female; Fulvestrant; In Vitro Techniques; Muscle Relaxation; Norepinephrine; Potassium Chloride; Propranolol; Rats; Rats, Wistar; Stereoisomerism; Tamoxifen; Uterine Contraction; Uterus | 2005 |
A selective estrogen receptor modulator, tamoxifen, and membrane fluidity of erythrocytes in normotensive and hypertensive postmenopausal women: an electron paramagnetic resonance investigation.
Topics: Aged; Analysis of Variance; Arginine; Cyclic GMP; Dose-Response Relationship, Drug; Drug Synergism; Electron Spin Resonance Spectroscopy; Enzyme Inhibitors; Erythrocyte Membrane; Erythrocytes; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Hypertension; Membrane Fluidity; NG-Nitroarginine Methyl Ester; Nitric Oxide Donors; Nitric Oxide Synthase; Postmenopause; S-Nitroso-N-Acetylpenicillamine; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
Diffusion-time distribution analysis reveals characteristic ligand-dependent interaction patterns of nuclear receptors in living cells.
Topics: Bacterial Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Diffusion; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Ligands; Luminescent Proteins; Recombinant Fusion Proteins; Spectrometry, Fluorescence; Tamoxifen; Trans-Activators; Transfection; Tumor Cells, Cultured | 2005 |
A short-incubation reporter-gene assay for high-throughput screening of estrogen receptor-alpha antagonists.
Topics: Animals; beta-Lactamases; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fluorescence Resonance Energy Transfer; Fulvestrant; Genetic Vectors; Raloxifene Hydrochloride; Recombinant Fusion Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors; Transcriptional Activation; Transfection | 2005 |
Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
Topics: Amphiregulin; Antineoplastic Agents, Hormonal; EGF Family of Proteins; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 2005 |
Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Bongkrekic Acid; Breast Neoplasms; Caspase 9; Cell Line, Tumor; Cytochromes c; Drug Screening Assays, Antitumor; Enzyme Activation; Estradiol; Estrogens; Female; Fulvestrant; Humans; Membrane Potential, Mitochondrial; Mitochondria; Onium Compounds; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Tamoxifen; Toremifene | 2005 |
Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2004 |
Tissue-specific modulation of cyclooxygenase-2 (Cox-2) expression in the uterus and the v. cava by estrogens and phytoestrogens.
Topics: Animals; Cyclooxygenase 2; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Enzymologic; Genistein; Phytoestrogens; Rats; Rats, Wistar; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus; Venae Cavae | 2005 |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
Topics: Breast Neoplasms; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Mammary Glands, Human; Mutation; Oligonucleotide Array Sequence Analysis; Protein Binding; Raloxifene Hydrochloride; Receptor Cross-Talk; Response Elements; Signal Transduction; Tamoxifen; Transcription Factors | 2005 |
Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gefitinib; Humans; Mice; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prognosis; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Trastuzumab; Tumor Cells, Cultured; Tumor Escape; Xenograft Model Antitumor Assays | 2005 |
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Proliferation; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Humans; Insulin; Insulin Antagonists; Insulin Receptor Substrate Proteins; Intracellular Signaling Peptides and Proteins; Phosphoproteins; Receptor, IGF Type 1; Tamoxifen; Transcription, Genetic | 2005 |
Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Melatonin; Ovarian Neoplasms; Receptor, Melatonin, MT1; Signal Transduction; Tamoxifen; Up-Regulation | 2006 |
Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure.
Topics: Adenosine Diphosphate; Animals; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Electron Transport; Electron Transport Complex I; Estradiol; Flavins; Fulvestrant; Hydrogen Peroxide; Male; Membrane Potentials; Mitochondria; Mitochondria, Liver; Models, Biological; Nucleotides; Oxygen; Oxygen Consumption; Phosphorylation; Rats; Rats, Wistar; Rotenone; Selective Estrogen Receptor Modulators; Submitochondrial Particles; Tamoxifen; Time Factors; Ubiquinone | 2006 |
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
Topics: Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Ibandronic Acid; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 2006 |
Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 2006 |
Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Tamoxifen | 2006 |
Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations.
Topics: Adolescent; Adult; Breast; Breast Neoplasms; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation; Genes, BRCA1; Genes, BRCA2; Humans; Middle Aged; Mutation; Receptors, Progesterone; Risk Factors; Tamoxifen | 2006 |
Estradiol and its membrane-impermeable conjugate estradiol-BSA inhibit tamoxifen-stimulated prolactin secretion in incubated rat pituitaries.
Topics: Animals; Depression, Chemical; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Organ Size; Ovariectomy; Pituitary Gland, Anterior; Prolactin; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Serum Albumin, Bovine; Tamoxifen; Thyrotropin-Releasing Hormone | 2006 |
AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines.
Topics: Acetyltransferases; Alleles; Breast Neoplasms; Cell Line, Tumor; Cloning, Molecular; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Receptor Coactivator 3; Oncogene Proteins; Peptides; Polymerase Chain Reaction; Pyrrolidines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Sequence Analysis, DNA; Tamoxifen; Thiophenes; Trans-Activators | 2006 |
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Microarray Analysis; Neoplasm Staging; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Urinary Bladder Neoplasms | 2006 |
Estradiol-induced conditioned place preference may require actions at estrogen receptors in the nucleus accumbens.
Topics: Animals; Behavior, Animal; Conditioning, Operant; Drug Administration Routes; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Nucleus Accumbens; Oligonucleotides, Antisense; Ovariectomy; Rats; Rats, Long-Evans; Receptors, Estrogen; Tamoxifen | 2007 |
Effects of estradiol on phenylephrine contractility associated with intracellular calcium release in rat aorta.
Topics: Animals; Aorta; Caffeine; Calcium; Cells, Cultured; Cycloheximide; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Indoles; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phenylephrine; Phosphodiesterase Inhibitors; Potassium Channel Blockers; Progesterone; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Serotonin; Tamoxifen; Testosterone; Tetraethylammonium; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2006 |
Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Proteins; Oligonucleotide Array Sequence Analysis; Oligonucleotides, Antisense; Polyunsaturated Alkamides; Receptor, IGF Type 1; Tamoxifen | 2006 |
Ligand-selective interdomain conformations of estrogen receptor-alpha.
Topics: Cell Line, Tumor; Cell Nucleus; Dimerization; DNA; Estradiol; Estrogen Receptor alpha; Estrogens; Fluorescence Resonance Energy Transfer; Fulvestrant; Humans; Kinetics; Ligands; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Tamoxifen | 2007 |
Estrogen produced in cultured hippocampal neurons is a functional regulator of a GABAergic machinery.
Topics: Animals; Aromatase; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Embryo, Mammalian; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; gamma-Aminobutyric Acid; Gene Expression; Gene Expression Regulation; Glutamate Decarboxylase; Hippocampus; Immunohistochemistry; Isoenzymes; Neurons; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2006 |
Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chickens; COUP Transcription Factor II; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Receptors, Progesterone; Tamoxifen; Transcription, Genetic; Transfection | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Aromatase and breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
[Fulvestrant].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Ovariectomy; Randomized Controlled Trials as Topic; Tamoxifen | 2006 |
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Topics: Antineoplastic Agents, Hormonal; Binding Sites; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tamoxifen; Transcription, Genetic; Trefoil Factor-1; Tumor Suppressor Proteins | 2006 |
The antiestrogen tamoxifen activates BK channels and stimulates proliferation of MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Large-Conductance Calcium-Activated Potassium Channels; Tamoxifen; Tetraethylammonium Compounds | 2007 |
Effect of antiestrogens on EGF-mediated movement of human breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cyclopropanes; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Tamoxifen | 2007 |
Molecular cloning and characterization of the human WISP-2/CCN5 gene promoter reveal its upregulation by oestrogens.
Topics: 5' Flanking Region; Base Sequence; Blotting, Western; Breast Neoplasms; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Cloning, Molecular; CREB-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Intercellular Signaling Peptides and Proteins; Molecular Sequence Data; Neoplasm Proteins; Promoter Regions, Genetic; Repressor Proteins; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Transcription Factors; Transcription, Genetic; Transfection | 2006 |
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Culture Media; DNA Methylation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Tamoxifen | 2006 |
Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Prohibitins; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Uterine Neoplasms | 2007 |
Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Phosphorylation; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tamoxifen | 2007 |
A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Topics: Binding, Competitive; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Humans; Ligands; Norpregnatrienes; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Steryl-Sulfatase; Tamoxifen; Tumor Cells, Cultured | 2007 |
Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity.
Topics: Amidines; Analysis of Variance; Animals; Antioxidants; Disease Models, Animal; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Interactions; Estradiol; Estrogen Antagonists; F2-Isoprostanes; Fulvestrant; Functional Laterality; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen | 2007 |
Estrogen receptor independent neurotoxic mechanism of bisphenol A, an environmental estrogen.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Blotting, Western; Cell Differentiation; Cell Survival; Estradiol; Estrogens, Non-Steroidal; Flavonoids; Fulvestrant; Neurons; NF-kappa B; PC12 Cells; Phenols; Rats; Receptors, Estrogen; Tamoxifen | 2007 |
Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
Topics: Breast Neoplasms; Carcinoma; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured; Up-Regulation | 2007 |
Estradiol, tamoxifen and ICI 182,780 alter alpha3 and beta1 integrin expression and laminin-1 adhesion in oral squamous cell carcinoma cell cultures.
Topics: Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Integrin alpha3; Integrin beta1; Laminin; Membrane Proteins; Mouth Neoplasms; Tamoxifen | 2008 |
Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Topics: Animals; Apoptosis; Bone Resorption; Cattle; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Dexamethasone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Lipopolysaccharide Receptors; Macrophage Colony-Stimulating Factor; Monocytes; Osteoclasts; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Tumor Necrosis Factor-alpha | 2007 |
Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line.
Topics: Animals; Blotting, Western; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Gonadotrophs; HeLa Cells; Humans; Insulin-Like Growth Factor I; Luciferases; Mice; Mice, Inbred C57BL; Phosphorylation; Promoter Regions, Genetic; Receptor Cross-Talk; Receptor, IGF Type 1; RNA, Messenger; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Transcription, Genetic; Transfection | 2007 |
Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha.
Topics: Bacterial Proteins; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fluorescence Resonance Energy Transfer; Fulvestrant; Humans; Luminescent Proteins; Models, Biological; Models, Chemical; Mutation; Piperidines; Tamoxifen; Transcriptional Activation | 2007 |
Estrogen inhibition of norepinephrine responsiveness is initiated at the plasma membrane of GnRH-producing GT1-7 cells.
Topics: Cell Line, Tumor; Cell Membrane; Cyclic AMP; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Estrogens; Estrogens, Conjugated (USP); Fluorescein-5-isothiocyanate; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Hypothalamus; NAD; Neurons; Norepinephrine; Phenols; Protein Binding; Pyrazoles; Serum Albumin, Bovine; Tamoxifen | 2007 |
Loss of tumourigenicity of stably ERbeta-transfected MCF-7 breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gelsolin; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Recombinant Fusion Proteins; Tamoxifen; Transfection; Transplantation, Heterologous | 2007 |
Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Casein Kinase II; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Polyunsaturated Alkamides; Proto-Oncogene Proteins c-bcl-2; Tamoxifen; Time Factors; Transfection | 2007 |
Functional characterization of estrogen receptor subtypes, ERalpha and ERbeta, mediating vitellogenin production in the liver of rainbow trout.
Topics: Animals; Binding, Competitive; Biological Assay; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Hepatocytes; Ligands; Nitriles; Oncorhynchus mykiss; Phenols; Piperidines; Propionates; Pyrazoles; Radioligand Assay; Tamoxifen; Vitellogenins | 2007 |
Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death.
Topics: Caspase 3; Caspase 9; Cell Death; Enzyme Activation; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Flavonoids; Fulvestrant; HeLa Cells; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Receptors, Estrogen; Tamoxifen; Time Factors | 2007 |
[Systemic therapy of male breast cancer].
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Combined Modality Therapy; Cyclophosphamide; Estradiol; Fluorouracil; Fulvestrant; Humans; Male; Methotrexate; Orchiectomy; Randomized Controlled Trials as Topic; Survival Rate; Tamoxifen; Treatment Outcome | 2007 |
Vasorelaxant action of 17 -estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors.
Topics: Animals; Arteries; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pregnancy; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen; Uterus; Vasodilation; Vasodilator Agents | 2007 |
Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Blotting, Southern; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; DNA, Mitochondrial; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Ethidium; Female; Flow Cytometry; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2008 |
Distribution plasticity of the human estrogen receptor alpha in live cells: distinct imaging of consecutively expressed receptors.
Topics: Animals; Blotting, Western; CHO Cells; Cricetinae; Cricetulus; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; Microscopy, Confocal; Microscopy, Fluorescence; Spectrometry, Fluorescence; Subcellular Fractions; Tamoxifen | 2007 |
Human prolactin gene promoter regulation by estrogen: convergence with tumor necrosis factor-alpha signaling.
Topics: Animals; Cell Line; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression Regulation; Humans; Luciferases; Pituitary Gland, Anterior; Prolactin; Promoter Regions, Genetic; Rats; Rats, Inbred F344; Receptors, Estrogen; Signal Transduction; Tamoxifen; Tumor Necrosis Factor-alpha | 2008 |
Tamoxifen stimulates calcium entry into human platelets.
Topics: Adenosine Diphosphate; Adult; Blood Platelets; Calcium; Calcium Signaling; Diethylstilbestrol; Drug Synergism; Estradiol; Estrenes; Estrogen Antagonists; Ethamoxytriphetol; Female; Fulvestrant; Humans; Male; Middle Aged; Molecular Structure; Phosphodiesterase Inhibitors; Pyrrolidinones; Stilbenes; Structure-Activity Relationship; Tamoxifen; Thrombin; Vasopressins | 2007 |
Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mitogen-Activated Protein Kinases; Nitriles; Phenotype; Protein Kinase Inhibitors; Receptor, ErbB-2; RNA, Messenger; Tamoxifen | 2007 |
Understanding the data, meeting patients' needs.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Mechanism of collagen biosynthesis up-regulation in cultured leiomyoma cells.
Topics: Blotting, Western; Cells, Cultured; Collagen; Dipeptidases; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Estradiol; Female; Fulvestrant; Humans; Leiomyoma; Middle Aged; Myometrium; Raloxifene Hydrochloride; Tamoxifen; Up-Regulation | 2007 |
Gender-specific protection of estrogen against gastric acid-induced duodenal injury: stimulation of duodenal mucosal bicarbonate secretion.
Topics: Animals; Bicarbonates; Cells, Cultured; Cytoprotection; Dogs; Duodenal Diseases; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gastric Acid; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Receptors, Estrogen; Sex Characteristics; Tamoxifen | 2008 |
Estrogens and genomic instability in human breast cancer cells--involvement of Src/Raf/Erk signaling in micronucleus formation by estrogenic chemicals.
Topics: Benzhydryl Compounds; Benzo(a)pyrene; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Fulvestrant; Genomic Instability; Humans; Kinetochores; Micronuclei, Chromosome-Defective; Phenols; raf Kinases; Receptors, Estrogen; Signal Transduction; src-Family Kinases; Tamoxifen | 2008 |
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Cell Line, Tumor; Coumarins; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Genes, Reporter; Genistein; Humans; Letrozole; Ligands; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; Tamoxifen; Thiazoles; Transfection; Triazoles | 2008 |
Fispemifene [Z-2-{2-[4-(4-chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol], a novel selective estrogen receptor modulator, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Estradiol; Estrogen Antagonists; Fos-Related Antigen-2; Fulvestrant; Immunohistochemistry; Male; Organ Size; Prolactin; Prostatitis; Rats; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Testosterone | 2008 |
Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Ovariectomy; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Tamoxifen; Xenograft Model Antitumor Assays | 2008 |
ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; bcl-Associated Death Protein; Blotting, Western; Cell Proliferation; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phenotype; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 2008 |
Involvement of estradiol-17beta and its membrane receptor, G protein coupled receptor 30 (GPR30) in regulation of oocyte maturation in zebrafish, Danio rario.
Topics: Androstatrienes; Animals; Aromatase Inhibitors; Cyclopentanes; Estradiol; Female; Fulvestrant; Hydroxyprogesterones; Oocytes; Quinolines; Receptors, Estradiol; Receptors, G-Protein-Coupled; Tamoxifen; Zebrafish; Zebrafish Proteins | 2009 |
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fetal Proteins; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Microtubule-Associated Proteins; Middle Aged; Models, Biological; Neoplasm Proteins; Nephroblastoma Overexpressed Protein; Nuclear Proteins; Phenotype; Prognosis; Recurrence; RNA, Messenger; Securin; Tamoxifen | 2009 |
Tamoxifen-induced [Ca2+]i rise and apoptosis in corneal epithelial cells.
Topics: Animals; Apoptosis; Calcium Channel Blockers; Calcium Signaling; Cell Nucleus; Cell Survival; Diploidy; Epithelial Cells; Epithelium, Corneal; Estradiol; Estrogen Antagonists; Flow Cytometry; Fulvestrant; In Vitro Techniques; Manganese; Protein Kinase C; Rabbits; Reactive Oxygen Species; Tamoxifen; Type C Phospholipases | 2009 |
Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.
Topics: Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Connexins; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen | 2009 |
Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Receptors, Estrogen; Tamoxifen; Tissue Distribution; Tumor Cells, Cultured | 2009 |
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Topics: Adult; Antigens, CD; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; Estradiol; Female; Flavonoids; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Mitogen-Activated Protein Kinases; Morpholines; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Receptors, Estrogen; Receptors, Transferrin; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; RNA, Messenger; Tamoxifen; Time Factors; Tissue Array Analysis; Transferrin; Treatment Outcome | 2010 |
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells.
Topics: 3' Untranslated Regions; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cycloheximide; Dactinomycin; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; MicroRNAs; Nucleic Acid Synthesis Inhibitors; Promoter Regions, Genetic; Protein Synthesis Inhibitors; ras GTPase-Activating Proteins; RNA-Binding Proteins; RNA, Antisense; Tamoxifen | 2009 |
Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study.
Topics: Adenocarcinoma; Adrenergic beta-Antagonists; Antihypertensive Agents; Arginine; Benzopyrans; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Size; Dose-Response Relationship, Drug; Drug Combinations; Elasticity; Endothelial Cells; Estradiol; Estrogen Antagonists; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Ethanolamines; Female; Fulvestrant; Genes, Reporter; Humans; Metoprolol; Nanotechnology; Nebivolol; Nitric Oxide; Nitrites; Tamoxifen; Time Factors; Transfection | 2009 |
ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands.
Topics: Binding Sites; Cell Line; Chromatin Immunoprecipitation; DNA; Estradiol; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation; Humans; Protein Binding; RNA Polymerase II; RNA, Messenger; Selective Estrogen Receptor Modulators; Sequence Analysis, DNA; Tamoxifen | 2009 |
17beta-Estradiol-induced enhancement of estrogen receptor biosynthesis via MAPK pathway in mouse skeletal muscle myoblasts.
Topics: Animals; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens; Flavonoids; Fulvestrant; Imidazoles; Mice; Mitogen-Activated Protein Kinase Kinases; Models, Animal; Muscle, Skeletal; Myoblasts, Skeletal; Pyridines; Receptors, Estrogen; Signal Transduction; Tamoxifen | 2009 |
Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors.
Topics: Animals; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Immunohistochemistry; Incidence; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Transforming Growth Factor alpha | 2009 |
Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway.
Topics: Breast Neoplasms; Carcinoma; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Promoter Regions, Genetic; Receptors, Estrogen; RNA, Messenger; Signal Transduction; Tamoxifen; Transcription, Genetic; Transfection; Tubulin | 2009 |
Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells.
Topics: Alternative Splicing; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Interactions; Ellagic Acid; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Telomerase | 2009 |
Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.
Topics: Adenocarcinoma; Amino Acid Motifs; Amino Acid Substitution; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Point Mutation; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Recombinant Fusion Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factor AP-1; Transfection | 2010 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2009 |
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Nucleus; Cyclin D1; Enzyme Activation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fluorescence; Fulvestrant; Genome, Human; Humans; Lung Neoplasms; Male; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Mutant Proteins; Phosphoserine; Protein Transport; Sex Characteristics; Signal Transduction; Subcellular Fractions; Tamoxifen | 2010 |
Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor.
Topics: Apoptosis Regulatory Proteins; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromosome Mapping; Clone Cells; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Flow Cytometry; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genome-Wide Association Study; Humans; Membrane Proteins; Mitochondrial Proteins; Oligonucleotide Array Sequence Analysis; Tamoxifen | 2009 |
Knockdown of ICB-1 gene enhanced estrogen responsiveness of ovarian and breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Ovarian Neoplasms; RNA, Small Interfering; Tamoxifen; Tumor Cells, Cultured | 2010 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Nitriles; Pyrrolidines; Receptor, Endothelin A; Tamoxifen; Time Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
4-Hydroxytamoxifen inhibits K(+) currents in mouse ventricular myocytes.
Topics: Animals; Dactinomycin; Electric Conductivity; Estradiol; Female; Fulvestrant; Heart Ventricles; Kinetics; Mice; Muscle Cells; Patch-Clamp Techniques; Potassium; Receptors, Estrogen; Tamoxifen; Transcription, Genetic | 2010 |
Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Keratins; Oligonucleotides; Proteasome Endopeptidase Complex; Receptors, Estrogen; Tamoxifen | 2010 |
Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Fulvestrant; GATA3 Transcription Factor; Gene Regulatory Networks; Hepatocyte Nuclear Factor 3-alpha; Humans; Insulin; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Prognosis; T-Box Domain Proteins; Tamoxifen; Transcription, Genetic | 2010 |
FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Estradiol; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Immunophilins; Immunoprecipitation; Kaplan-Meier Estimate; Meta-Analysis as Topic; Phosphorylation; Protein Binding; RNA Interference; Serine; Signal Transduction; Tacrolimus Binding Proteins; Tamoxifen; Transfection | 2010 |
Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Forkhead Transcription Factors; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immune Tolerance; Tamoxifen; Transforming Growth Factor beta | 2010 |
17beta-estradiol mediated protection against vascular leak after hemorrhagic shock: role of estrogen receptors and apoptotic signaling.
Topics: Animals; Capillary Leak Syndrome; Capillary Permeability; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Fulvestrant; Male; Membrane Potential, Mitochondrial; Mesentery; Mitochondria; Nitriles; Phenols; Propionates; Pyrazoles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Shock, Hemorrhagic; Tamoxifen; Venules | 2010 |
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fibroblast Growth Factor 2; Fulvestrant; Gene Amplification; Gene Silencing; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Phosphorylation; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Estrogen; RNA, Messenger; Tamoxifen | 2010 |
Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
Topics: Acetylation; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyclopentanes; ERRalpha Estrogen-Related Receptor; Estradiol; Fulvestrant; Gene Expression; Histones; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Transport; Quinolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; RNA Interference; Tamoxifen | 2010 |
Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance.
Topics: Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Estradiol; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, cdc; Humans; Immunoglobulins; Promoter Regions, Genetic; S Phase; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Endocrine System; Enzyme Inhibitors; Estradiol; Focal Adhesion Protein-Tyrosine Kinases; Fulvestrant; Humans; Inhibitory Concentration 50; Phenotype; Quinolones; Sulfones; Tamoxifen | 2011 |
In vitro effects of oestrogens, antioestrogens and SERMs on pancreatic solid pseudopapillary neoplasm-derived primary cell culture.
Topics: Adult; Antineoplastic Agents, Hormonal; Carcinoma, Papillary; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Pancreatic Neoplasms; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.
Topics: Carcinoma; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Phosphorylation; Raloxifene Hydrochloride; RNA, Small Interfering; Signal Transduction; Tamoxifen; Thyroid Neoplasms | 2010 |
Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status.
Topics: Breast Neoplasms; Cell Line, Tumor; Epithelial Cells; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Flavin-Adenine Dinucleotide; Fulvestrant; Humans; Mammary Glands, Human; Microscopy, Confocal; NAD; Oxidation-Reduction; RNA, Messenger; Tamoxifen | 2010 |
Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Topics: Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Cyclin D1; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Flow Cytometry; Fulvestrant; Humans; Immunization; Inhibitor of Apoptosis Proteins; Membrane Potential, Mitochondrial; Microtubule-Associated Proteins; Mucoproteins; Oncogene Proteins; Proteins; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survivin; Tamoxifen | 2010 |
Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression.
Topics: Base Sequence; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Culture Media; DNA Primers; Estradiol; Estrogen Receptor Modulators; Estrogens; Flow Cytometry; Fulvestrant; Humans; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2010 |
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Flow Cytometry; Fulvestrant; Humans; Immunoenzyme Techniques; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tamoxifen; Tumor Suppressor Protein p53 | 2011 |
The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Synergism; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Protein Isoforms; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tamoxifen; tau Proteins; Taxoids | 2010 |
Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Keratin-5; Neoadjuvant Therapy; Phenotype; Receptors, Progesterone; Tamoxifen | 2011 |
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; G1 Phase; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Quinazolines; src-Family Kinases; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Loss of BRCA1 leads to an increased sensitivity to Bisphenol A.
Topics: Animals; Benzhydryl Compounds; BRCA1 Protein; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mammary Glands, Animal; Mice; Mice, Inbred C57BL; Phenols; Tamoxifen | 2010 |
Mechanical loading-related bone gain is enhanced by tamoxifen but unaffected by fulvestrant in female mice.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Development; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Mice; Mice, Inbred C57BL; Ovariectomy; Pilot Projects; Tamoxifen; Uterus | 2010 |
Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.
Topics: Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Multigene Family; Nuclear Receptor Coactivator 3; Nuclear Receptor Coactivators; Tamoxifen; Transcriptional Activation | 2011 |
Ligands specify estrogen receptor alpha nuclear localization and degradation.
Topics: Cell Line, Tumor; Digitonin; Estradiol; Estrogen Receptor alpha; Fulvestrant; Green Fluorescent Proteins; Humans; Ligands; Microscopy, Immunoelectron; Proteasome Endopeptidase Complex; Recombinant Fusion Proteins; RNA, Messenger; Tamoxifen | 2010 |
Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
Topics: Animals; Antibodies; Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microarray Analysis; Neoplasm Invasiveness; Peptides; Prognosis; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Survival Rate; Tamoxifen; Transplantation, Heterologous; Trefoil Factor-3 | 2010 |
High content imaging-based assay to classify estrogen receptor-α ligands based on defined mechanistic outcomes.
Topics: Benzhydryl Compounds; Blotting, Western; Cell Line, Tumor; Cluster Analysis; Endocrine Disruptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Green Fluorescent Proteins; HeLa Cells; Humans; Microscopy, Fluorescence; Phenols; Principal Component Analysis; Promoter Regions, Genetic; Raloxifene Hydrochloride; Reproducibility of Results; Tamoxifen | 2011 |
Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Fluorescent Antibody Technique; Fulvestrant; Green Fluorescent Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Receptors, Estrogen; Tamoxifen; Tumor Burden; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2011 |
Fulvestrant for advanced male breast cancer patients: a case series.
Topics: Breast Neoplasms, Male; Estradiol; Fulvestrant; Humans; Male; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Testosterone | 2011 |
Tamoxifen regulation of bone growth and endocrine function in the ovariectomized rat: discrimination of responses involving estrogen receptor α/estrogen receptor β, G protein-coupled estrogen receptor, or estrogen-related receptor γ using fulvestrant (ICI
Topics: Animals; Bone Density; Bone Development; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Ovariectomy; Pituitary Gland; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen | 2011 |
Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Receptors, Estrogen; Tamoxifen | 2011 |
Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Humans; Insulin-Like Growth Factor I; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Tamoxifen | 2011 |
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus | 2011 |
Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Fibroblast Growth Factor 1; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phospholipase C gamma; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Estrogen; Signal Transduction; Tamoxifen | 2012 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Chemotherapy, Adjuvant; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Intracellular Signaling Peptides and Proteins; Luciferases, Renilla; Receptor Cross-Talk; Response Elements; Signal Transduction; Tamoxifen; Y-Box-Binding Protein 1 | 2012 |
Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoid synthesis.
Topics: Animals; Antineoplastic Agents, Hormonal; Aorta, Thoracic; Estradiol; Fulvestrant; Indomethacin; Male; NG-Nitroarginine Methyl Ester; Prostaglandins; Rats; Rats, Wistar; Tamoxifen; Vasodilation | 2011 |
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Insulin; Insulin-Like Growth Factor I; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein-Tyrosine Kinases; Pyrazines; Random Allocation; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Estrogen; RNA Interference; Signal Transduction; Tamoxifen; Xenograft Model Antitumor Assays | 2011 |
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fibroblasts; Fulvestrant; Humans; Hypoglycemic Agents; Intracellular Signaling Peptides and Proteins; Ketone Bodies; Lactic Acid; Metformin; Mitochondria; Oxides; Phosphoric Monoester Hydrolases; Poly(ADP-ribose) Polymerase Inhibitors; Tamoxifen; Tumor Microenvironment | 2011 |
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oligonucleotide Array Sequence Analysis; Pyrazoles; Receptor, IGF Type 1; Receptor, Insulin; Tamoxifen; Triazines; Triazoles; Xenograft Model Antitumor Assays | 2011 |
Chronic leptin treatment sensitizes MCF-7 breast cancer cells to estrogen.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Humans; Janus Kinase 2; Leptin; Phosphorylation; Signal Transduction; STAT3 Transcription Factor; Tamoxifen | 2011 |
Nanomolar dose of bisphenol A rapidly modulates spinogenesis in adult hippocampal neurons.
Topics: Animals; Benzhydryl Compounds; Dendritic Spines; Dizocilpine Maleate; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Flavonoids; Fulvestrant; Hippocampus; Humans; Male; Mitogen-Activated Protein Kinases; Neurons; Phenols; Rats; Rats, Wistar; Receptors, Estrogen; Receptors, N-Methyl-D-Aspartate; Tamoxifen | 2012 |
NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; NF-kappa B; NF-kappa B p50 Subunit; Phosphatidylinositol 3-Kinases; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen; Transcription Factor RelA; Transcription Factor RelB | 2012 |
Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Humans; MCF-7 Cells; Protein Conformation; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic | 2012 |
Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Humans; Ovarian Neoplasms; RNA, Messenger; Signal Transduction; Tamoxifen | 2012 |
Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland.
Topics: Animals; Cluster Analysis; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Genes; Genes, Neoplasm; Mammary Glands, Animal; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transcriptome | 2012 |
IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Caspase 7; Cell Line, Tumor; DNA, Complementary; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Library; Heat-Shock Proteins; Humans; Insulin-Like Growth Factor Binding Protein 3; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein Interaction Mapping; Tamoxifen; Two-Hybrid System Techniques | 2012 |
Development of a novel molecular sensor for imaging estrogen receptor-coactivator protein-protein interactions.
Topics: Animals; Biosensing Techniques; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Genes, Reporter; Genetic Complementation Test; Humans; Imaging, Three-Dimensional; Luciferases; Mice; Mice, Inbred BALB C; Mutation; Nuclear Receptor Coactivator 3; Protein Binding; Protein Structure, Secondary; Protein Structure, Tertiary; Recombinant Fusion Proteins; Tamoxifen; Time Factors | 2012 |
Carboplatin treatment of antiestrogen-resistant breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; bcl-2-Associated X Protein; bcl-X Protein; Breast Neoplasms; Carboplatin; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression; Humans; MCF-7 Cells; Proto-Oncogene Proteins c-bcl-2; Tamoxifen | 2012 |
Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
Topics: Apoptosis; Carcinoma, Transitional Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Immediate-Early Proteins; MCF-7 Cells; Poly(ADP-ribose) Polymerases; Raloxifene Hydrochloride; S-Phase Kinase-Associated Proteins; Tamoxifen; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
The antiestrogens tamoxifen and fulvestrant abolish estrogenic impacts of 17α-ethinylestradiol on male calling behavior of Xenopus laevis.
Topics: Animals; Behavior, Animal; Endocrine Disruptors; Estradiol; Ethinyl Estradiol; Fulvestrant; Male; Tamoxifen; Vocalization, Animal; Xenopus laevis | 2012 |
miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Movement; Cell Survival; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; MCF-7 Cells; MicroRNAs; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Tamoxifen; Tissue Array Analysis; Transcriptome; Treatment Outcome | 2012 |
In vivo and in vitro evaluation of the estrogenic properties of the 17β-(butylamino)-1,3,5(10)-estratrien-3-ol (buame) related to 17β-estradiol.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Corn Oil; Estradiol; Estradiol Congeners; Estrogens; Female; Fulvestrant; Humans; Lordosis; MCF-7 Cells; Progesterone; Propylene Glycol; Rats; Rats, Wistar; Receptors, Estrogen; Sexual Behavior, Animal; Tamoxifen | 2012 |
Transactivating function (AF) 2-mediated AF-1 activity of estrogen receptor α is crucial to maintain male reproductive tract function.
Topics: Animals; Estradiol; Estrogen Receptor alpha; Fertility; Fulvestrant; Homozygote; Ligands; Male; Mice; Mice, Knockout; Point Mutation; Protein Structure, Tertiary; Reproduction; Sperm Count; Sperm Motility; Tamoxifen; Testis; Transcriptional Activation | 2012 |
The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts.
Topics: Animals; Arginine; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mice; Mice, Nude; Neuropeptide Y; Receptors, Estrogen; Receptors, Neuropeptide Y; Tamoxifen | 2012 |
Neuroestrogens rapidly regulate sexual motivation but not performance.
Topics: Animals; Aromatase; Aromatase Inhibitors; Brain; Coturnix; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Male; Motivation; Neurons; Sexual Behavior, Animal; Tamoxifen; Testosterone | 2013 |
[Endocrine therapy for advanced breast cancer].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Neoplasms, Hormone-Dependent; Postmenopause; Premenopause; Tamoxifen; TOR Serine-Threonine Kinases | 2012 |
Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes.
Topics: Cell Line, Tumor; DNA; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression; HeLa Cells; Hep G2 Cells; Humans; Indoles; Ligands; Mutation; Promoter Regions, Genetic; Protein Multimerization; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Transcriptional Activation | 2013 |
Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
Topics: Apoptosis; Breast Neoplasms; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; MCF-7 Cells; Paclitaxel; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; RNA Interference; src-Family Kinases; Tamoxifen | 2013 |
Antiestrogens suppress effects of transforming growth factor-β in breast cancer cells via the signaling axis estrogen receptor-α and Y-box Binding Protein-1.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Signal Transduction; Survival Rate; Tamoxifen; Transforming Growth Factor beta; Y-Box-Binding Protein 1 | 2013 |
Heparanase procoagulant activity is elevated in women using oral contraceptives.
Topics: Adult; Blood Coagulation; Case-Control Studies; Cell Line; Contraceptives, Oral; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Glucuronidase; Humans; Israel; Mammary Glands, Human; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Thrombophilia; Thromboplastin; Young Adult | 2013 |
Estrogen modulates in vitro T cell responses in a concentration- and receptor-dependent manner: effects on intracellular molecular targets and antioxidant enzymes.
Topics: Animals; Antioxidants; Catalase; Cell Proliferation; Cells, Cultured; Concanavalin A; Cytokines; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Fulvestrant; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Intracellular Space; Nitric Oxide; Nitriles; Phenols; Propionates; Pyrazoles; Rats; Rats, Sprague-Dawley; Spleen; Superoxide Dismutase; T-Lymphocytes; Tamoxifen | 2013 |
The exposure of breast cancer cells to fulvestrant and tamoxifen modulates cell migration differently.
Topics: Animals; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Invasiveness; Receptors, Estrogen; Tamoxifen | 2013 |
Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha.
Topics: Animals; Binding Sites; Diethylstilbestrol; Dimerization; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; Hydrogen Bonding; Ligands; Models, Molecular; Molecular Dynamics Simulation; Phytoestrogens; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Resveratrol; Stilbenes; Tamoxifen | 2013 |
Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Curcumin; Estradiol; Estrogen Receptor beta; Estrogen Receptor Modulators; Fulvestrant; Genistein; Humans; Male; Prostatic Neoplasms; Raloxifene Hydrochloride; Tamoxifen | 2014 |
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Antagonists; Estrogen Receptor Antagonists; Everolimus; Female; Fulvestrant; Humans; Immunosuppressive Agents; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases | 2014 |
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
Topics: Animals; Azepines; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenomics; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Histone-Lysine N-Methyltransferase; Humans; Mice; Nuclear Proteins; Repressor Proteins; RNA-Binding Proteins; Signal Transduction; Tamoxifen; Transcription Factors; Triazoles | 2014 |
Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
Topics: Animals; Apoptosis; Autophagy; Blotting, Western; Breast Neoplasms; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Hydroxychloroquine; Immunoenzyme Techniques; Macrophages; Mice; Mice, Nude; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fluorescent Antibody Technique; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Immunoprecipitation; Karyopherins; Microscopy, Confocal; Ovarian Neoplasms; Protein Transport; Proteins; Tamoxifen; Tumor Cells, Cultured; WAP Four-Disulfide Core Domain Protein 2 | 2014 |
Estradiol regulates Tumor Necrosis Factor-α expression and secretion in Estrogen Receptor positive breast cancer cells.
Topics: Cell Line, Tumor; Chromatin Immunoprecipitation; Epithelial Cells; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mammary Glands, Human; Promoter Regions, Genetic; Protein Binding; RNA, Messenger; Signal Transduction; Tamoxifen; Tumor Necrosis Factor-alpha | 2014 |
Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant.
Topics: Cell Line; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Fulvestrant; Gene Expression Regulation; Humans; Inhibitory Concentration 50; Microarray Analysis; Protein Binding; Receptors, Estrogen; Tamoxifen | 2014 |
ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Fulvestrant; Humans; Neoplastic Stem Cells; Tamoxifen | 2014 |
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Topics: Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Androgen; Tamoxifen; Triazoles | 2014 |
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Doxycycline; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression; Gene Knockdown Techniques; Humans; MCF-7 Cells; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
Topics: Aged; Aged, 80 and over; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Survival Analysis; Tamoxifen; TRPP Cation Channels; Vimentin | 2014 |
Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Survival; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Estradiol; Female; Fulvestrant; Inflammation; Male; Microglia; Neurons; Plasmids; Raloxifene Hydrochloride; Rats; Rats, Wistar; Receptors, Estrogen; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Topics: Apoptosis; Aurora Kinase A; Biomarkers, Tumor; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Cyanoacrylates; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Fulvestrant; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; RNA Interference; Survival Analysis; Tamoxifen; Triazoles | 2015 |
Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Receptors, Estrogen; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Furans; Humans; Ketones; Neoplastic Stem Cells; Tamoxifen | 2016 |
Deciphering the GPER/GPR30-agonist and antagonists interactions using molecular modeling studies, molecular dynamics, and docking simulations.
Topics: Amino Acid Motifs; Benzodioxoles; Binding Sites; Estradiol; Fulvestrant; Humans; Hydrogen Bonding; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Sequence Data; Protein Binding; Protein Structure, Secondary; Protein Structure, Tertiary; Quinolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Thermodynamics | 2015 |
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Models, Biological; Nitriles; Tamoxifen; Triazoles | 2015 |
Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Recurrence, Local; Nuclear Receptor Coactivator 3; Receptors, Estrogen; Tamoxifen | 2015 |
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
Topics: Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Molecular Targeted Therapy; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression; Gene Expression Profiling; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Ligands; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Aurora Kinase B; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mitosis; Neoplasm Recurrence, Local; Organophosphates; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Survival Analysis; Tamoxifen | 2015 |
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mutation; Piperazines; Pyridines; Selective Estrogen Receptor Modulators; Tamoxifen; Xenograft Model Antitumor Assays | 2015 |
Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis.
Topics: Catalysis; Cytosol; Estradiol; Fulvestrant; Hep G2 Cells; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Sulfates; Sulfotransferases; Tamoxifen | 2015 |
Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Codon, Initiator; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genetic Variation; HEK293 Cells; HeLa Cells; Hep G2 Cells; Humans; MCF-7 Cells; Oxidoreductases; Phenols; Prognosis; Pyrazoles; Receptors, Estrogen; Sequence Analysis, RNA; Survival Analysis; Tamoxifen | 2015 |
Effect of tamoxifen and fulvestrant long-term treatments on ROS production and (pro/anti)-oxidant enzymes mRNA levels in a MCF-7-derived breast cancer cell line.
Topics: Antineoplastic Agents, Hormonal; Antioxidants; Cell Line, Tumor; Cyclic N-Oxides; Enzymes; Estradiol; Fulvestrant; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kelch-Like ECH-Associated Protein 1; MCF-7 Cells; NADPH Oxidases; Reactive Oxygen Species; Spin Labels; Tamoxifen | 2016 |
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents, Hormonal; Basic Helix-Loop-Helix Transcription Factors; Benzazepines; Breast Neoplasms; Calcium-Binding Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Isoenzymes; Jagged-1 Protein; Membrane Proteins; Mice; Neoplastic Stem Cells; p-Aminoazobenzene; Proto-Oncogene Proteins; Receptor, Notch4; Receptors, Estrogen; Receptors, Notch; Retinal Dehydrogenase; Serrate-Jagged Proteins; Signal Transduction; Survival Analysis; Tamoxifen; Transcription Factor HES-1; Xenograft Model Antitumor Assays | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
Effects of Gender and Estrogen Receptors on Iron-Induced Brain Edema Formation.
Topics: Animals; Brain; Brain Edema; Caudate Nucleus; Chlorides; Disease Models, Animal; Estradiol; Estrogen Antagonists; Estrogen Receptor Antagonists; Female; Fulvestrant; Iron; Iron Compounds; Male; Mice; Mice, Inbred C57BL; Receptors, Estrogen; Sex Factors; Tamoxifen | 2016 |
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Pathology, Molecular; Piperazines; Precision Medicine; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab | 2016 |
Selective estrogen receptor modulators and betulinic acid act synergistically to target ERα and SP1 transcription factor dependent Pygopus expression in breast cancer.
Topics: Antineoplastic Agents; Betulinic Acid; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Hydroxytestosterones; Intracellular Signaling Peptides and Proteins; Microarray Analysis; Pentacyclic Triterpenes; Promoter Regions, Genetic; Selective Estrogen Receptor Modulators; Signal Transduction; Sp1 Transcription Factor; Tamoxifen; Triterpenes | 2016 |
Improved specificity of hippocampal memory trace labeling.
Topics: Animals; Bacterial Proteins; Cell Count; Channelrhodopsins; Conditioning, Psychological; Estradiol; Fear; Fulvestrant; Hippocampus; Immunohistochemistry; Luminescent Proteins; Memory; Mice, Transgenic; Microscopy, Confocal; Models, Animal; Neurons; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Untranslated; Selective Estrogen Receptor Modulators; Tamoxifen | 2016 |
MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Autophagy; Base Sequence; Binding Sites; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression; Humans; Ion Channels; MCF-7 Cells; MicroRNAs; Mitochondrial Proteins; RNA Interference; Tamoxifen; Uncoupling Protein 2 | 2015 |
Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Breast Neoplasms; Cell Line, Tumor; Estradiol; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Membrane Proteins; MicroRNAs; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; TOR Serine-Threonine Kinases; Transfection | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Characterisation of Signalling by the Endogenous GPER1 (GPR30) Receptor in an Embryonic Mouse Hippocampal Cell Line (mHippoE-18).
Topics: Adenylyl Cyclases; Aldosterone; Animals; Cell Line; Colforsin; Cyclic AMP; Embryo, Mammalian; Estradiol; Fulvestrant; Hippocampus; MAP Kinase Signaling System; Mice; Nitriles; Phenols; Pyrazoles; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Tamoxifen | 2016 |
Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.
Topics: Aphidicolin; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; G1 Phase; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lovastatin; MCF-7 Cells; RNA, Small Interfering; S Phase; Signal Transduction; Tamoxifen | 2016 |
In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA).
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; COS Cells; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Immunohistochemistry; MCF-7 Cells; Middle Aged; Protein Multimerization; Tamoxifen | 2017 |
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; src-Family Kinases; Tamoxifen; Transcriptional Activation | 2016 |
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Leupeptins; MCF-7 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen | 2016 |
Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Prognosis; Steroids; Tamoxifen; Triple Negative Breast Neoplasms; Up-Regulation | 2016 |
Tamoxifen and Fulvestrant Hybrids Showed Potency as Selective Estrogen Receptor Down-Regulators.
Topics: Down-Regulation; Drug Design; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; MCF-7 Cells; Tamoxifen | 2017 |
Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport.
Topics: Acetyl-CoA C-Acetyltransferase; Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G; Biological Transport; Cholesterol; Cholesterol Esters; Diet, Western; Esterification; Estradiol; Feces; Fulvestrant; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; THP-1 Cells; Toremifene | 2016 |
Estrogen receptor activation by tobacco smoke condensate in hormonal therapy-resistant breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Reporter; Green Fluorescent Proteins; Hormones; Humans; Ligands; MCF-7 Cells; Nicotiana; Oligonucleotide Array Sequence Analysis; Phosphorylation; Signal Transduction; Smoke; Tamoxifen | 2017 |
Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mutation; Progestins; Tamoxifen; Unfolded Protein Response | 2016 |
Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.
Topics: Adult; Animals; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Phosphorylation; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2017 |
Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Databases, Factual; Drug Prescriptions; Estradiol; Female; France; Fulvestrant; Germany; Humans; Italy; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome | 2017 |
Tamoxifen and ICI 182,780 activate hypothalamic G protein-coupled estrogen receptor 1 to rapidly facilitate lordosis in female rats.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Estradiol; Female; Fulvestrant; Lordosis; Male; Rats; Rats, Long-Evans; Receptors, G-Protein-Coupled; Stimulation, Chemical; Tamoxifen | 2017 |
A Novel Effect of β-Adrenergic Receptor on Mammary Branching Morphogenesis and its Possible Implications in Breast Cancer.
Topics: Animals; Breast Neoplasms; Catecholamines; Cell Adhesion; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Estradiol; Estrogens; Female; Fulvestrant; Humans; Isoproterenol; Mammary Glands, Animal; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Morphogenesis; Receptors, Adrenergic, beta-2; Receptors, Estrogen; Tamoxifen | 2017 |
Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Proliferation; Estradiol; Estrogen Receptor beta; Female; Fulvestrant; Gene Knockdown Techniques; Glycolysis; Humans; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Phenotype; Pyrazoles; Pyrimidines; Spheroids, Cellular; Tamoxifen; Triple Negative Breast Neoplasms; Tumor Burden; Up-Regulation | 2017 |
FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gene Amplification; Goserelin; Humans; Piperazines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases | 2017 |
Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Estradiol; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Letrozole; Male; Neoplasms, Multiple Primary; Nitriles; Prostatic Neoplasms; Tamoxifen; Triazoles | 2017 |
Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Topics: Acetylation; Anilides; Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Cell Cycle; Cell Line, Tumor; Cell Survival; Estradiol; Female; Fulvestrant; Histone Deacetylase 6; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Immunohistochemistry; Lactams, Macrocyclic; Mice; Tamoxifen; Triple Negative Breast Neoplasms | 2017 |
Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.
Topics: Anastrozole; Animals; Bone Morphogenetic Protein Receptors, Type II; Disease Models, Animal; Echocardiography; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hemodynamics; Humans; Hypertension, Pulmonary; Insulin Resistance; Lung; Mice; Mice, Knockout; Mutation; Nitriles; Signal Transduction; Tamoxifen; Triazoles | 2017 |
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Germany; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen | 2018 |
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; Mutation; Selective Estrogen Receptor Modulators; Tamoxifen | 2017 |
Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; MicroRNAs; Tamoxifen | 2018 |
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Estrogens; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Neoplasms, Hormone-Dependent; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tamoxifen | 2018 |
A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
Topics: Apoptosis; Biomarkers, Tumor; Breast Neoplasms; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Knockdown Techniques; Genome, Human; GTP-Binding Protein beta Subunits; Humans; MCF-7 Cells; Tamoxifen | 2018 |
In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Computer Simulation; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mitoxantrone; Neoplasm Metastasis; Reproducibility of Results; Tamoxifen; Thioridazine | 2018 |
Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.
Topics: Breast Neoplasms; Chromatin Assembly and Disassembly; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Proteins; Sumoylation; Tamoxifen; Transcription, Genetic | 2019 |
Tamoxifen induces apoptosis and inhibits respiratory burst in equine neutrophils independently of estrogen receptors.
Topics: Animals; Apoptosis; Dose-Response Relationship, Drug; Estrogen Antagonists; Fulvestrant; Horses; Neutrophils; Phosphatidylserines; Receptors, Estrogen; Respiratory Burst; Tamoxifen | 2019 |
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Ligands; MCF-7 Cells; Mutant Proteins; Mutation; Piperazines; Protein Binding; Protein Domains; Protein Structure, Secondary; Pyridines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2018 |
Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; RNA, Long Noncoding; Tamoxifen | 2018 |
Acquired HER2 mutations in ER
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; HEK293 Cells; Humans; MCF-7 Cells; Mutation; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen | 2019 |
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Cinnamates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Heterografts; Humans; Indoles; MCF-7 Cells; Mice; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Tamoxifen | 2019 |
The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Estrogen Receptor alpha; Female; Fulvestrant; Genetic Variation; Germ-Line Mutation; Humans; Incidence; MCF-7 Cells; Middle Aged; Phosphorylation; Survival Analysis; Tamoxifen; Treatment Outcome | 2019 |
Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
Topics: Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Datasets as Topic; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Neoplasm Proteins; Protein-Tyrosine Kinases; Signal Transduction; Tamoxifen | 2019 |
Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fulvestrant; Furans; Humans; Ketones; MCF-7 Cells; Tamoxifen; Trastuzumab | 2019 |
Repression of insulin gene transcription by indirect genomic signaling via the estrogen receptor in pancreatic beta cells.
Topics: Animals; Biological Assay; Cell Line; Cricetinae; Estradiol; Fulvestrant; Genome; Humans; Insulin; Insulin-Secreting Cells; Ligands; Promoter Regions, Genetic; Protein Binding; Protein Domains; Rats; Receptors, Estrogen; RNA, Messenger; Sequence Deletion; Tamoxifen; Transcription, Genetic | 2019 |
PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression; Humans; MCF-7 Cells; Meta-Analysis as Topic; Neoplasm Metastasis; Neoplastic Stem Cells; p21-Activated Kinases; Prognosis; Receptors, Estrogen; Small Molecule Libraries; Tamoxifen | 2019 |
Hormonal Therapy Resistance and Breast Cancer: Involvement of Adipocytes and Leptin.
Topics: Adipocytes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Communication; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Leptin; MCF-7 Cells; Neoplastic Stem Cells; Signal Transduction; STAT3 Transcription Factor; Tamoxifen; Tumor Microenvironment | 2019 |
mSWI/SNF Component ARID1A Mediates Breast Cancer Treatment Response.
Topics: Breast Neoplasms; Cell Cycle Proteins; DNA-Binding Proteins; Fulvestrant; Histone Deacetylase 1; Humans; Nuclear Proteins; Tamoxifen; Transcription Factors | 2020 |
UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.
Topics: Animals; Breast Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mice; Mice, Nude; Tamoxifen; Ubiquitin Thiolesterase; Up-Regulation | 2020 |
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Retinoblastoma Protein; RNA Interference; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; China; Circulating Tumor DNA; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Progression-Free Survival; Retrospective Studies; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Toremifene | 2020 |
Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chymases; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; HSC70 Heat-Shock Proteins; Humans; Immunohistochemistry; Lysosomal-Associated Membrane Protein 2; Lysosomes; Phosphorylation; Protein Stability; Receptors, Estrogen; Receptors, G-Protein-Coupled; RNA, Small Interfering; Signal Transduction; Tamoxifen; Transcription Factors | 2020 |
Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment.
Topics: Antineoplastic Agents, Hormonal; Berberine Alkaloids; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dopamine Antagonists; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Models, Molecular; Protein Conformation; Tamoxifen | 2020 |
Fasting-mimicking diet and hormone therapy induce breast cancer regression.
Topics: Animals; Biological Factors; Breast Neoplasms; Diet Therapy; Diet, Healthy; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Fasting; Female; Fulvestrant; Humans; Insulin; Insulin-Like Growth Factor I; Leptin; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Piperazines; PTEN Phosphohydrolase; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Lapatinib; Mice; Mice, Nude; Oncogene Proteins, Fusion; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Fulvestrant-Mediated Attenuation of the Innate Immune Response Decreases ER
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Immunity, Innate; MCF-7 Cells; Mice, Nude; Microdialysis; Neovascularization, Pathologic; Receptors, Estrogen; Tamoxifen; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zebrafish | 2020 |
Identification of Antiestrogen-Bound Estrogen Receptor α Interactomes in Hormone-Responsive Human Breast Cancer Cell Nuclei.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Tamoxifen | 2020 |
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Prospective Studies; Pyridines; Receptor, ErbB-2; Survival Rate; Tamoxifen; Thymidine Kinase | 2020 |
Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Fulvestrant; Humans; Imidazoles; Magnetic Resonance Imaging; MCF-7 Cells; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Oxazepines; Protein Kinase Inhibitors; Receptors, Estrogen; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Fatty Acid Synthase, Type I; Female; Fulvestrant; Humans; MAP Kinase Signaling System; MCF-7 Cells; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Proteins; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Tamoxifen | 2020 |
Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crizotinib; Drug Synergism; Estrogen Receptor alpha; Fulvestrant; Humans; Inhibitory Concentration 50; Ki-67 Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Tamoxifen | 2021 |
Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Models, Biological; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2021 |
MLL3 is a de novo cause of endocrine therapy resistance.
Topics: Antineoplastic Agents, Hormonal; Binding Sites; Breast Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mutation; Tamoxifen | 2021 |
Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer.
Topics: Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Cinnamates; Collagen; Drug Combinations; Enhancer of Zeste Homolog 2 Protein; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Indazoles; Laminin; Mammary Glands, Human; Mechanotransduction, Cellular; p38 Mitogen-Activated Protein Kinases; Phenotype; Proteoglycans; Tamoxifen; Tissue Culture Techniques; Transcriptome | 2021 |
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endocrine Gland Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplasm Recurrence, Local; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Receptors, Neuropeptide Y; Tamoxifen | 2022 |
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
Topics: Androgen Receptor Antagonists; Androgens; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Naphthalenes; Piperidines; Pyrrolidines; Radiation Tolerance; Receptors, Androgen; Receptors, Estrogen; Tamoxifen; Thiazoles; Triazoles | 2022 |
Clinical Translation: Targeting the Estrogen Receptor.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Receptors, Estrogen; Tamoxifen | 2022 |
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
Topics: Animals; Aromatase Inhibitors; Breast Neoplasms; Carbolines; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Mice; Mutation; Progesterone; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2022 |
Electrophysiological Safety Profile of Antiestrogenic Therapies in the Isolated Rabbit Heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Fulvestrant; Heart; Rabbits; Tamoxifen | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Furylfuramide; Humans; Ligands; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Sumoylation; Tamoxifen | 2023 |
ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Protein Isoforms; Tamoxifen; Tretinoin | 2023 |
Small change - big consequence: The impact of C15-C16 double bond in a D‑ring of estrone on estrogen receptor activity.
Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrone; Female; Fulvestrant; Humans; Molecular Docking Simulation; Receptors, Estrogen; Tamoxifen | 2023 |
Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fulvestrant; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Signal Transduction; Tamoxifen | 2023 |